

Connecting via winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?): 2

* * * * * welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN seminar schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 EXTEND option available in structure searching
NEWS 4 Polymer links for the POLYLINK command completed in
REGISTRY
NEWS 5 May 27 New upm (update Code maximum) field for more
efficient patent
SDIs in Caplus
NEWS 6 May 27 Caplus super roles and document types searchable in
REGISTRY
NEWS 7 Jun 28 Additional enzyme-catalyzed reactions added to
CASREACT
NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG,
MECHENG,
NEWS 9 Jul 12 and WATER from CSA now available on STN(R)
options, BEILSTEIN enhanced with new display and select
resulting in a closer connection to BABS
NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in
conjunction
NEWS 11 AUG 02 with the 228th ACS National Meeting
IFIPAT/IFIDB/IFICDB reloaded with new search and
display
NEWS 12 AUG 02 fields
Caplus and CA patent records enhanced with European
and Japan
NEWS 13 AUG 02 Patent Office Classifications
STN user update to be held August 22 in conjunction
with the
NEWS 14 AUG 02 228th ACS National Meeting
The Analysis Edition of STN Express with Discoveri
(Version 7.01 for Windows) now available
NEWS 15 AUG 04 Pricing for the Save Answers for SciFinder wizard
within
STN Express with Discoveri will change September 1,
2004
NEWS 16 AUG 27 BIOCCommerce: Changes and enhancements to content
coverage
NEWS 17 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added

for legal

status data from INPADOC
NEWS 18 SEP 01 INPADOC: New family current-awareness alert (SDI)

available
NEWS 19 SEP 01 New pricing for the Save Answers for SciFinder
wizard within

STN Express with Discoveri
NEWS 20 SEP 01 New display format, HITSTR, available in
WPIDS/WPIX

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0C(ENG) AND V6.01C(JP)

AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to
STN

NEWS WWW CAS world wide web site (general information)
Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to
scientific research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004

=> file reg
COST IN U.S. DOLLARS
TOTAL
SINCE FILE
ENTRY

SESSION
FULL ESTIMATED COST
0.21
0.21

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when

conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/req1strvss.html>

=> uploading H:\STN queries\09913722.str

*--0

2*1--23



chain nodes : 1 2 9 10 13 14 15 16 17 18 21 22 23

ring/chain nodes : 3 7 8

chain bonds : 1-2 2-3 8-9 9-10 9-13 10-14 10-15 15-16 15-21 16-17 16-18

ring/chain bonds : 3-7 7-8

exact/norm bonds : 1-2 2-3 3-7 7-8 9-10 9-13 10-14 10-15 15-21 16-17 16-18

exact bonds : 8-9 15-16

G1:Cb, Cy, Hy, Ak, CH3, Ph, MeO, EtO, n-BuO, NH, O, Et

G2: Ak, H

G3: O, SO2, NH

G4: Cb, Cy, Hy, Ak
G5: SO2, [1]

Match [level] :
1:CLASS 2:CLASS 3:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 21:CLASS
22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> s 11 sam
SAMPLE SEARCH INITIATED 10:50:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 61724 TO ITERATE

1.6% PROCESSED 1000 ITERATIONS 50

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
PROJECTED ITERATIONS: BATCH **INCOMPLETE**
EXCEEDS 100000
PROJECTED ANSWERS: EXCEEDS 806392

L2 50 SEA SSS SAM L1

=> s 11 fu
FULL SEARCH INITIATED 10:51:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 23.9% PROCESSED 294112 ITERATIONS 218486

< 28.2% PROCESSED 347900 ITERATIONS 260522

< 32.1% PROCESSED 395417 ITERATIONS 303965

< 32.5% PROCESSED 400000 ITERATIONS 308369

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.58

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
PROJECTED ITERATIONS: BATCH **INCOMPLETE**
EXCEEDS 100000
PROJECTED ANSWERS: EXCEEDS 947141

L3 308369 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE

TOTAL	
SESSION	ENTRY
FULL ESTIMATED COST	156.26
156.47	

FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 SEP 2004 VOL 141 ISS 11
 FILE LAST UPDATED: 8 SEP 2004 (20040908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12 44 L2
 L4

=> s 14 and pd<20000217
 20432235 PD<20000217
 (PD<20000217)
 L5 0 L4 AND PD<20000217

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
 L2 STRUCTURE UPLOADED
 L3 50 S L1 SAM
 308369 S L1 FULL

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
 L5 44 S L2
 0 S L4 AND PD<20000217

=> s 13 and pd<20000217
 TOO MANY TERMS FOR FILE CROSSOVER IN L3
 There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> s 13
 TOO MANY TERMS FOR FILE CROSSOVER IN L3
 There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> file reg	
COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY
SESSION	
FULL ESTIMATED COST	3.58
160.05	

FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
 DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
 L2 STRUCTURE UPLOADED
 L3 50 S L1 SAM
 308369 S L1 FULL


L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
 L5 44 S L2
 0 S L4 AND PD<20000217

FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004


=> d scan 13
 L3 308369 ANSWERS REGISTRY COPYRIGHT 2004 ACS ON STN
 IN INDEX NAME NOT YET ASSIGNED

MF C95 H156 N30 O25
Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




PAGE 1-C




PAGE 2-A

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2
L3 308369 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C65 H93 N13 O26 S4
Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



L3 308369 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C45 H69 N11 O9
Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1
L3 308369 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C46 H71 N13 O10
Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1
L3 308369 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C28 H44 N4 O3 S2
CI COM

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0
=> DIS L3 1-10 IDE
L3 ANSWER 1 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
RN 741635-65-4 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C37 H65 N9 O8 S
CI COM
SR CA


Absolute stereochemistry.



—Me



L3 ANSWER 2 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741635-23-4 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 FS STEREOSEARCH
 MF C23 H40 N8 O3
 CI COM
 SR CA

Absolute stereochemistry.




L3 ANSWER 3 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741635-17-6 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 FS STEREOSEARCH
 MF C66 H85 N13 O11
 CI COM
 SR CA

Absolute stereochemistry.




L3 ANSWER 4 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741634-32-2 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 MF C19 H31 N3 O5 S
 CI COM
 SR CA




L3 ANSWER 5 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741633-50-1 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 FS STEREOSEARCH
 MF C64 H89 N9 O13
 CI COM
 CA

Absolute stereochemistry.




L3 ANSWER 6 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741632-63-3 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 MF C25 H36 N6 O5
 CI COM
 CA




L3 ANSWER 7 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741630-46-6 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 FS STEREOSEARCH
 MF C68 H88 N10 O12 S
 CI COM
 CA

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B






L3 ANSWER 8 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741630-35-3 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 FS STEREOSEARCH
 MF C65 H99 N13 O21
 CI COM
 CA




Absolute stereochemistry.




CO2H



L3 ANSWER 9 OF 308369 REGISTRY COPYRIGHT 2004 ACS ON STN
 RN 741628-80-8 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 MF C72 H98 CO N20 O30 S3
 CI CCS, COM



L3 ANSWER 10 OF 308369 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 741628-41-1 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 MF C33 H56 N6 O6
 CI COM
 CA



=>
 => Executing the logoff script...

=> LOG H
 COST IN U.S. DOLLARS
 TOTAL
 SESSION
 FULL ESTIMATED COST
 181.53
 SINCE FILE
 ENTRY
 21.48

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:00:01 ON 09 SEP 2004
Connecting via winsock to STN

We]come to STN International! Enter x:x

LOGINID:ssspta1653adk

PASSWORD:







***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 11:32:09 ON 09 SEP 2004
FILE 'REGISTRY' ENTERED AT 11:32:09 ON 09 SEP 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SESSION
FULL ESTIMATED COST
181.53

SINCE FILE
ENTRY
21.48

=>
Uploading H:\STN queries\09913722b.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 45 50 51 52 53 54 55 56 57 58
59 62 63 64 65 66 68 69 70 71 72 73 74 76 77 78 79
80 81 83 84 85 86 87 88 89 91 92 93 94 95 96 100 101
102 105 119 120 121 122 126 127 128 129 130 132 133 134
ring nodes :
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28 29 30 33 34 35 36 37 38 39 40 41 42 43 44 106 107
108 110 111 112 113 114 115 116
chain bonds :
1-2 1-4 2-3 4-5 6-9 6-7 6-8 10-100 39-45 50-51 50-53 51-52
53-54 55-56 56-57 57-58 57-59 62-63 62-64 62-65 65-66 68-69
69-70 70-71 71-72 72-73 73-74 76-77 76-78 76-79 79-80 80-81
83-84 84-85 85-86 86-87 87-88 88-89 91-92 92-93 92-94 93-95
95-96 100-105 101-102 105-119 105-120 120-121 121-122 122-126
122-127 127-128 127-132 128-129 128-130 130-133 130-134

ring bonds :
1-2 1-4 2-3 4-5 6-9 6-7 6-8 10-100 39-45 50-51 50-53 51-52
53-54 55-56 56-57 57-58 57-59 62-63 62-64 62-65 65-66 68-69
69-70 70-71 71-72 72-73 73-74 76-77 76-78 76-79 79-80 80-81
83-84 84-85 85-86 86-87 87-88 88-89 91-92 92-93 92-94 93-95
95-96 100-105 101-102 105-119 105-120 120-121 121-122 122-126
122-127 127-128 127-132 128-129 128-130 130-133 130-134

11-12 11-16 12-13 13-14 14-15 15-16 15-17 16-20 17-18 18-19
 19-20 21-22 22-23 23-24 24-25 25-26 25-27 26-30 27-28
 28-29 29-30 33-34 33-35 35-36 36-37 37-38 39-40 39-44
 40-41 41-42 42-43 43-44 106-107 106-108 107-108 110-111 110-
 116 111-112 112-113 113-114 114-115 115-116
 exact/norm bonds :
 10-100 33-34 33-38 34-35 35-36 36-37 37-38 39-40 39-44 40-41
 41-42 42-43 43-44 50-51 50-53 55-56 62-65 65-66 92-93 93-95
 100-105 101-102 105-119 105-120 106-107 106-108 107-108 110-
 111 110-116 111-112 112-113 113-114 114-115 115-116 122-126
 122-127 127-128 127-132 130-133 130-134
 exact bonds :
 1-2 1-4 2-3 4-5 6-9 6-7 6-8 39-45 51-52 53-54 56-57 57-58
 57-59 62-63 62-64 68-69 69-70 70-71 71-72 72-73 73-74 76-77
 76-78 76-79 79-80 80-81 83-84 84-85 85-86 86-87 87-88 88-89
 91-92 92-94 95-96 120-121 121-122 128-129 128-130
 normalized bonds :
 11-12 11-16 12-13 13-14 14-15 15-16 15-17 16-20 17-18 18-19
 19-20 21-22 21-26 22-23 23-24 24-25 25-26 25-27 26-30 27-28
 28-29 29-30

G1:CH3,t-Bu,Ph,P⁻
 C6H4,[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

G2:SO2,[*12]

G3:Ph,H,[*4],[*13],[*14]

G4:H,CH3,i-Pr,t-Bu,[*1],[*9],[*10]

G5:O,S,NH

Connectivity :
 120:4 X maximum C chain 121:4 X maximum C chain 128:3 X maximum C
 chain
 Match level :

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal653adk

PASSWORD :
 * * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
 SESSION RESUMED IN FILE 'REGISTRY' AT 11:34:12 ON 09 SEP 2004
 FILE 'REGISTRY' ENTERED AT 11:34:12 ON 09 SEP 2004
 COPYRIGHT (C) 2004 American Chemical Society (ACS)
 COST IN U.S. DOLLARS
 TOTAL
 SINCE FILE
 ENTRY
 SESSION

FULL ESTIMATED COST 21.90
 181.95
 => d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
 STRUCTURE UPLOADED

L2 50 S L1 SAM
 L3 308369 S L1 FULL

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
 44 S L2
 L5 0 S L4 AND PD<20000217

L6 FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
 STRUCTURE UPLOADED

=> s 16 sam
 SAMPLE SEARCH INITIATED 11:34:30 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 36115 TO ITERATE

2.8% PROCESSED 1000 ITERATIONS 38
 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 PROJECTED ITERATIONS: BATCH
 710956 TO 73644
 PROJECTED ANSWERS: 25225 TO 29669

L7 38 SEA SSS SAM L6

=> file reg
 COST IN U.S. DOLLARS
 TOTAL
 SINCE FILE
 ENTRY

SESSION
 FULL ESTIMATED COST 22.32
 182.37

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
 DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: <http://www.cas.org/ONLINE/DBSS/Registryss.html>

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

ENTRY

FULL ESTIMATED COST

0.42

182.79

FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2004 VOL 141 ISS 11
FILE LAST UPDATED: 8 Sep 2004 (20040908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
STRUCTURE UPLOADED

L1 50 S L1 SAM
L2 308369 S L1 FULL
L3

FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
44 S L2
0 S L4 AND PD<20000217

L4
L5
L6 FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
STRUCTURE UPLOADED

L7 38 S L6 SAM

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004

FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004

=> s 17 47 L7

=> d 18 1-5 1b1b

L8 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2004:252189 CAPLUS Full-text
DOCUMENT NUMBER: 140:286142
TITLE: Hybrid polypeptides comprising Ii-key motif
and MHC class I or II-presented epitope of antigen,
allergen

infection,
or tumor antigen as vaccines against
allergy and cancer

INVENTOR(S): Humphreys, Robert E.; Xu, Minzhen
PATENT ASSIGNEE(S): Antigen Express, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
------	------------	------	------	-----------------

20020924	US 2004058881	A1	20040325	US 2002-253286
WO 2004030616	A2	20040415	WO 2003-US28574	
20030912				

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
20020917 US 2002-245871 A
20020924 US 2002-253286 A

L8 ANSWER 2 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:234843 CAPLUS Full-text
DOCUMENT NUMBER: 141:397
TITLE: Structure - activity studies on the
corticotropin
leading to a
minimal sequence necessary for antagonistic
releasing factor antagonist astressin,
rijckers, Dirk T. S.; Kruijtzter, John A. W.;
van
oosterbrugge, Marja; Ronken, Eric; den
Hartog, Jack A.
CORPORATE SOURCE: J. Jiskamp, Rob M. J.
Institute Department of Medicinal Chemistry Utrecht
Pharmaceutical Sciences Faculty of
Sciences, Utrecht University, Utrecht, 3508
Neth.
SOURCE: ChemBiochem (2004), 5(3), 340-348
CODEN: CBCHFX; ISSN: 1439-4227
Wiley-VCH Verlag GmbH & Co. KGaA
PUBLISHER: Journal
DOCUMENT TYPE: English
LANGUAGE: THERE ARE 78 CITED REFERENCES
REFERENCE COUNT:
AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L8 ANSWER 3 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:689567 CAPLUS Full-text
DOCUMENT NUMBER: 139:323782
TITLE: Formation of β -hairpins in L-Pro-Gly
containing
peptides facilitated by 3-aminobenzoic acid
Rao, M. H. V. Ramana; Kumar, S. Kiran;
AUTHOR(S): NMR Center, Indian Institute of Chemical
Kumar, A. C. Hyderabad, 500 007, India
CORPORATE SOURCE: Tetrahedron Letters (2003), 44(39), 7369-
Technology, Hyderabad, 500 007, India
SOURCE: CODEN: TETL; ISSN: 0040-4039
7372 Elsevier Science B.V.
PUBLISHER: Journal
DOCUMENT TYPE: English
LANGUAGE: THERE ARE 28 CITED REFERENCES
REFERENCE COUNT: 28
AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L8 ANSWER 4 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:352159 CAPLUS Full-text
DOCUMENT NUMBER: 138:354246
TITLE: Preparation of benzenes as bone resorption
inhibitors
for treatment of osteoporosis
Fujimoto, Katsumi; Shibata, Tomoyuki;
INVENTOR(S): Echigo, Yuki
Nakamura, Yuji; Sankyo Co., Ltd., Japan
PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 179 pp.
SOURCE: CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	-----	-----	-----
JP 2003128640	A2	20030508	JP 2001-327592	
20011025				
PRIORITY APPLN. INFO.:				
20011025				
OTHER SOURCE(S):				
MARPAT 138:354246				

L8 ANSWER 5 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:903706 CAPLUS Full-text
DOCUMENT NUMBER: 138:217027
TITLE: Regulatory implications of a novel mode of
interaction
of calmodulin with a double IQ-motif target
sequence
from murine dilute myosin V
AUTHOR(S): Martin, Stephen R.; Bayley, Peter M.
CORPORATE SOURCE: Division of Physical Biochemistry, National
Institute
for Medical Research, London, NW7 1AA, UK
SOURCE: CODEN: PRCTEI; ISSN: 0961-8368
PUBLISHER: Cold Spring Harbor Laboratory Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 56
AVAILABLE FOR THIS
THERE ARE 56 CITED REFERENCES
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> s 18 and pd<20020312
22270249 PD<20020312
(PD<20020312)
L9 41 L8 AND PD<20020312
=> s 19 and pd<20000217

20432235 PD<20000217
(PD<20000217)
L10 33 L9 AND PD<20000217

=> s 10 and pd<19990218

3482357 10
19597386 PD<19990218
(PD<19990218)
L11 2918396 10 AND PD<19990218

=> s 110 and pd<19990218
19597386 PD<19990218
(PD<19990218)

L12 32 L10 AND PD<19990218

=> d 112 1-32 ibib abs hitstr hitseq

L12 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999;798844 CAPLUS Full-text
DOCUMENT NUMBER: 132;102416

TITLE: Inhibition of G-protein-coupled receptor
function by

disruption of transmembrane domain

interactions
AUTHOR(S): Tarasova, Nadya I.; Rice, William G.;

Michajda,

CORPORATE SOURCE: Christopher J.
Molecular Aspects of Drug Design Section,
Research Program, NCI-Frederick Cancer

Research and

Development Center, Frederick, MD, 21702,

USA
SOURCE: Journal of Biological Chemistry (1999),
274(49), 34911-34915

PUBLISHER: CODEN: JBCHA3; ISSN: 0021-9258
Molecular American Society for Biochemistry and

DOCUMENT TYPE: Biology
JOURNAL

LANGUAGE: English

AB G-protein-coupled receptors (GPCR) represent a superfamily of proteins that mediate the function of neurotransmitters and peptide hormones and are involved in viral entry and perception of light, smell, and taste. GPCRs are characterized by the presence of seven transmembrane domains (TMs). The authors demonstrate here that structural analogs of individual TMs of GPCRs can serve as potent and specific receptor antagonists. Peptides derived from the transmembrane regions of CXCR4 and CCR5 chemokine receptors specifically inhibited receptor signaling and the in vitro replication of human immunodeficiency virus-1 (HIV-1) at concns. as low as 0.2 µM. Similarly, peptides mimicking the TMs of cholecystokinin receptor A, were found to abolish ligand binding and signaling through the receptor. Neg. charges positioned at the extracellular termini of peptide antagonists appeared to be important for correct

spontaneous insertion of the compds. into the cell membrane and for their activity. Targeting of the specific interactions between transmembrane domains of GPCRs is suggested as a general sequence-based method to disrupt receptor function for application in drug design and for structure-function studies of the receptors.


IT 255884-11-8D, Rhodamine derivative
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)





(Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions with peptides applied to CXCR4 and CCR5 chemokine receptors and cholecystokinin receptor A and HIV-1 virus inhibition)





RN 255884-11-8 CAPLUS
CN L-Aspartic acid, N-acetyl-L-leucyl-L-leucyl-L-phenylalanyl-L-valyl-L-isoleucyl-L-threonyl-L-leucyl-L-prolyl-L-phenylalanyl-L-tryptophyl-L-alanyl-L-valyl-L-α-aspartyl-L-alanyl-L-asparaginy-L-tryptophyl-L-tyrosyl-L-phenylalanylglycyl-L-asparaginy-L-α-aspartyl-L-α-aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







— Bu-i

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L12 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS, on STN
ACCESSION NUMBER: 1999:376757 CAPLUS Full-text
DOCUMENT NUMBER: 131:72651
TITLE: Therapeutic potential of TCR antagonists is
determined

repertoire of
autoreactive T cells
AUTHOR(S):
Lamont, Alan
CORPORATE SOURCE:
Medical
UK


SOURCE:
European Journal of Immunology (1999),
29(6), 1850-1857
CODEN: EJIMAF; ISSN: 0014-2980
PUBLISHER:
Wiley-VCH Verlag GmbH
DOCUMENT TYPE:
Journal
LANGUAGE:
English
AB The use of altered peptide ligands (APL) with TCR antagonist
properties holds promise as an antigen-specific therapy for

autoimmune disorders. We are investigating the therapeutic potential of APL in expt1. autoimmune encephalomyelitis (EAE) using the Acl-9 peptide of myelin basic protein in H-2u mice. Encephalitogenic T cells recognize Acl-9 using residues 361n and 6pro as the major TCR contact sites. Use of position 6 APL is compromised by the heterogeneous nature of the Acl-9-specific repertoire. Here we identify two position 3 APL that act as TCR antagonists on transgenic T cells expressing Acl-9-specific TCR and that inhibit EAE in H-2u mice. However, the therapeutic capacity of these two APL correlated directly with the ability to maximally inhibit activation of a heterogeneous T cell pool. The implications of these findings for the requirements for EAE induction, the relative contribution of a given T cell subpopulation to pathol. and the mechanism underlying EAE inhibition in this model are discussed.


IT 229156-75-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (uses)

(therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells) RN 229156-75-6 CAPLUS CN L-Arginimide, N-acetyl-L-alanyl-L-seryl-L-isoleucyl-L-tyrosyl-L-arginyl-L-prolyl-L-seryl-L-glutaminy1- (9CI) (CA INDEX NAME) Absolute stereochemistry.



PAGE 1-A




PAGE 2-A


IT 229156-75-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (uses)

(therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells) RN 229156-75-6 CAPLUS CN L-Arginimide, N-acetyl-L-alanyl-L-seryl-L-isoleucyl-L-tyrosyl-L-arginyl-L-prolyl-L-seryl-L-glutaminy1- (9CI) (CA INDEX NAME) NTE modified SEQ 1 ASIVRPSQR Absolute stereochemistry.



PAGE 1-A



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT



L12 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:677800 CAPLUS Full-text
 DOCUMENT NUMBER: 129:276355
 TITLE: Preparation of peptides and peptidomimetics
 as VLA-4

INVENTOR(S): antagonists
 Thomas S. He, Ya-Bo; Ellices, Mariano J.; Arrhenius,
 PATENT ASSIGNEE(S): Cytel Corporation, USA
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 English
 PATENT INFORMATION:

DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT:
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.
WO 9842656	A1	19981001	WO 1998-US5709

19980320 <--
 W: CA, JP
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
 NL, PT, SE
 PRIORITY APPLN. INFO.: US 1997-821825
 19970321
 OTHER SOURCE(S): MARPAT 129:276355
 GI




AB


Title compds. I [R1 = alkyl, adamantyl, (un)substituted non-heterocyclic, heterocyclic, aromatic, or partially or fully saturated ring; R2 = lower alkyl, alkenyl, or alkynyl group in which each group optionally can contain a carbonyl, ether, thioether, aminocarbonyl group, etc., or E-C(R7)-F where R7 = S, O; E = CX1X2, NX3, or O; F = CX4X5, NX6, or O; X1-X6 = independently H or a lower alkyl], with the proviso that E and F are not simultaneously oxygen atoms and if R1 is an alkyl group, R2 must be of formula E-C(R7)-F; R3 = 5-, 6-, 6,5-, or 6,6-membered aromatic ring optionally containing 1-3 heteroatoms selected from the group O, N, S; R4 = H, lower alkyl; R5 = H, lower alkyl, (un)substituted lower alkyl, amido group, or a 5- or 6-membered non-heterocyclic saturated ring connected directly by a bond or through a lower alkyl group; R6 = substituted azepine, or CH(R8)COAR9R10 where A = N, O; R8 = H, lower alkyl, hydroxyalkyl, thioalkyl, a ring structure connected directly by a bond or through a lower alkyl group, or R8 and R9 together form a ring structure, etc.; R9 = lower alkyl, hydroxyalkyl, morpholino group, or together with R10 form a ring structure; R10 = (un)substituted lower alkyl, or together with R9 form a ring structure; when A = O, R10 is absent] and pharmaceutically-acceptable derivs. thereof, were prepared as VLA-4 antagonists. Thus, II (solution phase preparation given) was assayed for binding inhibition potency (IC50 = 0.4 nM) toward Jurkat cells.

IT 213989-41-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); PREP (Preparation); USES (Uses) (Preparation of peptides and peptidomimetics as VLA-4 antagonists)
 RN 213989-41-4 CAPLUS
 CN L-phenylalaninamide, N-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]]


acetyl]-L-leucyl-L- α -aspartyl-N-[2-(dimethylamino)ethyl]-N-methyl]-
(9CI) (CA INDEX NAME)
Absolute stereochemistry.




PAGE 1-B



IT 213989-41-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study; unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); PREP (Preparation); USES (uses)
BIOL (Biological study); PREP (Preparation); USES (uses)
(Preparation of peptides and peptidomimetics as VLA-4
antagonists)
RN 213989-41-4, CAPLUS
CN L-phenylalaninamide, N-[[4-[[[(2-
methylphenyl)amino]carbonyl]amino]phenyl]
acetyl]-L-leucyl-L- α -aspartyl-N-[2-(dimethylamino)ethyl]-N-
methyl]-
(9CI) (CA INDEX NAME)
Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT
L12 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:672073 CAPLUS Full-text
DOCUMENT NUMBER: 130:22096
TITLE: Identification of inhibitors of prohormone
convertases
Library
AUTHOR(S): Apletalina, Ekaterina; Appel, Jon; Lamango,
Nazarius
CORPORATE SOURCE: S.; Houghten, Richard A.; Linberg, Iris
Biology, Department of Biochemistry and Molecular
New Louisiana State University Medical Center,
Orleans, LA, 70112, USA
SOURCE: Journal of Biological Chemistry (1998),
273(41), 26589-26595
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and
Molecular Biology
DOCUMENT TYPE: English
LANGUAGE: Journal
AB A positional scanning synthetic peptide combinatorial library
contg. approx. 52 million hexapeptides was used to identify
potential inhibitory peptides for recombinant mouse prohormone

convertase 1 (PC1) and PC2 and to provide information on the specificity of these enzymes. The library surveys revealed that a p6 Leu, a p4 Arg, a p2 Lys, and a p1 Arg were most inhibitory against PC1, and a p6 Ile and a p4 Arg were most inhibitory against PC2. Using information derived from the library surveys, hexapeptide sets were synthesized and screened for inhibition of PC1 and PC2. The data obtained revealed the preference of both enzymes for a p3 Val. At p5, many substitutions were well tolerated. PC1 and PC2 proved to differ mainly in the selectivity of their S6 substrates. In PC1, this subite displayed a strong preference toward occupation by Leu; the Ki value for peptide Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2 was 28 times lower than that for peptide Ac-Ile-Ile-Arg-Val-Lys-Arg-NH2. In contrast, PC2 discriminated little between Leu and Ile at p6, as evidenced by the small (1.5-fold) difference in Ki values for these two peptides. Several hexapeptides synthesized as a result of the screen were found to represent potent inhibitors of PC2 (with Ki values in the sub-micromolar range) and, particularly, of PC1 (with Ki values in the low nanomolar range). The most potent inhibitor, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2, proved to be the same peptide for both enzymes and inhibited PC1 and PC2 in a competitive, fast-binding manner with Ki values of 3.2 and 360 nM, resp. The four most potent peptide inhibitors of PC1 and PC2 were also tested against soluble human furin and found to exhibit a different rank order of inhibition; for example, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2 was 440-fold less potent against furin than against PC1, with a Ki of 1400 nM.




IT 216384-08-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library)

RN 216384-08-6 CAPLUS

CN L-Arginamide, N-acetyl-L-α-glutamyl-L-isoleucyl-L-arginyl-L-valyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 216384-08-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library)




RN 216384-08-6 CAPLUS

CN L-Arginamide, N-acetyl-L-α-glutamyl-L-isoleucyl-L-arginyl-L-valyl-L-lysyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 EIRVKR

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

45 THERE ARE 45 CITED REFERENCES

RE FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE

L12 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:635612 CAPLUS Full-text
DOCUMENT NUMBER: 129:254976
TITLE: Method to treat microbial infections by
uncoupling of phosphotransferase system, and appropriate
agents

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

therefor
Erni, Bernhard
Arpida, Switz,
Eur. Pat. Appl., 25 pp.
CODEN: EPXDDW
English
2

DATE PATENT NO. KIND DATE APPLICATION NO.

EP 866075 A2 19980923 EP 1998-101704
19980202 <--
EP 866075 A3 20000607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO
JP 10327894 A2 19981215 JP 1998-52878
19980218 <--
19970219



PRIORITY APPLN. INFO.:
AB The bacterial phosphotransferase system (PTS) as a drug target
system catalyzes the uptake and phosphorylation of
carbohydrates. It is further involved in signal transduction,
e.g. catabolite repression, chemotaxis, and allosteric
regulation of metabolic enzymes and transporters. It is
ubiquitous in bacteria but does not occur in eukaryotes. This
uniqueness and the pleiotropic function make the PTS a target
for the development of new antimicrobials. Assays are described
that lead to the discovery of compds. which uncouple the PTS, by
acting as protein histidine/cysteine phosphatases. Uncoupling
of the PTS leads to inhibition of carbohydrate transport,
repression of catabolite controlled genes (e.g. certain
virulence genes) and depletion of phosphoenolpyruvate. Compds.
from combinatorial libraries with high affinity for
phosphoenolpyruvate-protein-phosphatase (Enzyme I) serve as lead
structures for the development of inhibitors and uncouplers of
the PTS. Sequences and inhibitory activities of a number of
identified peptides are included.

IT 213541-14-1
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); PAP (Properties); THU (Therapeutic use);



BIOL (Biological study); USES (Uses)
(agents and method to treat microbial infections by
uncoupling of phosphotransferase system)

RN 213541-14-1 CAPLUS
CN Glycine, N-acetyl-L-methionyl-L-arginyl-L-leucyl-L-
lysyl-L-threonyl-L-leucyl-L-cysteinyl-L-phenylalanylglycyl-L-leucyl-L-
cysteinyl- (CA INDEX NAME)
(9CI)

Absolute stereochemistry.



Absolute stereochemistry.



IT 213541-14-1
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL
 (Biological study); USES (Uses)
 (agents and method to treat microbial infections by
 uncoupling of
 phosphotransferase system)
 RN 213541-14-1 CAPLUS
 CN Glycine, N-acetyl-L-methionyl-L-arginyl-L-leucyl-L-
 lysyl-L-
 threonyl-L-leucyl-L-cysteinyl-L-phenylalanyl-L-leucyl-L-
 cysteinyl-
 (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 MRLKLTLCFG LCG

L12 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:597874 CAPLUS Full-text
 DOCUMENT NUMBER: 130:930
 TITLE: Gene transfer method using oligopeptides
 AUTHOR(S): Ohmori, Naoya; Nidome, Takuro; Wada,
 Akihito;
 Haruhiko
 CORPORATE SOURCE: Faculty of Engineering, Nagasaki University,
 Nagasaki,
 SOURCE: 852, Japan
 Peptide Symposium, 24th, Edinburgh, Sept. 8-13, 1996

(
 Editor(s):
 scientific:
 Ramage, Robert; Epton, Roger. Mayflower
 1998), Meeting Date 1996, 691-692.


DOCUMENT TYPE:
 LANGUAGE:
 AB
 Cationic amphiphilic α -helical peptides which interact with
 lipid bilayers could bind plasmid DNA and were able to transfer
 a luciferase reporter gene into COS-7 cells. Furthermore, the
 transfection ability of the peptides was increased by addition
 of chloroquine in the transfection procedure. This result
 indicated that the internalization of the peptide/DNA aggregates
 was mediated by an endocytosis pathway.

IT 215664-55-4
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); BUU (Biological use, unclassified); BIOL
 (Biological study); USES (Uses)
 (gene transfer method using oligopeptides)


RN 215664-55-4 CAPLUS
 CN L-leucinamide, N-acetyl-L-leucyl-L-alanyl-L-arginyl-L-
 leucyl-L-alanyl-L-arginyl-L-seryl-L-leucyl-L-arginyl-L-alanyl-L-
 arginyl-L-seryl-L-alanyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-L-
 seryl-L-arginyl-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




PAGE 2-B





IT 215664-55-4
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); BUU (Biological use, unclassified); BIOL
 (Biological study); USES (Uses)
 (gene transfer method using oligopeptides)
 RN 215664-55-4 CAPLUS
 CN L-leucinamide, N-acetyl-L-leucyl-L-alanyl-L-arginyl-L-
 leucyl-L-alanyl-L-arginyl-L-seryl-L-leucyl-L-arginyl-L-alanyl-L-
 arginyl-L-seryl-L-alanyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-L-
 seryl-L-arginyl-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)
 NTE modified

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS, ON STN
 ACCESSION NUMBER: 1998:324816 CAPLUS Full-text
 DOCUMENT NUMBER: 129:12757
 TITLE: Peptide inhibitors of TNF containing predominantly

INVENTOR(S): D-amino acids
 Shealy, David
 PATENT ASSIGNEE(S): Heavner, George A.; Kruszynski, Marian;
 SOURCE: Centocor, Inc., USA
 U.S.: 12 pp.
 CODEN: USXXAM
 LANGUAGE: Patent
 English
 DOCUMENT TYPE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.
US 5753628	A	19980519	US 1995-482009
19950607			US 1995-482009

PRIORITY APPLN. INFO.:
 19950607
 OTHER SOURCE(S): MARRPAT 129:12757


AB Peptides are disclosed which consist of 6-8 predominately D-amino acids and which bind to TNF- α , prevent TNF- α from binding to its receptors, and inhibit TNF- α activity. Methods of inhibiting TNF- α activity and of treating individuals suffering from TNF- α -mediated diseases and disorders are disclosed.

IT 207789-41-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide inhibitors of TNF containing predominantly D-amino acids) 207789-41-1 CAPLUS CN L-methioninamide, N-acetyl-L-histidyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)



IT 207789-41-1 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide inhibitors of TNF containing predominantly D-amino acids) 207789-41-1 CAPLUS CN L-methioninamide, N-acetyl-L-histidyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:323270 CAPLUS Eui]-text
 DOCUMENT NUMBER: 129:16388
 TITLE: Preparation of constrained helical peptides
 INVENTOR(S): Braisted, Andrew; Judice, J. Kevin;
 McDowell, Robert
 McJessa A.;
 S.; Phelan, J. Christopher; Starovasnik, Wells, James A.
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 281 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 119
 PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19971105	WO 9820036	A1	19980514	WO 1997-US20069
19971105	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	19971105	19980529	AU 1998-54287
19971105	AU 9854287	A1	19980529	AU 1998-54287
19971105	AU 745101	B2	20020314	20020314
19971105	ZA 970947	A	19990505	ZA 1997-9947
19971105	EP 938497	A1	19990901	EP 1997-948165
19971105	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	T2	20010306	JP 1998-521703
19971105	JP 2001503064	A	20040130	NZ 2000-517395
20000309	NZ 517395	A	20040130	NZ 2000-517395

20010525	US 2002058309	A1	20020516	US 2001-866028		LK, LR,	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
US 6642360	B2	20031104				LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
JP 2004520811	T2	20040715	JP 2002-522282			OM, PH,	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
20010530	AU 758921	B2	20030403	AU 2001-57764		TT, TZ,	UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
20010801	AU 759004	B2	20030403	AU 2001-57765		RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT,
JP 2004520810	T2	20040715	JP 2002-522275			BE, CH,	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
US 2003082546	A1	20030501	US 2001-941992			SE, TR,	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
20010828	US 2003207803	A1	20031106	US 2001-143026		TD, TG	EP 1402260
20011019	US 2003170254	A1	20030911	US 2001-17191		20020403	A2 20040331 EP 2002-731246
20011024	US 2003199021	A1	20031023	US 2001-13924		MC, PT,	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
20011025	US 2003008297	A1	20030109	US 2001-997653		IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
20011115	US 2003049681	A1	20030313	US 2001-997514		US 2003148438	A1 20030807 US 2002-145821
20011115	US 2003049682	A1	20030313	US 2001-997573		US 2003170788	A1 20030911 US 2002-145634
20011115	US 2003049638	A1	20030313	US 2001-991157		US 2003166084	A1 20030904 US 2002-146793
20011116	US 2003050457	A1	20030313	US 2001-991172		US 2003134380	A1 20030717 US 2002-147509
20011116	US 2003050457	A1	20030313	US 2001-991172		US 2003180875	A1 20030925 US 2002-147505
20011116	US 2002072496	A1	20020613	US 2001-989279		US 2003199027	A1 20031023 US 2002-152396
20011119	US 2002072067	A1	20020613	US 2001-989722		US 2003068695	A1 20030410 US 2002-192012
20011119	US 2002072092	A1	20020613	US 2001-989723		US 2003068696	A1 20030410 US 2002-192014
20011119	US 2002072497	A1	20020613	US 2001-989727		US 2003049743	A1 20030313 US 2002-194394
20011119	US 2003130182	A1	20030710	US 2001-989862		US 2003049745	A1 20030313 US 2002-194485
20011119	EP 1397383	A2	20040317	EP 2001-990229		US 2003064446	A1 20030403 US 2002-194460
20011213	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,					US 2003153037	A1 20030814 US 2002-194457
MC, PT,	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					US 2003059879	A1 20030327 US 2002-194456
20020201	AU 772759	B2	20040506	AU 2002-14767		US 2003064448	A1 20030403 US 2002-194484
20020201	AU 772723	B2	20040506	AU 2002-14769		US 2003049747	A1 20030313 US 2002-195899
20020201	AU 772734	B2	20040506	AU 2002-14771		US 2003064449	A1 20030403 US 2002-195884
20020201	WO 2002101069	A2	20021219	WO 2002-US10513		US 2003063112	A1 20030403 US 2002-195896
20020403	WO 2002101069	A3	20030904			US 2003068705	A1 20030410 US 2002-195886
CH, CN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,					US 2003068706	A1 20030410 US 2002-195891
DE, GH,	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,						


20020715	US 2003071834	A1	20030417	US 2002-195898	20021126		A1	20031023	US 2003-410552	
20020715	US 2003049749	A1	20030313	US 2002-196750	US 2003199044				US 1996-743698	A
20020716	US 2003065159	A1	20030403	US 2002-196757	20030408				US 1997-876698	A
20020716	US 2003068710	A1	20030410	US 2002-196761	PRIORITY APPLN. INFO.:				US 1997-49787P	P
20020716	US 2003104547	A1	20030605	US 2002-197701	19970616				US 1997-62250P	P
20020717	US 2003104548	A1	20030605	US 2002-197706	19971017				US 1997-63564P	P
20020717	US 2003207398	A1	20031106	US 2002-198759	19971028				US 1997-63870P	P
20020718	US 2003215910	A1	20031120	US 2002-199463	19971031				US 1997-965056	A1
20020723	US 2003180881	A1	20030925	US 2002-202475	19971105				WO 1997-US20069	W
20020726	US 2003064462	A1	20030403	US 2002-206919	19971105				US 1997-65186P	P
20020726	US 2003064463	A1	20030403	US 2002-206922	19971112				US 1997-65311P	P
20020726	US 2003068756	A1	20030410	US 2002-206912	19971113				US 1997-66770P	P
20020726	US 2003068759	A1	20030410	US 2002-206920	19971124				US 1998-75945P	P
20020726	US 2003068760	A1	20030410	US 2002-206921	19980225				US 1998-78910P	P
20020726	US 2003073183	A1	20030417	US 2002-206917	19980320				US 1998-82704P	P
20020726	US 2003096359	A1	20030522	US 2002-205910	19980422				US 1998-83322P	P
20020726	US 2004048334	A1	20040311	US 2002-205890	19980428				US 1998-84600P	P
20020726	US 2003068765	A1	20030410	US 2002-207916	19980507				US 1998-85339P	A1
20020729	US 2003068766	A1	20030410	US 2002-207917	19980513				US 1998-87106P	P
20020729	US 2003068769	A1	20030410	US 2002-207920	19980528				US 1998-87607P	P
20020729	US 2003068773	A1	20030410	US 2002-208023	19980602				US 1998-87609P	P
20020729	US 2003068774	A1	20030410	US 2002-208026	19980602				US 1998-87759P	P
20020729	US 2003073184	A1	20030417	US 2002-207923	19980602				US 1998-87827P	P
20020729	US 2003073185	A1	20030417	US 2002-207924	19980603				US 1998-88021P	P
20020729	US 2003215912	A1	20031120	US 2002-207915	19980604				US 1998-88025P	P
20020729	US 2004048335	A1	20040311	US 2002-208024	19980604				US 1998-88026P	P
20021105	US 2003120056	A1	20030626	US 2002-289498	19980604				US 1998-88028P	P
20021105	US 2003144498	A1	20030731	US 2002-289527	19980604				US 1998-88029P	P
20021105	US 2003224984	A1	20031204	US 2002-305654	19980604					


19980604	US 1998-88030P	P	19990309	US 1999-267213	BI
19980604	US 1998-88033P	P	19990312	US 1999-284291	BI
19980604	US 1998-88326P	P	19990412	US 1999-131293P	P
19980605	US 1998-88167P	P	19990427	US 1999-380139	AI
19980605	US 1998-88202P	P	19990625	US 1999-920594	A
19980605	US 1998-88212P	P	19990908	US 1999-921090	A
19980605	US 1998-88217P	P	19990915	WO 1999-US21090	A
19980609	US 1998-88655P	P	19990915	WO 1999-US21547	A
19980610	US 1998-88734P	P	19990915	US 1999-403296	BI
19980610	US 1998-88738P	P	19991018	WO 1999-US28313	W
19980610	US 1998-88742P	P	19991130	WO 1999-US28301	W
19980610	US 1998-88810P	P	19991201	WO 1999-US28634	W
19980610	US 1998-88824P	P	19991201	WO 1999-US30095	W
19980610	US 1998-88826P	P	19991216	US 1999-99309	A
19980610	US 1998-88858P	P	19991220	WO 1999-US30911	W
19980611	US 1998-88861P	P	19991220	WO 2000-US219	W
19980619	US 1998-89947P	P	20000105	WO 2000-US376	W
19980730	US 1998-94651P	AI	20000106	WO 2000-US3565	W
19980826	US 1998-97974P	P	20000211	WO 2000-US4341	A
19980914	AU 1998-93881	A3	20000218	US 2000-441400	A
19980917	WO 1998-US19437	A	20000222	WO 2000-US4414	A
19981002	AU 1998-93178	A3	20000222	WO 2000-US4914	W
19981007	WO 1998-US21141	A	20000224	WO 2000-US5004	W
19981201	WO 1998-US25108	A	20000224	WO 2000-US5841	A
19981216	US 1998-216021	BI	20000302	WO 2000-US6471	W
19981222	US 1998-218517	BI	20000309	WO 2000-US6319	W
19990105	WO 1999-US106	A	20000310	WO 2000-US6884	W
19990303	US 1999-254311	AI	20000315	WO 2000-US7377	W
	US 1999-254460	BI	20000320		

20000330	WO 2000-US8439	A
20000418	US 2000-198121P	P
20000418	US 2000-198585P	P
20000425	US 2000-199397P	P
20000425	US 2000-199550P	P
20000503	US 2000-201516P	P
20000515	WO 2000-US13358	A
20000517	US 2000-204675P	P
20000517	WO 2000-US13705	A
20000522	WO 2000-US14042	A
20000530	WO 2000-US14941	A
20000602	WO 2000-US15264	A
20000728	WO 2000-US20710	A
20000811	WO 2000-US22031	A
20000823	WO 2000-US23522	A
20000824	WO 2000-US23328	A
20000915	US 2000-232887P	P
20001016	US 2000-690189	A3
20001108	WO 2000-US30952	A
20010314	US 2001-808689	B1
20010515	US 2001-854816	A1
20010525	US 2001-866034	A1
20010530	WO 2001-US17443	W
20010601	US 2001-872035	B1
20010601	WO 2001-US17800	A
20010612	US 2001-880457	A
20010614	US 2001-882636	B1
20010620	WO 2001-US19692	A
	WO 2001-US21066	A

20010629	WO 2001-US21735	A
20010709	WO 2001-US26626	W
20010823	US 2001-2796	A
20011115	WO 2001-US48938	W
20011213	US 2002-52586	A1
20020115	WO 2002-US10513	W
20020403	<p>Cyclic peptides, e.g.: [NHCO(CH₂)_mCH(NHX)CO-Z- NHCH(COYs)(CH₂)_n[(CH₂)_n is attached to NH end groups, S is absent or is a macromol., X is H or is any amino acid or amino acid sequence, Y is absent or is hydroxyl if S is absent or is any amino acid or amino acid sequence, Z is any amino acid sequence consisting of six amino acids, m and p are 0-6, n is an integer greater than zero], with constrained region(s) having an α-helical conformation, were prepared Constrained helical peptides having amino acid sequences from HIV gp41 are provided, as is their use in preparing antibodies that prevent viral membrane fusion. Thus, cyclic peptide FNM(5)QQRPR(6)ALH (5 and 6 represent glutamic acid residues cyclized via 1,5-pentanediamine) was prepared by standard solid phase protocols.</p>	
IT 185335-90-4P	<p>RL: PRP (Properties): SPN (Synthetic preparation); PREP (Preparation) RN 185335-90-4 CAPLUS CN L-Alaninamide, N-acetyl-L-alanyl-L-α-glutamyl-L- glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-phenylalanyl-L-leucyl-N- methyl-L-glutaminy-L-alanyl-L-histidyl- (9CI) (CA INDEX NAME)</p>	



Absolute stereochemistry.





IT 185335-90-4P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP
 (Preparation)
 RN 185335-90-4 CAPLUS
 (Preparation of constrained helical peptides)
 CN L-Alaninamide, N-acetyl-L-alanyl-L- α -glutamyl-N-methyl-L-glutaminyl-L-alanyl-L-alanyl-L-tyrosyl-L-phenylalanyl-L-leucyl-N-methyl-L-glutaminyl-L-alanyl-L-histidyl- (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 AEQAAKFLQ AHA

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:249083 CAPLUS Full-text
 DOCUMENT NUMBER: 129:64810
 TITLE: Substrate specificity of mammalian prenyl protein-specific endoprotease activity.

[Erratum to

AUTHOR(S): Jang, Geeng-Fu; Gelb, Michael H.
 CORPORATE SOURCE: Departments of Chemistry and Biochemistry,
 University of Washington, Seattle, WA, 98195, USA

SOURCE: Biochemistry (1998), 37(15), 5336
 CODEN: BICHAW; ISSN: 0006-2960


PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

LANGUAGE: English
AB The following paragraph should have been included on page 4481: Supporting Information Available: Description of the synthesis of the peptides used in this paper and attempts to further purify PEP activity (19 pages). Ordering information is given on any current masthead page.


IT 205696-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study)
(Biological study); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(substrate specificity of mammalian prenyl protein-specific endoprotease activity (Erratum))

RN 205696-27-1 CAPLUS
CN L-Leucine, N-acetyl-S-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-L-cysteinyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B




IT 205696-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study); SPN (Synthetic preparation); BIOL


(Biological study); PREP (Preparation)
(substrate specificity of mammalian prenyl protein-specific endoprotease activity (Erratum))
RN 205696-27-1 CAPLUS
CN L-Leucine, N-acetyl-S-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-L-cysteinyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)
SEQ 1 CIVL

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B



L12 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:161340 CAPLUS Full-text
DOCUMENT NUMBER: 128:280150
TITLE: Substrate Specificity of Mammalian Prenyl Protein-Specific Endoprotease Activity
AUTHOR(S): Jang, Geeng-Fu; Gelb, Michael H.
CORPORATE SOURCE: Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195, USA
SOURCE: Biochemistry (1998), 37(13), 4473-4481


The authors have previously identified proteolytic activity in rat liver microsomes that cleaves an intact tripeptide, Val-Ile-Ser, from S-farnesylated Cys-Val-Ile-Ser tetrapeptide. This enzymic activity, termed prenyl protein-specific endoprotease (PEP) activity, has been solubilized in CHAPS and purified 5-fold. To probe the peptide recognition features of PEP activity, 64 tripeptides Ac-Cys(Farnesyl)-a1-a2 were prepared and tested as competitive inhibitors of PEP activity-catalyzed hydrolysis of Ac-Cys(Farnesyl)-Val-Ile-[3H]Ser. It was found that PEP activity prefers large hydrophobic residues in the a1 and a2 positions. A subset of Ac-Cys(Farnesyl)-a1-a2 peptides were prepared in radiolabeled form, and it was found that PEP activity preferences for these substrates correlated well in most cases with the inhibition data. The exception is that Arg in the a1 position does not prevent binding of peptide to PEP activity, but such peptides are poor substrates. The anionic residue Asp in the a2 position is not tolerated by PEP activity. Five farnesylated radiolabeled tetrapeptides, Ac-Cys(Farnesyl)-Phe-Met-[3H]Leu, Ac-Cys(Farnesyl)-Leu-Ile-[3H]Leu, Ac-Cys(Farnesyl)-Leu-Leu-[3H]Leu, Ac-Cys(Farnesyl)-Val-Ile-[3H]Leu were prepared, and PEP activity kinetic studies reveal that they are all good substrates and show comparable KM values (2.2-13.5 μM). Ac-Cys(Farnesyl)-Arg-Leu-[3H]Ser is a poor PEP activity substrate. The reported peptide binding preferences of PEP activity should be useful in designing compds. that block the C-terminal proteolysis of prenylated proteins. Nonprenylated peptides do not bind to PEP activity, and replacement of the farnesyl group with an n-pentadecyl group modestly reduces PEP activity binding. Peptide-membrane partitioning studies are used together with theor. arguments to fully understand the substrate specificity of PEP activity toward these compds.

IT 205696-27-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study; unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (substrate specificity of mammalian prenyl protein-specific endoprotease activity)

RN 205696-27-1 CAPLUS
CN L-Leucine, N-acetyl-S-[(2E,6E)-3,7,11-trimethyl]-2,6,10-dodecatrieny]-L-cysteiny]-L-valyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Abstract stereochemistry.
Double bond geometry as shown.



PAGE 1-B



IT 205696-27-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study; unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (substrate specificity of mammalian prenyl protein-specific endoprotease activity)

RN 205696-27-1 CAPLUS
CN L-Leucine, N-acetyl-S-[(2E,6E)-3,7,11-trimethyl]-2,6,10-dodecatrieny]-L-cysteiny]-L-valyl-L-isoleucyl]- (9CI) (CA INDEX NAME)


NTE modified (modifications unspecified)

SEQ 1 CIVL

Abstract stereochemistry.
Double bond geometry as shown.



PAGE 1-B



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L12 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:147346 CAPLUS Full-text
 DOCUMENT NUMBER: 128:213381
 TITLE: Compositions and methods for treating
 infections using
 INVENTOR(S): analogs of indolicidin
 Krieger, Fraser, Janet R.; West, Michael H. P.;
 PATENT ASSIGNEE(S): Timothy J.; Taylor, Robert; Erfle, Douglas
 Janet R.; Micrologix Biotech, Inc., Can.; Fraser,
 West, Michael H. P.; Krieger, Timothy J.;
 Taylor, Robert; Erfle, Douglas
 SOURCE: PCT Int. Appl., 130 pp.
 DOCUMENT TYPE: CODEN: PIXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 3
 PATENT INFORMATION: 3

DATE PATENT NO. KIND DATE APPLICATION NO.

WO 9807745	A2	19980226	WO 1997-US14779
19970821 <---			
WO 9807745	A3	19980709	
W: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,			
DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR,			
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,			
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,			
UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FI, FR, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,			
CM, GA, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,			
GN, ML, MR, NE, SN, TD, TG			
AU 9743279	A1	19980306	AU 1997-43279
19970821 <---			
EP 925308	A2	19990630	EP 1997-941352
19970821 <---			
EP 925308	B1	20020605	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,			
MC, PT, IE, FI			
JP 2001500477	T2	20010116	JP 1998-510994
19970821 <---			
EP 1174439	A2	20020123	EP 2001-119148
19970821 <---			
EP 1174439	A3	20030326	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,			
MC, PT, IE, FI			
AT 218579	E	20020615	AT 1997-941352
19970821	T3	20021216	ES 1997-941352
ES 2178000			
19970821	A1	20030221	HK 1999-106212
HK 1021824			
19991230			
US 2004009910	A1	20040115	US 2003-351985
20030124			
PRIORITY APPLN. INFO.:			
19960821			
19970113			
US 1997-34949P	P		
19970820			
US 1997-915314	A1		
19970821			
EP 1997-941352	A3		
WO 1997-US14779	W		
19970821			
US 2000-667486	A1		
20000922			
OTHER SOURCE(S):			
MARKPAT 128:213381			

IT 204248-50-0

(Biological)


(Therapeutic)

RN 204248-50-0 CAPLUS

prolyl

NAME)

PAGE 1-A



IT 204248-50-0

(Biological)

(Therapeutic


RN 204248-50-0 CAPLUS

tryptophy]-L-

(CA INDEX)

3

PAGE 1-A



AUTHOR(S): Phe1an, J. Christopher; Skelton, Nicholas J.;

CORPORATE SOURCE: Department of Bioorganic Chemistry and Protein Engineering, Genentech Inc., South San Francisco, CA 94080

SOURCE: Francisco, CA, 94080, USA
Journal of the American Chemical Society

) 119(3), 455-460
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: journal
 LANGUAGE: English
 AB A method for constraining short peptides (confg.


A method for constraining short peptides (contg. fewer than 20 residues) of an arbitrary sequence to an α -helical conformation (approx. 100% helical in H₂O at 25 °C) is presented. Gln residues at positions *i* and *i* + 7 of the peptides were tethered with an alkanediyl chain between the side chain nitrogen atoms. Peptides containing this tether were readily synthesized on the solid phase by amide formation between an α,ω -diaminokane and the side chain carboxylates of Glu residues. The resulting cyclic peptides were studied by NMR and CD and were found to adopt an α -helical conformation in aqueous solution and this α -helix was thermally stable to $\geq 40^\circ$. Corresponding untethered

(preparation of short peptides constrained to an α -helical conformation)


RN	185335-90-4	CAPLUS
CN	L- γ -aminoamide, N-acetyl-L-alanyl-L- α -glutamyl-N-methyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-phenylalanyl-L-leucyl-N-methyl-L-	
	glutaminyl-L-alanyl-L-histidyl- (9CI)	(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




IT 185335-90-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of short peptides constrained to an α -helical conformation)
 RN 185335-90-4 CAPLUS
 CN L-Alaninamide, N-acetyl-L-alanyl-L- α -glutamyl-N-methyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-phenylalanyl-L-leucyl-N-methyl-L-glutamyl-L-alanyl-L-histidyl- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 AEQAAKFLQ AHA

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B

L12 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1996:661297 CAPLUS Full-text
 DOCUMENT NUMBER: 125:32829
 TITLE: Cell wall synthesis is a major target of mycoparasitic

AUTHOR(S): antagonism by *Trichoderma harzianum* Lortito, Matteo; Farkas, Vladimir; Rebuffat, Sylvie;

CORPORATE SOURCE: Bodo, Bernard; Kubicek, Christian P. Inst. Biochem. Technol. Microbiol., univ. Vienna, A-1060, Austria

SOURCE: Journal of bacteriology (1996), 178(21), 6382-6385

PUBLISHER: CODEN: JOBAAY; ISSN: 0021-9193
 DOCUMENT TYPE: American Society for Microbiology Journal

LANGUAGE: English

AB We have investigated the mol. basis for the reported synergism between peptaibols and cell wall hydrolytic enzymes in the antagonism of phytopathogenic fungi by *Trichoderma harzianum*.

β -glucan synthase activity on isolated plasma membranes of *Botrytis cinerea* was inhibited in vitro by the peptaibols trichorzianin TA and TB, and this inhibition was reversed by the addition of phosphatidylcholine. β -glucan synthesis in vivo, assayed by the incorporation of [3 H]glucose into cell wall material, was inhibited by the presence of peptaibols, and this inhibition was synergistic with exogenously added T. *harzianum* β -1,3-glucanase. This synergism is therefore explained by an inhibition of the membrane-bound β -1,3-glucan synthase of the host by the peptaibols, which inhibit the resynthesis of cell wall β -glucans, sustain the disruptive action of β -glucanases, and all together enhance the fungicidal activity. Therefore, we have identified cell wall turnover as a major target of mycoparasitic antagonism.




IT 109173-30-0, Trichorzianin A IIA

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)




antagonism by (cell wall synthesis is major target of mycoparasitic

antagonism by *Trichoderma harzianum*)

RN 109173-30-0 CAPLUS
 CN Trichorzianin A IIA (9CI) (CA INDEX NAME)



IT 109173-30-0, Trichorzianin A IIa
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); BIOL (Biological study)
 (Cell wall synthesis is major target of mycoparasitic
 antagonism by Trichoderma harzianum)
 RN 109173-30-0 CAPLUS
 CN Trichorzianin A IIa (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 XAAXXQXXS LXPLXIQW



Me

L12 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1996:610213 CAPLUS Full-text
 DOCUMENT NUMBER: 125:296665

TITLE: Scanning synthetic peptide combinatorial
 libraries: oligopeptide mixture sets having one

predetermined

methods

INVENTOR(S):

Houghten, of making and using the same
 Houghten, Pinilla, Clementia; Appel, Jon R., Jr.;

SOURCE: Richard A.
 Houghten Pharmaceutical Inc., USA
 U.S. Pat. 75 pp., Cont.-in-part of U.S. Ser. No.
 767,551, abandoned.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.
US 5556762	A	19960917	US 1992-943709
19920911 <--	AA	19920522	CA 1991-2090860
CA 2090860	C	20030916	AT 1992-902209
19911120 <--	E	19990215	


ES 2129442 T3 19990616 ES 1992-902209
 19911120 <-- B1 20010306 US 1993-63279
 19930518 <-- A 19960402 US 1994-253854
 US 5504190
 19940603 <--
 PRIORITY APPLN. INFO.:
 19901121

19910516 US 1991-701658 B2
 19911119 US 1991-797551 B2
 US 1992-943709 A2

19920911
 AB Synthetic peptide combinatorial libraries (sets) having a single, predetd. amino acid residue at a single, predetd. oligopeptide chain position and mixts. of amino acid residues at the other chain positions are disclosed, as are their processes of synthesis and use in determining the amino acid residue sequence of an oligopeptide ligand that binds to an acceptor mol.; e.g., antibody, antibody combining site-containing antibody fragment, or cell receptor. A major benefit of this invention is the facilitation of the formation and identification of specific biol. active oligopeptide sequences for pharmaceutical, diagnostic, and other uses, especially those oligopeptide sequences that are of particular efficacy for the therapeutic treatment of target diseases. The peptides were used in studies of: binding inhibition of a monoclonal antibody, binding to opioid receptors, inhibition of melittin hemolysis activity, and inhibition of trypsin.


IT 182569-95-5P
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (Scanning synthetic peptide combinatorial libraries and oligopeptide mixture sets with 1 predetd. residue at 1 predetd. position)
 RN 182569-95-5 CAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-L-isoleucyl-L-L-valyl-L-L-isoleucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 182569-95-5P
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (Scanning synthetic peptide combinatorial libraries and oligopeptide mixture sets with 1 predetd. residue at 1 predetd. position)
 RN 182569-95-5 CAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-L-isoleucyl-L-L-valyl-L-L-isoleucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 IVIFAF

Absolute stereochemistry.



L12 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1995:996893 CAPLUS Full-text
 DOCUMENT NUMBER: 124:76493
 TITLE: Peptides for inhibition of human immunodeficiency virus (HIV) Schramm, Wolfgang, Germany; Schramm, Hans J. ger. Offen., 7 pp.
 PATENT ASSIGNEE(S):
 SOURCE:

DOCUMENT TYPE: CODEN: GWXXBX
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: German

PATENT NO.	KIND	DATE	APPLICATION NO.
DE 4412174	A1	19951019	DE 1994-4412174
19940408 <--			
EP 680973	A1	19951108	EP 1995-105382
19950410 <--			
R: DE, ES, FR, GB, IT			
PRIORITY APPLN. INFO.:			
19940408		DE 1994-4412174	A


OTHER SOURCE(S): MARPAT 124:76493

Peptides VALA2A3A4X [Y = H, amino acid (esp. Ile, Leu, Met, Phe, Val, Arg), peptide; A1 = Ser, Thr, homoserine, Asn, Glu; A2 = Arg, Tyr, Phe; A3 = Glu, Gln, Asn, Asp; A4 = Leu, Phe, Met, Tyr, Trp, Ile, Nle; X = OH, NH₂, amino acid (especially Glu, Gln, Asp, Asn), peptide] are inhibitors of HIV proteases and can be used for treatment of HIV infections. The peptides assume a β -pleated sheet conformation characteristic of retroviral protease inhibitors. Their therapeutic efficacy can be enhanced by attachment of the peptide at its N-terminus via a linker to a (modified) N-terminal fragment of an HIV protease which may be further conjugated to a carboxylic acid, aliphatic/aromatic hydrocarbon, vitamin, steroid, hormone, antigen, receptor-binding peptide, toxin, cytokine, or a B complex for neutron therapy. Thus, HIV-1 protease was inhibited by the bifunctional peptide LETTLWEXXISYEL (X = 6-aminohexanoic acid linker) with IC₅₀ = 0.5 μ M.

IT 172357-65-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (therapeutic use); BIOL (Biological study); USES (uses)

(HIV)
 RN 172357-65-2 CAPLUS
 CN L-Leucine, N-[N2-[N-[N2-(N2-acetyl)-L-arginyl]-L-arginyll]-L-tyrosyl]-L-asparaginyll]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







IT 172357-65-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (therapeutic use); BIOL (Biological study); USES (uses)

(HIV)
 RN 172357-65-2 CAPLUS
 CN L-Leucine, N-[N2-[N-[N2-(N2-acetyl)-L-arginyll]-L-arginyll]-L-tyrosyl]-L-asparaginyll]- (9CI) (CA INDEX NAME)

NTE modified
 SEQ 1 RRSYNL

Absolute stereochemistry.




Absolute stereochemistry.




IT 165253-65-6P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study; unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (analogs of ribonucleotide reductase, peptide as inhibitor;
 and design of inhibitors for treatment of malaria)
 RN 165253-65-6 CAPLUS
 CN L-Phenylalanine, N2-acetyl-L-glutaminyl-L-lysyl-L-serylglycyl-L-
 valyl-L-
 methionyl-L-alanyl-L-glutaminy-L-arginyl-L-lysyl-L- α -aspartyl-L-
 histidyl-L-valyl-L-phenylalanyl-L-cysteinyl-L-leucyl-L-
 asparaginy-L-
 threonyl-L- α -glutamyl- (9CI) (CA INDEX NAME)
 NTE modified

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1995:673547 CAPLUS Full-text
 DOCUMENT NUMBER: 123:314491
 TITLE: Design and synthesis of a quenched
 fluorogenic peptide
 substrate for human cytomegalovirus

proteinase
 AUTHOR(S):
 Broadhurst,
 Handa, B. K.; Keech, E.; Conway, E. A.;

CORPORATE SOURCE:
 Dep. Physical Methods, Roche Products

SOURCE:
 Garden City, Hertfordshire, AL7 3AY, UK
 Antiviral Chemistry & Chemotherapy (1995),
 6(4), 255-61
 CODEN: ACCHDH; ISSN: 0956-3202
 Blackwell

PUBLISHER:
 DOCUMENT TYPE:
 LANGUAGE:
 Journal
 English

AB A fluorogenic peptide substrate for human cytomegalo virus

proteinase was synthesized by solid-phase peptide synthesis. The amino acid sequence of this substrate is derived from the maturation cleavage site (M site) of the natural substrate, the assembly protein precursor. The min. sequence for efficient cleavage requires at least seven residues (P4-P3'). A systematic modification of the peptide substrate was carried out to identify positions suitable for the introduction of the fluorescent donor and the quencher acceptor groups.

IT 170159-65-6DP, resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT

(Reactant or reagent) (design and synthesis of quenched fluorogenic peptide

substrate for human cytomegalo virus proteinase)

RN 170159-65-6 CAPLUS

CN L-Aspartamide, N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-

benzopyran-6-

yl)sulfonyl]amino]iminomethyl]-N2-[4-[[4-

(dimethylamino)phenyl]azo]benzoyl

]-L-ornithyl]-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-

benzopyran-6-

yl)sulfonyl]amino]iminomethyl]-L-ornithyl]-L-valyl]-L-valyl]-N-

(triphenylmethyl)-L-asparaginyl]-L-alanyl]-O-(1,1-dimethylethyl)-

aminobutanoyl]-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-

benzopyran-6-

yl)sulfonyl]amino]iminomethyl]-L-ornithyl]-L-leucyl]-N4-[2-[(5-


sulfo-1-

naphthalenyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 2-A







IT 170159-65-6DP, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT
 (Reactant or reagent)
 (Design and synthesis of quenched Fluorogenic peptide
 substrate for



human cytomegalovirus proteinase)
 RN 170159-65-6 CAPLUS
 CN L-Aspartamide, N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-
 benzopyran-6-
 y1)sulfonyl]amino]iminomethyl]-N2-[4-[[4-
 (dimethylamino)phenyl]azo]benzoyl
]-L-ornithyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-
 benzopyran-6-
 y1)sulfonyl]amino]iminomethyl]-L-ornithyl-L-valyl-L-valyl-N-
 (triphenylmethyl)-L-asparaginy1-L-alanyl-O-(1,1-dimethylethyl)-
 L-seryl-L-2-
 aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-
 benzopyran-6-
 y1)sulfonyl]amino]iminomethyl]-L-ornithyl-L-leucyl-N4-[2-[(5-
 sulfo-1-
 naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 RRWNASXRL N

Absolute stereochemistry.
 Double bond geometry unknown.






DATE

US 5382569	A	19950117	US 1992-995480	
19921221 <--				
CA 2108754	AA	19921117	CA 1992-2108754	
19920424 <--				
ES 2151888	T3	20010116	ES 1992-923584	
19920424 <--				
CA 2146874	AA	19940707	CA 1993-2146874	
19931217 <--				
WO 9414843	A1	19940707	WO 1993-US12377	
19931217 <--				
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE				
AU 9458280	A1	19940719	AU 1994-58280	
19931217 <--				
AU 679712	B2	19970710		
EP 675902	A1	19951011	EP 1994-904089	
19931217 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,				
NL, PT, SE				
JP 08504823	T2	19960528	JP 1993-515347	
19931217 <--				
JP 3494649	B2	20040209	JP 1994-515347	
19931217				
US 5641752	A	19970624	US 1994-316533	
19940930 <--				
US 5773414	A	19980630	US 1997-813625	
19970307 <--				
PRIORITY APPLN. INFO.:				
19910516				
19911218				
US 1991-701274				B2
19921221				
US 1991-809746				B2
19931217				
WO 1993-US12377				W
19940930				
US 1994-316533				A3
OTHER SOURCE(S):				
AB				
MARPAT 122:282262				
Novel antagonist peptides (Markush included) of endothelin are described, as well as methods for the preparation and pharmaceutical compns. of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinol., neuro. disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes. More than 300 specific peptides are claimed. Preparation of peptides is described, and activities (rat heart ventricle binding assay, inositol phosphate accumulation, arachidonic acid release assay) are included for selected peptides.				


L12 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1995:362667 CAPLUS Full-text
 DOCUMENT NUMBER: 122:282262
 TITLE: Endothelin antagonist peptides
 INVENTOR(S): Cody, Wayne L.; Depue, Patricia; Doherty, Annette M.;
 PATENT ASSIGNEE(S): He, John X.; Taylor, Michael D.
 SOURCE: Warner-Lambert Co., USA
 809, 746, U.S., 32 pp. Cont.-In-part of U.S. Ser. No. abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO.

IT 148003-27-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Endothelin antagonist peptides for therapeutic use)
 RN 148003-27-4 CAPLUS
 CN L-Tryptophan, N-[N-[N-[N-(N-acetyl)-D-tyrosyl]-L-leucyl]-L- α -
 aspartyl]-L-valyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




IT 148003-27-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Endothelin antagonist peptides for therapeutic use)
 RN 148003-27-4 CAPLUS
 CN L-Tryptophan, N-[N-[N-[N-(N-acetyl)-D-tyrosyl]-L-leucyl]-L- α -
 aspartyl]-L-valyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 YLDVIW
 Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



L12 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004, ACS, on STN
 ACCESSION NUMBER: 1995:314153 CAPLUS Full-text
 DOCUMENT NUMBER: 122:106542
 TITLE: Preparation of peptide endothelin
 antagonists.
 INVENTOR(S): Cody, Wayne Livingston; Depue, Patricia;
 Doherty, Annette Marian; He, John Xiaoliang; Taylor,
 Michael Douglas
 PATENT ASSIGNEE(S): Warner-Lambert Co.; USA
 SOURCE: PCT Int. Appl., 145 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.
WO 9414843	A1	19940707	WO 1993-US12377
19931217 <--			
PT, SE			
US 5382569	A	19950117	US 1992-995480
19921221 <--			
AU 9458280	A1	19940719	AU 1994-58280
19931217 <--			
AU 679712	B2	19970710	

EP 672902 A1 19951011 EP 1994-904089
 19931217 <-- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE
 JP 08504823 T2 19960528 JP 1993-515347
 19931217 <-- JP 3494649 B2 20040209 JP 1994-515347
 19931217 JP 3494649 B2 20040209 JP 1994-515347
 PRIORITY APPLN. INFO.:
 19910516 US 1992-995480 A
 19911218 US 1991-701274 B2
 US 1991-809746 B2
 WO 1993-US12377 W
 19931217 MARPAT 122:106542
 OTHER SOURCE(S):
 GI




AB A1A2A3A4A5A6 [I: A1 = RCH[(CH2)NR2]CO, Q1, etc.; n = 0-6; R = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, fluorenylmethyl, NR3R4, OR3, CO2R3, etc.; R2 = H, alkyl, trityl, NR3R4, etc.; R3, R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, fluorenylmethyl; A2-A5 = null, NR1CH[(CH2)NR10]CO, Q2, Q3, etc.; q = 0-4; R10 = H, alkyl, aryl, cycloalkyl, alkenyl, alkynyl, OR3, NR3R4, CONR3R4, etc.; R11 = H, alkyl, aryl; A6 = NR1CH[(CH2)NR12]R13, Q4, etc.; R12 = aryl, heteroaryl, heterocycloalkyl; R13 = (CH2)nCO2H, (CH2)nOH, (CH2)nCONR3R4, etc.; with proviso(s)], were prepared. I are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinol., neurot. disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes. Thus, Ac-D-Dip-Leu-Asp-Ile-Ile-

TRP-OH (Dip = 3,3-diphenylalanyl) (prepared by solid phase synthesis) at 1.0 μM/kg i.v. in rats significantly attenuated systemic depressor response to endothelin-1 but had no effect on pressor responses.
 IT 148003-27-4P
 RL: BAC (biological activity or effector, except adverse); BSU (biological study; unclassified); SPN (synthetic preparation); THU (therapeutic use); PREP (preparation); USES (uses) (preparation of peptide endothelin antagonists)
 RN 148003-27-4 CAPLUS
 CN L-Tryptophan, N-[N-[N-[N-(N-acetyl)-D-tyrosyl]-L-leucyl]-L-α-aspartyl]-L-valyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




PAGE 1-A



IT 148003-27-4P
 RL: BAC (biological activity or effector, except adverse); BSU (biological study; unclassified); SPN (synthetic preparation); THU (therapeutic use); PREP (preparation); USES (uses) (preparation of peptide endothelin antagonists)
 RN 148003-27-4 CAPLUS
 CN L-Tryptophan, N-[N-[N-[N-(N-acetyl)-D-tyrosyl]-L-leucyl]-L-α-aspartyl]-L-valyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 YLDVIW

CC(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

PAGE 1-B



Investigation of antigen-antibody

Library composed of four trillion (4 + 1012) sequences

A.
Torrey pines Institute for molecular

Diego, CA, 92121, USA

CODEN: BIJOAK; ISSN: 0264-6021


CODEN: BJJOAK; ISSN: 0264-6021

Functional-scanning synthetic-peptide


combinatorial library (PS-SPLC) made up of 4 trillion (4.1012) decapeptides was synthesized; its use is illustrated here for the study of a peptide-antibody interaction. This library was prepared by a chemical-mixture approach using a specific ratio of amino acids empirically determined to give approx. equimolar incorporation of each amino acid during each coupling step. Despite the immense number of decapeptides making up each peptide mixture [approx. 200 billion (2.1011)], specific sequences having nanomolar affinities for a peptide-antibody

[illegible]

Absolute stereochemistry.




PAGE 1-A




IT	157206-25-2	RL: USES (uses)
		(in study of antigen-antibody interaction with soluble
		decapeptide library
		composed of 4 trillion sequences)
RN	157206-25-2	CAPLUS
CN		L-Alaninamide, N-acetyl-L- α -aspartyl-L- α -aspartyl-L- α -
		aspartyl-L-valyl-L- α -aspartyl-L- α -aspartyl-L- α -aspartyl-L-
		L- α -aspartyl-L- α -aspartyl- (9CI) (CA INDEX NAME)
MTE	modified	
SEQ	1 DDDVDDDDDA	

Absolute stereochemistry.



PAGE 1-A




L12 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993-671706 CAPLUS Full-text
DOCUMENT NUMBER: 119-271706
TITLE: Endothelin receptor ligands. Multiple D-
amino acid
AUTHOR(S): replacemnt net approach
Gregory Spellmeyer, David C.; Brown, suzy; stauber,
B.; Geysen, H. Mario; Valerio, Robert
Chiron Corp., Emeryville, CA, 94608, USA
CORPORATE SOURCE: Bioorganic & Medicinal Chemistry Letters
SOURCE: (1993)

DOCUMENT TYPE:

AB All possible single and multiple L- and D-amino acid replacements of potent hexapeptide endothelin receptor (ETR) ligand Ac-D-Phe-Orn-Asp-Ile-Tyr-OH were synthesized and tested. While most of these 64 analogs were inactive on the ETRA receptor, three showed submicromolar activity. Interestingly, two of these contain 5 D-amino acids and may be stable to proteolysis.

IT 151378-88-0P
RL: SPN (Synthetic Preparation); PREP (Preparation)
(Preparation and endothelin A receptor binding affinity of
RN 151378-88-0 CAPLUS
CN L-Tryptophan, N-[N-[N-(N-acetyl-L-phenylalanyl)-L-
ornithinyl]-L-isoleucyl]-D-isoleucyl]-9(CI) (CA INDEX NAME)
 α -aspartyl]-L-isoleucyl]-D-isoleucyl]-9(CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 151378-88-0P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and endothelin A receptor binding affinity of)
 RN 151378-88-0 CAPLUS
 CN L-Tryptophan, N-[N-[N-(N2-(N-acetyl)-L-phenylalanyl)-L-ornithyl]-L-
 α -aspartyl]-L-isoleucyl]-D-isoleucyl]- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 FXDIW

Absolute stereochemistry.



L12 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:581212 CAPLUS Full-text

DOCUMENT NUMBER: 119:181212

TITLE: Endothelin receptor ligands. Replacement net approach

AUTHOR(S): to SAR determination of potent hexapeptides
 Gregory Spellmeyer, David C.; Brown, Suzy; Stauber,

CORPORATE SOURCE: B.; Geysen, H. Mario; Valerio, Robert
 SOURCE: Chiron Corp., Emeryville, CA, 94608, USA
 Bioorganic & Medicinal Chemistry Letters


), 3(4), 519-24
 CODEN: BMCL8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English
 AB The SAR of the potent hexapeptide endothelin ligand Ac-D-Phe-Orn-Asp-Ile-Ile-Trp-OH was determined through the systematic replacement of each residue with 50 amino acid substitutes. Multiple peptide synthesis methods allowed the rapid synthesis and screening of all 300 analogs.

IT 150298-32-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and endothelin receptor antagonist activity of)
 RN 150298-32-1 CAPLUS
 CN L-Tryptophan, N-[N-[N2-(N-acetyl)-D-phenylalanyl)-L-ornithyl]-D-
 arginyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 150298-32-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and endothelin receptor antagonist activity of)

RN 150298-32-1 CAPLUS
 CN L-Tryptophan, N-[N-[N2-(N-acetyl)-D-phenylalanyl)-L-ornithyl]-D-
 arginyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

NTE modified


SEQ 1 FXRIW

Absolute stereochemistry.




L12 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1993:517782 CAPLUS Full-text

DOCUMENT NUMBER: 119:117782
 TITLE: Inhibitors of HIV-1 proteinase. Substrate analogs containing substituted aminobenzoic acids as proline mimics
 AUTHOR(S): Xie, J.; Mazaleyrat, J. P.; Savrda, J.; Waksztein, M.
 CORPORATE SOURCE: CNRS, Thiais, F-94320, Fr; Bulletin de la Société Chimique de France (1993), 129(6), 642-54
 SOURCE: CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:117782
 GI




AB A series of title linear peptides, e.g. I [R = Me₃CO₂C (Boc), Ac-Gly], II (R₁ = H, Me) and III (R₂ = CF₃CO, Ac-Gly-Ala; R₃ = Me, Ph), that are simplified analogs of the sequence around the p17-p24 cleavage site of the Pr55gag human immunodeficiency virus (HIV) polypeptide, were prepared by solution peptide synthesis. The above peptides are potential inhibitors (competitive inhibitors, affinity labels, or suicide substrates) of the HIV-1 proteinase. The p1-p1' tyrosyl-proline segment was replaced by phenylalanyl-(phenoxymethyl) or sulfonylmethyl substituted ortho- or meta-aminobenzoic fragments. In order to obtain a closer proline mimic, N-methylation of the aminobenzoic residue was also performed. II (R₁ = H, Me) weakly inhibit the in vitro activity of the enzyme.

IT 149381-37-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and HIV-one proteinase-inhibiting activity of)
 RN 149381-37-3 CAPUS
 CN L-Valine, N-[N-[5-[[N-[N-[N-[N-[1,1-dimethylethoxy)carbonyl]-L-seryl]-L-alanyl]-L-phenylalanyl]methylamino]-2-(phenoxymethyl)benzoyl]-L-isoleucyl]-, methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




IT 149381-37-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and HIV-one proteinase-inhibiting activity of)
 RN 149381-37-3 CAPUS
 CN L-Valine, N-[N-[5-[[N-[N-[N-[N-[1,1-dimethylethoxy)carbonyl]-L-seryl]-L-alanyl]-L-phenylalanyl]methylamino]-2-(phenoxymethyl)benzoyl]-L-isoleucyl]-, methyl ester (9CI) (CA INDEX NAME)
 NTE modified (modifications unspecified)
 SEQ 1 SAAFXIV

Absolute stereochemistry.



IT 148003-27-4P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (Preparation of, as endothelin antagonist)
 RN 148003-27-4 CAPLUS
 CN L-Tryptophan, N-[N-[N-[N-(N-acetyl)-D-tyrosyl]-L-leucyl]-L- α -
 aspartyl]-L-valyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)
 NTE modified
 SEQ 1 YLDVIW

Absolute stereochemistry.



PAGE 1-B

L12 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1992:50877 CAPLUS Full-text
 DOCUMENT NUMBER: 116:50877
 TITLE: structure-function studies of peptides
 inhibiting the
 simple
 ribonucleotide reductase activity of herpes
 virus type I
 AUTHOR(S): Gaudreau, Pierrette; Brazeau, Paul; Richer,
 Manon;
 YES Cormier, Jean; Langlois, Daniel; Langelier,
 CORPORATE SOURCE: Res. Cent., Notre-Dame Hosp., Montreal, QC,


H2L 4M1,
 SOURCE: Can.
 Journal of Medicinal Chemistry (1992),
 35(2), 346-50
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: English
 LANGUAGE: English
 AB AC-Tyr298-Ala299-gly300-Thr301-Val302-Ile303-Asn304-Asp305-
 Leu306-OH [Ac-VZV R2-(298-306)] represents the acetylated form
 of the C-terminus of varicella-zoster virus (VZV) ribonucleotide
 reductase subunit 2 (R2). This peptide possesses a high degree
 of homol. with the C-terminus nonapeptide of the herpes simplex
 virus (HSV) type 1 and II ribonucleotide reductase R2 protein
 and is 15 times more potent than the latter in its in vitro
 inhibition of HSV-1 reductase activity. Accordingly, a new
 series of analogs based on this structure was studied in vitro.

The replacement of Asp305 by Asn, Glu, Gln, Ser, or Cys; of
 Asn304 by Gln or Ser; of Ile303 and Val302 by D-Val; and of
 Tyr298 by Cha. induced an important loss of inhibitory potency.
 The substitution of Asn304 by Asp; of Thr301 by Cys, Ser, or
 Val; of Gly300 by Ala or Val; of Ala299 by Val; or of Tyr298 by
 homophenyl, 4'-fluoro-Phe, 4'-chloro-Phe, 3'-iodo-Tyr, Me-Tyr, or
 For-Trp led to a moderate decrease of the Ac-VZV R2-(298-306)
 potency. The replacement of Val302 by Ile; Ala299 by Cys, Ser,
 or Thr; or the insertion of a six- or eight-carbon chain between
 Tyr298 and the NH₂ terminus either preserved or slightly
 increased the inhibitory potency of Ac-VZV R2-(298-306).
 Finally, the substitution of Tyr298 by Trp or the addition of
 4'-nitro-Phe at the amino terminus resulted in a 3-fold increase
 of potency. Altogether, these results stress the importance of
 the structural integrity of the min. active core 302-306 in
 preserving the inhibitory potency and suggest that further
 studies on monosubstitutions could be directed at the portion
 298-301 of the peptide.

IT 138334-08-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation and herpes virus ribonucleotide reductase
 inhibition by)
 RN 138334-08-4 CAPLUS
 CN L-Leucine, N-[N-[N-[N-(N-acetyl)-L-tyrosyl]-L-
 alanyl][glycyl]-L-
 threonyl]-L-valyl]-L-isoleucyl]-L- α -aspartyl]-L- α -aspartyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 138334-08-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and herpes virus ribonucleotide reductase
 inhibition by)
 CN 138334-08-4 CAPUS
 L-leucine, N-[N-[N-[N-[N-[N-(N-acetyl-L-tyrosyl)]-L-
 alanyl]glycyl]-L-
 threonyl]-L-valyl]-L-isoleucyl]-L- α -aspartyl]-L- α -aspartyl]-
 (9cC) (CA INDEX NAME)

NTE modified

SEQ 1 YAGTVIDDL

Absolute stereochemistry.



L12 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STM
ACCESSION NUMBER: 1989:534755 CAPLUS Full-text
DOCUMENT NUMBER: 111:134755
TITLE: Preparation of decapeptides as LHRH
antagonists having high and slow-acting activity and

histamine

INVENTOR(S) :
Anders;

PATENT ASSIGNEE(S) :
SOURCE :

University of Texas System, USA
PCT Int. Appl., 70 pp.

DOCUMENT TYPE:

FAMILY ACC. NUM. COUNT:

2

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE			

WO 8901944	AL	19890309	WO 1988-US2922
19880824 <--			
LK, LU,	W: AT, AU, BB, BG, BR, CH, DE, DK, FI, GB, HU, JP, KP, KR,		
	MC, MG, MW, NL, NO, RO, SD, SE, SU, US		
MR, NL,	RW: AT, BE, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML,		
	SE, SN, TD, TG		
US 4935491	A	19900619	US 1987-88431
19870824 <--			
AU 8825294	AL	19890331	AU 1988-25294
19880824 <--			


AU 619221	B2	19920123	
EP 377665	A1	19900718	EP 1988-908786
19880824 <---			
EP 377665	B1	19950712	
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE	T2	19910509	JP 1988-507982
JP 03501969			
19880824 <---	A2	19920728	HU 1988-5868
HU 59940			
19880824 <---	B	19970228	
HU 213098	A1	19980203	CA 1988-587364
CA 1339659			
19881230 <---	B1	19980423	KR 1989-700699
KR 135276			
19890421 <---	A	19900419	DK 1990-486
DK 9000486			
19900223 <---	B1	20010910	
DK 173753	A	19900423	NO 1990-888
NO 9000888			
19900223 <---	A	19900423	NO 1994-2179
NO 9402179			
19940610 <---			
PRIORITY APPLN. INFO.:	US 1987-88431	A2	
19870824	WO 1988-US2922	A	
	NO 1990-888	A	

19900223 CASREACT 111:134755


AB Decapeptide analogs of LHRH, e.g. [N-Ac-D-2-Nal¹, D-pc²Phen², D-3-Pal³, Niclys⁵, D-Niclys⁶, Ilys⁸, D-Ala¹⁰-LHRH [2-Nal = 3-(2-naphthyl)alanine, pc²Phen = 3-(4-chlorophenyl)alanine, 3-Pal = 3-(3-pyridyl)alanine, Niclys = Ne-anisotiny¹, Ilys = Ne-isopropyllysine] (1) (Antide) having high ovulation inhibition activity and very low histamine release activity, were prepared I and other decapeptides were synthesized by the solid phase method using a Beckman Model 990 peptide synthesizer, new lysine, ornithine, alanine, glutamic acid and arginine derivs., and benzhydroxylamine hydrochloride resin as a solid support. I showed antiovalatory activity (AOA) of 100% at 1 µg and 36% at 0.5 µg in rats and an ED50 of ≥300 µg/mL for histamine release in a rat mast cell assay.

IT 112443-68-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of, as LHRH antagonist)
 RN 112443-68-2 CAPLUS
 CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(1-methylethyl)-D-lysyl-L-leucyl-N6-(3-pyridinylcarbonyl)-L-lysyl-L-prolyl-(9CI)
 (CA
 INDEX NAME)

Absolute stereochemistry.





PAGE 1-A



PAGE 1-B

IT 112443-68-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of, as LHRH antagonist)
 RN 112443-68-2 CAPLUS
 CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(1-methylethyl)-D-lysyl-L-leucyl-N6-(3-pyridinylcarbonyl)-L-lysyl-L-prolyl-(9CI)
 (CA
 INDEX NAME)
 NTE modified
 SEQ 1 AFASYKLKPA

Absolute stereochemistry.



L12 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1989:497725 CAPLUS Full-text
 DOCUMENT NUMBER: 111:97725
 TITLE: Preparation and testing of linear arginine
 vasopressin
 INVENTOR(S): antagonists
 PATENT ASSIGNEE(S): Manning, Maurice; Sawyer, Wilbur Henderson
 UNIVERSITY: Medical College of Ohio, USA; Columbia
 SOURCE: Eur. Pat. Appl., 18 pp.
 DOCUMENT TYPE: CODEN: EPXODW
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1


PATENT NO. KIND DATE APPLICATION NO.

DATE

EP 296892 A2 19881228 EP 1988-305927
 19880627 <---
 EP 296892 A3 19900711
 R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
 US 5055448 A 19911008 US 1987-66949
 19870625 <---
 JP 02019397 A2 19900123 JP 1988-155126
 19880624 <---
 19870625
 PRIORITY APPLN. INFO.:
 MARPAT 111:97725
 OTHER SOURCE(S):
 AB A-X-D-Tyr(R)-phe-y-Asn-T-u-Z-Q (I: A = 1-adamanty1, Ph,
 cyclohexyl, cyclopentyl, 1-mercaptocyclohexyl, Me, etc.; X =
 CH2CO; R = Cl-4 alkyl; Y = Val, Ile, Thr, Ala, Lys, Cha, Nva,
 Met, Nle, Orn, Ser, Asn, Gln, Phe, Tyr, Gly, Abu, Leu; T = Pen,
 Abu, Orn, Lys, Arg, Ala, Cha, Thr; U = Pro, Arg, Lys, Orn, bond;
 Z = D- or L-Arg, Orn, Lys; Q = Gly-NH2, Arg-NH2, Orn-NH2, Lys-
 NH2, Ser-NH2, Val-NH2, D- or L-Ala-NH2, Phe-NH2, Ile-NH2, Thr-
 NH2, Pro-NH2, Tyr-NH2, amino, OH; Abu = 2-aminobutanoyl; Cha =
 3-cyclohexylalanyl; Nva = norvalyl; Pen = 3-mercaptopivalyl),
 useful as arginine vasopressin antagonists, were prepared Aaa-
 D-Tyr(ET)-phe-val-Asn-Abu-Pro-Arg-NH2 (Aaa = 1-adamanty1acetyl)
 was prepared by the solid-phase method on Merrifield resin. In
 rats I administered i.v. effectively antagonized the
 antidiuretic effect of arginine vasopressin with PA2 of 6.55-
 7.81.

IT 121199-57-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for vasopressin antagonist)
 RN 121199-57-3 CAPLUS
 CN L-Ornithinamide, O-ethyl-N-(tricyclo[3.3.1.1.3,7]dec-1-ylacetyl)-
 D-tyrosyl-
 (2- L-phenylalanyl-L-valyl-L-asparaginy1-2-aminobutanoyl-L-prolyl-N-
 aminoethyl)-N5-[imino[[[(4-methylphenyl)sulfonyl]amino]methyl]]-
 (9CI) (CA
 INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A




IT 121199-57-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for vasopressin antagonist)

RN 121199-57-3 CAPLUS
 CN L-ornithinamide, O-ethyl-N-(tricyclo[3.3.1.1.3,7]dec-1-yl)acetyl)-
 D-cytrosyl-
 L-phenylalanyl-L-valyl-L-asparaginy-2-aminobutanoyl-L-prolyl-N-
 (2-
 aminoethoxy)-N5-[imino[[4-methylphenyl)sulfonyl]amino]methyl]-
 (9CI (CA
 INDEX NAME)

NTE modified (modifications unspecified)


SEQ 1 YFVNXP

PAGE 1-A



PAGE 1-8





L12 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1988:545736 CAPLUS Full-text
 DOCUMENT NUMBER: 109:145736
 TITLE: Yield optimization in the kinetically controlled

AUTHOR(S): enzymic peptide synthesis
 CORPORATE SOURCE: Bratovanova, E.; Stoineva, I.; Petkov, D.
 SOURCE: Lab. Biocatal., Inst. Org. Chem., Sofia, 1040, Bulg.
 Tetrahedron (1988), 44(12), 3633-7
 CODEN: TETRA8; ISSN: 0040-4020


DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The yield and its time-dependence in acyl-enzyme mechanism-based enzymic peptide synthesis are controlled by the proteinase kinetic specificity. The maximum yield is limited by a nonequilibrium constant K_{max} . Both K_{max} and the time, t_{max} , taken to attain the maximum yield, are directly related to the enzyme kinetic parameters. These relationships allow kinetic determination of yield optimization in kinetically controlled enzymic peptide synthesis.

IT 116653-30-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (hydrolysis of, by chymotrypsin or alkaline mesentericopeptidase, kinetics of)

RN 116653-30-6 CAPLUS
 CN L-Leucine, N-[N-[N-(N-acetyl[glycyl]glycyl)]-4-nitro-L-phenylalanyl]glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 116653-30-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (hydrolysis of, by chymotrypsin or alkaline mesentericopeptidase, kinetics of)
 RN 116653-30-6 CAPLUS
 CN L-Leucine, N-[N-[N-(N-acetyl[glycyl]glycyl)]-4-nitro-L-phenylalanyl]glycyl]- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 GGFGL

Absolute stereochemistry.



L12 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1988:108298 CAPLUS Full-text
 DOCUMENT NUMBER: 108:108298
 TITLE: Isolation and sequence determination of

Trichoderma trichorizianines A antifungal peptides from harzianum
 El Hajji, Mohamed; Rebuffat, Sylvie;
 Leclercq, Didier; Bodo, Bernard
 CORPORATE SOURCE: Lab. Chem., Natl. Mus. Nat. Hist., Paris, 75231, Fr.

SOURCE: International Journal of Peptide & Protein Research (1987), 29(2), 207-15
 CODEN: IJPPC3; ISSN: 0367-8377


DOCUMENT TYPE: English
 LANGUAGE: Journal

AB Trichorizianines A, membrane active peptides of the peptaibol class, were isolated from cultures of T. harzianum. Trichorizianines A were separated into pure components by HPLC on octadecyl bonded and SiO₂ phases successively. Nine trichorizianines A (IIa, IIb, IIc, IVb, Vb, VIa, VIb, and VII) were isolated from the complex microheterogeneous mixture. Their N-terminal amino acid is acetylated, the C-terminal amino alc. is either tryptophanol or phenylalanyl, and 7 to 8 of the 19 residues are α -aminoisobutyric acid (Aib). Gas chromatog.

on a chiral phase showed isovaline to have the D-configuration and all the other optically active amino acids and amino alcs. to have the L-configuration. The amino acid sequences were determined from their position fast-atom bombardment mass spectra, which exhibited the preferential cleavage of the Aib 12-pro 13 amide bond as a main fragmentation. The resulting fragments subsequently underwent amide bond ruptures that generated two series of abundant acylium ions which enabled direct determination of the 1-19 sequence. The relative position of the isomeric amino acids in the sequence of trichorzianine A VII was assigned from anal. of the N- and C-terminal oligopeptides yielded by its selective acidic hydrolysis. The microheterogeneity of trichorzianines A results mainly from single or multiple substitution of amino acids at the specific positions 5, 14, 16, and 19.


IT 109173-30-0
RN (of Trichoderma harzianum, amino acid sequence of)
CN Trichorzianin A IIia (9CI) (CA INDEX NAME)

PAGE 1-A




Me

PAGE 2-A






PAGE 1-B



PAGE 1-C

IT 109173-30-0
RN (of Trichoderma harzianum, amino acid sequence of)
CN Trichorzianin A IIia (9CI) (CA INDEX NAME)
NTE modified
SEQ 1 XAAXXQXXX LXPLXIQW



Me

L12 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1988:49436 CAPLUS Full-text
 DOCUMENT NUMBER: 108:49436
 TITLE: Design, synthesis and bioassays of
 antagonists of

and

AUTHOR(S):
 Puti Fun

Zhang,

Folkers,

CORPORATE SOURCE:
 78712,

SOURCE:
 Communications (

DOCUMENT TYPE:
 AB

LANGUAGE:
 English

Potent antagonists of LH-RH were achieved which release negligible histamine. [N-Ac-D-2-Nal¹, D-pClPhe², D-3-Pal³, NtCl⁵, D-NtCl⁵, D-Ala¹⁰]-LHRH (2-Nal = 3-(2-naphthyl)alanine; 3-Pal = 3-(3-pyridyl)alanine); NtCl⁵ = Ne-nicotinoyllysine; Lys = Ne-isopropyllysine) showed 100% antiovulatory activity (AOA)/1 µg and 36% AOA/0.5 µg; the ED₅₀ for histamine release was >300 µg/mL. [N-Ac-D-2-Nal¹, D-pClPhe², D-3-Pal³, P1Cl⁵, D-P1Cl⁵, Ily⁸, D-Ala¹⁰]-LHRH (P1Cl⁵ =

LH-RH which have high antiovulatory activity

release negligible histamine

Ljungqvist, Anders; Feng, Dong Mei; Tang,

Louisa; Kubota, Minoru; Okamoto, Tadashi;

Yawen; Bowers, Cyril Y.; Hook, William A.;

Karl Inst. Biomed. Res., Univ. Texas, Austin, TX,

USA

Biochemical and Biophysical Research

1987, 148(2), 849-56

CODEN: BBRC9; ISSN: 0006-291X

Journal


Ne-picoloyllysine) showed 100% AOA/0.5 µg, 40% AOA/0.25 µg, and an ED50 for histamine release of 93 µg/mL; it was the most potent of 52 new peptides. These antagonists feature designs with weakly basic acylated D-Lys6 (D-NicLys6 and D-PicLys6), alkylated Lys8 or Orn8 (ILys8 and IOrn8 (N6-isopropylornithine)), NicLys5, and PicLys5. Concepts included balanced overall basicity, superiority of ILys8 and IOrn8 which are sequence dependent, and sensitivity of positions 5 and 6 for potency.

IT 112443-68-2
 RL: BIOL (Biological study)
 (ovulation inhibition by, with negligible histamine release, mol.


structure in relation to)
 RN 112443-68-2 CAPLUS
 CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(1-methylethyl)-D-lysyl-L-leucyl-N6-(3-pyridinylcarbonyl)-L-lysyl-L-prolyl-(9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 112443-68-2
 RL: BIOL (Biological study)
 (ovulation inhibition by, with negligible histamine release, mol.


structure in relation to)
 RN 112443-68-2 CAPLUS
 CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(1-methylethyl)-D-lysyl-L-leucyl-N6-(3-pyridinylcarbonyl)-L-lysyl-L-prolyl-(9CI)
 (CA INDEX NAME)


NTE modified

SEQ 1 AFASYKLKPA

Absolute stereochemistry.

PAGE 1-A






D-Ne-nicotinoyl-lysine6 (I) moiety provided peptides comparable in activity. Frequently, D-2-Nal, D-pClpHe, and D-Cl2Phe are comparable in position 1. Histamine release was substantially low for a I analog.

IT 110697-54-6
 RL: BAC (Biological activity or effector, except adverse); BSU (biological study, unclassified); PRP (properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(Biological study): USES (Uses)
 (ovulation-inhibiting activity of, structure in relation to)
 RN 110697-54-6 CAPLUS
 CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-3-(2,3-dihydro-1-methyl-1H-indol-3-yl)alanyl-L-leucyl-L-arginyl-L-prolyl- (9CI)
 (CA INDEX NAME)




Absolute stereochemistry.



L12 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1987:568921 CAPLUS Full-text
 DOCUMENT NUMBER: 107:168921
 TITLE: Activities of antagonists of the luteinizing hormone releasing hormone with emphasis on positions 1, 5 and 6 and on positions 1, 2 and 3
 AUTHOR(S): Folkers, Karl; Bowers, Cyril; Xiao, Shao Bo; Tang, Pu
 Janusz, Kubiak, Teresa
 CORPORATE SOURCE: Inst. Biomed. Res., Univ. Texas, Austin, TX, USA
 SOURCE: Zeitschrift fuer Naturforschung, B: (1987), 42(1), 101-6
 Chemical sciences CODEN: ZNBSEN; ISSN: 0932-0776

DOCUMENT TYPE: English Journal
 LANGUAGE: English
 AB Analogs of LH-RH which are antagonists for controlling ovulation require potency and negligible release of histamine as a side effect. Forty analogs were designed, synthesized, and bioassayed in 2 groups with emphasis on positions 1, 5, and 6 and on positions 1, 2, and 3. N-Ac-D-2-Nal1,D-pClpHe2,D-3-Pal3,Ser4,Tyr5,D-Lys6,Leu7,Arg8,Pro9,D-Ala10-NH2 (where 2-Nal = 2-naphthylalaline) and N-Ac-D-Cl2Phe1,D-α-Me-pClpHe2,D-3-Pal3,Ser4,Tyr5,D-Arg6,Leu7,Arg8,Pro9,D-Ala10-NH2 (where pClpHe = p-chlorophenylalaline, Cl2Phe = 3,4-dichlorophenylalaline, and 3-Pal = 3-pyridylalaline) caused 100% inhibition of ovulation at 0.5 μg in rats. The former analog showed 12.5% antiovarial activity (AOA) and the latter analog showed 40% AOA at 0.25 μg. The neutral citrulline moiety is unique, since it and the basic






IT 110697-54-6
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); USES (uses)
 (Ovulation-inhibiting activity of, structure in relation to)
 RN 110697-54-6 CAPLUS
 D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-
 phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-cyrosyl-3-(2,3-
 dihydro-1-methyl-1H-indol-3-yl)alanyl-L-leucyl-L-arginyl-L-prolyl- (9CI)
 (CA INDEX NAME)

NTE modified

SEQ 1 AFASYWL RPA

Absolute stereochemistry.



L12 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1967:55742 CAPLUS Full-text
 DOCUMENT NUMBER: 66:55742
 TITLE: Amino acids and peptides. LXV. Analogs of
 oxytocin
 with isoleucine replaced by L-
 diethylalanine,
 cyclohexylglycines
 AUTHOR(S): Eisler, K.; Rudinger, Josef; Sorm, Frantisek
 CORPORATE SOURCE: Ceskoslov. Akad. Ved, Prague, Czech.
 SOURCE: Collection of Czechoslovak Chemical
 Communications (1966), 31(12), 4563-80
 CODEN: CCCCAK; ISSN: 0010-0765


DOCUMENT TYPE: English
 LANGUAGE: Journal
 AB CF. CA 66, 11171p. A suspension of 43.7 g. hippuric acid, 19.4
 g. freshly fused NaOAc and 1050 ml. Et2CO was treated dropwise
 over 30 min. with 61.5 ml. Ac2O, the whole refluxed 2 hrs.,

concentrated, the residue neutralized with aqueous NaHCO_3 , extracted with Et₂O, and the extract evaporated to give oily 4-(3-pentylidene)-2-phenyl-5-oxazolone. The oil was refluxed with 95 ml, 56% aqueous HI, 5.6 g, red P, and 130 ml, AcOH 90 min., the mixture filtered, the filtrate evaporated, the residue dissolved in H₂O, the solution washed with Et₂O, filtered through 200 ml, Zeolite 225 (H+) ion-exchange resin, the column washed with H₂O, and eluted with 5% aqueous NH_3 to give crude DL-Et₂CHCH(NHCO₂CH₂Ph)CO₂H (I) which with 5.5 ml, Ac₂O and 33 ml, AcOH yielded 4.3 g, I N-Ac derivative (II), m. 197-8° (H₂O). II (3.12 g) refluxed with 38.5 ml, azeotropic HBr and 25.5 ml, H₂O 2 hrs; gave 2.06 g, I, m. 240-3° (moist MeOH-Et₂O). A stirred mixture of 1.43 g, DL-cyclopentylglycine (III) and 5 ml, 2M NaOH was treated at -5° with 0.9 ml, ClCH₂COCl and addn. 2M NaOH at such a rate as to keep the pH value at approx. 9 to give 48% III N-COCH₂Cl derivative, m. 140-2° (H₂O) III (8.4 g.) refluxed with 150 ml, AcOH and 10.5 ml, Ac₂O 2 min. and the solution evaporated gave 9.4 g, III N-Ac derivative (IV), m. 170-2° (H₂O). Acetyl-DL-cyclohexylglycine (V), m. 196-7° (H₂O), was obtained similarly. Resolution of IV with hog renal acylase I afforded 87% L-cyclopentylglycine (VI), [α]_D 25 D 17.8° (c 0.4, 5M HCl), 13.8° (c 0.38, 2M HCl), [α]_D 25 350 84.3° (c 0.4, 5M HCl) and 95% acetyl-D-cyclopentylglycine (VII), [α]_D 25 D 35.8° (c 0.47, 5M HCl), [α]_D 25 310 215.9° (c 0.86, 1M HCl), and 73% acetyl-D-cyclohexylglycine, m. 210-11° (30% aqueous AcOH), [α]_D 25 D 32.8° (c 0.65, 98% AcOH). A similar incubation of II in the presence of CoCl₂ gave 75% L-Et₂CHCH(NH₂)CO₂H, [α]_D 25 D 36.9° (c 0.33, 5M HCl), and 95% acetyl-D-Et₂CHCH(NH₂)CO₂H, m. 175-7° (H₂O), [α]_D 25 D -13.6° (c 0.5, 98% AcOH). Refluxing the corresponding N-Ac derivs. with aqueous HBr 2 hrs. gave D-cyclopentylglycine, [α]_D 25 D -17.0° (c 0.3, 5M HCl), D-cyclohexylglycine (VIII), [α]_D 25 310 -217.8° (c 0.85, 1M HCl), and D-Et₂CHCH(NH₂)CO₂H (IX), [α]_D 25 D -34.5° (c 0.4, 5M HCl). VI (3.17 g.) was added at -10° to a mixture of 1.77 ml, SOCl₂ and 6.7 ml, MeOH, the whole refluxed 2 hrs., evaporated, and the residue reesterified to give 4.3 g, VI Me ester (X) HCl salt, m. 177-9°, [α]_D 25 D 31.3° (c 0.17, MeOH). Similarly were prepared VII Me ester-HCl, m. 188-9° (MeOH-Et₂O), [α]_D 25 D 33.4° (c 0.52, MeOH), 24.2° (c 0.44, H₂O), VIII Me ester-HCl, m. 190-1° (MeOH-Et₂O), and IX Me ester-HCl, m. 159-60° (MeOH-Et₂O), [α]_D 25 D -37.4° (c 0.36, MeOH). Acylation of free X with p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-tyrosine azide (Xa) gave 81% p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-tyrosyl-L-cyclopentylglycine (XI) Me ester (XII), m. 201-3° (aqueous MeOH), [α]_D 25 D -47.4° (c 0.48, MeOH). Similarly were prepared p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-tyrosyl-L-cyclohexylglycine (XIII) Me ester, m. 208-10° (MeOH), [α]_D 25 D -37.3° (c 0.43, MeOH), and p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-tyrosyl-D-cyclohexylglycine (XIV) Me ester, m. 228-9° (MeOH), m. 228-9° (MeOH), [α]_D 25 D -34.5° (c 0.41, MeOH). XII (1 g.) was kept with 1 ml, 92% NH_4 3 days and the mixture

diluted with 50 ml, EtOH to give 97% XI hydrazide, m. 252-5° (HCONMe₂-H₂O). Similarly prepared were XIII hydrazide, m. 249-53° (aqueous AcOH), and XIV hydrazide, m. 234-6° (75% aqueous EtOH). Coupling XI azide with L-glutamyl-L-asparaginyl-S-benzyl-L-cysteiny-L-prolyl-L-leucylglycine amide (XV) in HCONMe₂ gave p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-leucylglycyl-L-glutamyl-L-leucylglycine amide, m. 232-5° (HCONMe₂-H₂O), [α]_D 25 D -21.7° (c 0.31, HCONMe₂), and D-isomer, m. 216-19° (HCONMe₂-H₂O), [α]_D 25 D -24.4° (c 0.35, HCONMe₂). Treatment of IX in 0.5M NaHCO₃ with ClCO₂CH₂Ph and 0.5M NaOH (to keep the pH at 9) gave the N-CO₂CH₂Ph analog of IX, m. 75-7° (AcOEt-petroleum ether), [α]_D 25 D 0.85° (c 0.24, 98% AcOH), 0° (c 0.21; EtOH), [α]_D 25 350 -227° (c 0.21, EtOH). Treatment of XVI and tert-Bu carbazate with dicyclohexylcarbodiimide (DCC) in MeCN gave XVI tert-butyloxycarbonylhydrazide, m. 124-6° (AcOEt-petroleum ether). Treatment of XVI and p-O₂NC₆H₄OH with DCC in AcOEt gave XVI p-nitrophenyl ester (XVII), m. 69-71° (Et₂O-petroleum ether); D-isomer, m. 61-2° (Et₂O-petroleum ether). XV (702 mg) in 5.4 ml, HCONMe₂ treated with 390 mg, XVII in 3.3 ml, AcOEt at 0° and the mixture kept 2 days at room temperature gave 646 mg, benzylloxycarbonyl-L-diethylalanyl-L-glutamyl-L-leucylglycyl-L-S-benzyl-L-cysteiny-L-prolyl-L-leucylglycine amide (XVIII) hydrazide, m. 229-31° (aqueous AcOH), [α]_D 25 D -48.9° (c 0.24, HCONMe₂). This was kept in AcOH containing 35% HBr 30 min. at 37° to give 91% L-diethylalanyl-L-glutamyl-L-leucylglycyl-L-S-benzyl-L-cysteiny-L-prolyl-L-leucylglycine amide dihydrate. This treated with Xa gave 75% p-toluenesulfonyl-L-S-benzyl-L-cysteiny-L-tyrosyl-L-diethylalanyl-L-glutamyl-L-leucylglycyl-L-S-benzyl-L-cysteiny-L-prolyl-L-leucylglycine amide (XVIII) hydrazide, m. 238-42° (HCONMe₂-H₂O), [α]_D 25 D -31.8° (c 0.21, HCONMe₂). The protecting groups of XVIII were removed by reduction with Na in liquid NH_3 and the disulfide bridges were formed by oxidation with air to give XIX, [α]_D 25 D -31.6° (c 0.114, 1M AcOH). Similarly were prepared XX, [α]_D 25 D -3.7°, [α]_D 25 350 -10.4° (c 0.11, 1M AcOH), XXI, [α]_D 25 D -26.5° (c 0.1, 1M AcOH), and XXII, [α]_D 25 D -8.9° (c 0.09, 1M AcOH). [TABLE OMITTED] The isolation was performed by countercurrent distribution and freeze-drying. The free peptides were characterized by quant. amino acid analysis. XIX and XX showed a relatively high uterotropic, avian depressor, and galactobolic activity; XXI was less active and the activity of XXII was negligible.


IT 14979-14-7p
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 14979-14-7 CAPLUS
 Glycinamide, S-benzyl-N-p-tolylsulfonyl-L-cysteiny-L-tyrosyl-L-cyclopentylglycyl-L-glutamyl-L-leucyl-L-asparaginyl-S-benzyl-L-

cysteiny]~L-prolyl]-
L-leucyl]- (8CI) (CA INDEX NAME)
Absolute stereochemistry.




PAGE 1-A

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



PAGE 1-B



=> DIS HIST

IT 14979-14-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 14979-14-7 CAPLUS
CN Glycineamide, S-benzyl-N-p-toylsulfonyl-L-cysteiny]-L-tyrosyl]-L-
2- cyclopropylglycyl]-L-glutaminyl]-L-asparaginy]-S-benzyl]-L-
cysteiny]-L-prolyl]-
L-leucyl]- (8CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 CYXQNCPLG

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
STRUCTURE UPLOADED

L1 50 S L1 SAM
L2 308369 S L1 FULL
L3

FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004

L4 44 S L2
L5 0 S L4 AND PD<20000217

FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
STRUCTURE UPLOADED
L6 38 S L6 SAM
L7

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004

FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004

L8 47 S L7
L9 41 S L8 AND PD<20020312
L10 33 S L9 AND PD<20000217
L11 2918396 S 10 AND PD<19990218
L12 32 S L10 AND PD<19990218

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY

SESSION	
FULL ESTIMATED COST	304.08
486.87	

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	ENTRY

SESSION	
CA SUBSCRIBER PRICE	-22.40
22.40	

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:38:04 ON 09 SEP 2004

Connecting via winsock to STN

Welcome to STN International! Enter X:X

LOGINID:ssspta1653adk

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****

SESSION RESUMED IN FILE 'CAPLUS' AT 12:09:53 ON 09 SEP 2004
FILE 'CAPLUS' ENTERED AT 12:09:53 ON 09 SEP 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY

SESSION
FULL ESTIMATED COST 304.08
486.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE
TOTAL ENTRY

SESSION
CA SUBSCRIBER PRICE -22.40
22.40

=> file reg
COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY

SESSION
FULL ESTIMATED COST 304.08
486.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE
TOTAL ENTRY

SESSION
CA SUBSCRIBER PRICE -22.40
22.40

FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SMARTSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for
details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/reqistryss.html>

=> s [gavl][-fwht][-fwhtp][gavl]/sqsp
L13 3645970 [gavl][-fwht][-fwhtp][gavl]/sqsp

=> s 113 and sq=4
L14 62048 SQL=4
5874 L13 AND SQL=4

=> d 114 1-5 seq

L14 ANSWER 1 OF 5874 REGISTRY COPYRIGHT 2004 ACS on STN
SEQ 1 VVAL
HITS AT: 1-4

L14 ANSWER 2 OF 5874 REGISTRY COPYRIGHT 2004 ACS on STN
SEQ 1 LPNV
HITS AT: 1-4

***RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L14 ANSWER 3 OF 5874 REGISTRY COPYRIGHT 2004 ACS on STN
SEQ 1 VPV
HITS AT: 1-4

***RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L14 ANSWER 4 OF 5874 REGISTRY COPYRIGHT 2004 ACS on STN
SEQ 1 GGG
HITS AT: 1-4

***RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L14 ANSWER 5 OF 5874 REGISTRY COPYRIGHT 2004 ACS on STN
SEQ 1 ARVA
HITS AT: 1-4

***RELATED SEQUENCES AVAILABLE WITH SEQLINK**

RELATED SEQUENCES AVAILABLE WITH SEQLINK

=> file caplus
COST IN U.S. DOLLARS
TOTAL

SESSION
FULL ESTIMATED COST
541.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
TOTAL

SESSION
CA SUBSCRIBER PRICE
22.40

FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 SEP 2004 VOL 141 ISS 11
FILE LAST UPDATED: 8 Sep 2004 (20040908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
L2 STRUCTURE UPLOADED
L3 308369 S L1 SAM

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
L5 44 S L2
0 S L4 AND PD<20000217

FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004

L6 STRUCTURE UPLOADED
L7 38 S L6 SAM

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004

L8 FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
L9 47 S L7
L10 41 S L8 AND PD<20020312

L11 33 S L9 AND PD<20000217
L12 2918396 S L10 AND PD<19990218
32 S L10 AND PD<19990218

FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
L13 3645970 S [GAVL][F-WHT][GAVL]/SQSP
L14 5874 S L13 AND SQL=4

FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004

=> s L14
L15 4169 L14

=> L15 and pd<19990218
19597386 PD<19990218
(PD<19990218)

L16 3256 L15 AND PD<19990218

=> d L16 1-10 ibib abs hitseq

L16 ANSWER 1 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:414513 CAPLUS FULL-TEXT
DOCUMENT NUMBER: 140:419882
TITLE: Fluorescent peptide substrates for the
detection of

INVENTOR(S): enzyme activity in biological samples
PATENT ASSIGNEE(S): packard, Beverly S.; Komortiya, Akira
SOURCE: Oncoimmunin, Inc., USA
part of Appl. U.S. Pat. Appl. Publ., 114 pp., cont.-in-

NO. PCT/US00/24882.

DOCUMENT TYPE: CODEN: USXXCO
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 5

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
------	------------	------	------	-----------------

US 2004096926	A1	20040520	US 2001-874350
20010604			
US 6037137	A	20000314	US 1997-802981
19970220			
WO 9837226	A1	19980827	WO 1998-US3000
19980220			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

KE, KG, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

ES, FI, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

WO 2001018238 A1 20010315 WO 2000-US24882

20000911 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CH, CY, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1997-802981 A2

19980220 WO 1998-US3000 A2

19990910 US 1999-394019 A2

WO 2000-US24882 A2

20000911 MARPAT 140:419882

OTHER SOURCE(S):

AB The present invention provides for novel reagents whose fluorescence increases in the presence of particular proteases. The reagents comprise a characteristically folded peptide backbone conjugated to two fluorophores such that the fluorophores are located opposite sides of a cleavage site. When the folded peptide is cleaved, as by digestion with a protease, the fluorophores provide a high intensity fluorescent signal at a visible wavelength. Because of their high specificity and their high fluorescence signal in the visible wavelengths, these protease indicators are particularly well suited for detection of protease activity in biol. samples, in particular in frozen tissue sections. In one example, the protease indicator having the formula FI-ASP-Ala-Ile-Pro-Nle-Ser-Ile-Pro-Cys-F2, where FI is a donor fluorophore (5-carboxytetramethylrhodamine) linked to aspartic acid via the α -amino group and F2 is an acceptor fluorophore (rhodamine x

acetamide (R492)) linked via the sulphydryl group of the cysteine, exhibits changes in emission spectrum after addn of an elastase protease. Thus this invention also provides for methods of detecting protease activity in situ in frozen sections.

IT 637-84-3


RL: PRP (Properties)

(unclaimed sequence; fluorescent peptide substrates for the detection of enzyme activity in biol. samples)

RN 637-84-3 CAPLUS

CN Glycine, glycyl[glycyl]glycyl- (9CI) (CA INDEX NAME)

SEQ 1 GGGG



L16 ANSWER 2 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:402748 CAPLUS FULL-TEXT

DOCUMENT NUMBER: 140:387555

TITLE: Photoresponsive bioelastomeric polypeptides which display inverse temperature transitions and are useful in transducing light energy with a change in hydrophobicity or polarity

INVENTOR(S): Urry, Dan W.; Tirrell, David A.; Heimbach, Catherine

Jean

PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 34 pp., Cont. of U.S. Ser. No.

32,373.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
US 2003166840	A1	20030904	US 2001-759947	
20010112	A	19990504	US 1995-487594	
19950607	WO 9723729	A1	19970703	WO 1996-US9776
19960607	<---			

W: AU, CA, JP
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
 NL, PT, SE
 EP 830509 A1 19980325 EP 1996-921441
 19960607 <--
 EP 830509 B1 20010912
 JP 11508274 R: DE, FR, GB T2 19990721 JP 1996-519202
 DE 69615179 T2 20020704 DE 1996-69615179
 19960607 DE 69615179 T2 20020704 DE 1996-69615179
 PRIORITY APPLN. INFO.:
 19940124 US 1994-187441 B3
 19950607 US 1995-485426 B1
 19980227 US 1998-32373 B1
 19950607 US 1995-487594 A
 WO 1996-US9776 W


19960607 AB A bioelastomeric compn. is provided that expands or contracts upon a change in exposure to light energy that comprises a protein or protein-based polymeric material having an inverse temperature transition in the range of liquid water. At least a fraction of the monomers in the polymer contain a light energy-responsive group that undergoes a change in hydrophobicity or polarity upon a change in exposure to light energy and is present in an amount sufficient to provide a shift in the inverse temperature transition of the polymer upon the change in exposure to light energy. Comps. of the invention, including those further containing a side-chain chemical couple, can be used in a variety of different applications to produce mech. work. Cause turbidity changes, cause chemical changes in an enclosed environment, or transduce other free energies by varying the exposure to light energy on the composition. The degree and efficiency of mech. or chemical change can be controlled by, inter alia, selection of the type, amount, position, and mole fraction of the light energy-responsive side chain group and hydrophobic residues in the polymer. Thus, a copolymer comprising poly[0.68(VPGVG), 0.32(VPEGG)] coupled via the glutamic acid residues to phenylazobenzene displays cis-trans isomerization on irradiation at 350 nm, and an inverse temperature transition sensitive to the configuration of the azobenzene chromophore: approx. 32° for the trans form and approx. 42° for the cis form when buffered at pH 4.1. Reversible photomodulation of the transition is achieved isothermally at 40°. Addnl. copolymers derivatized with cinnamic acid, cinnamaldehyde, or spiropyran display inverse temperature transition responsive to irradiation with light in the visible, UV, or IR ranges.

IT 53356-54-0
 RL: PRP (Properties)
 (unclaimed sequence; photoresponsive bioelastomeric polypeptides which display inverse temperature transitions and are useful in transducing light

energy with a change in hydrophobicity or polarity)
 RN 53356-54-0 CAPLUS
 CN Glycine, L-valyl-L-prolylglycyl- (9CI) (CA INDEX NAME)

SEQ 1 VPGG

Absolute stereochemistry.



L16 ANSWER 3 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:688962 CAPLUS FULL-text
 DOCUMENT NUMBER: 139:208245
 TITLE: Mammalian activity-dependent neurotrophic factor III
 neuronal
 INVENTOR(S): cell death
 Bassan, Merav; Gozes, Iltana; Breneman, Douglas E.;
 PATENT ASSIGNEE(S): Ramot University Authority for Applied
 Research and Industrial Development Ltd., Israel; The
 United States of America, Department of Health and Human
 Services U.S., 105 pp., Cont.-in-part of Appl. No.
 SOURCE: PCT/US98/02485.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19981106	US 6613740	B1	20030902	US 1998-187330
19980206	WO 9835042	A2	19980813	WO 1998-US2485

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,


DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19990929	US 6610839	B1	20030826	US 1999-402181
19970814	US 6475789	B1	20021105	US 1997-912951
19971001	WO 9814593	A2	19980409	WO 1997-US17885
19971001	WO 9814593	A3	19990218	
CZ, DE,	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
20010523	AU 763956	B2	20030807	AU 2001-47992
20021220	US 2003204069	A1	20031030	US 2002-325810
19970814	PRIORITY APPLN. INFO.:			
19970814				US 1997-911312 B2
19970814				US 1997-912951 A2
19970814				US 1997-915503 B2
19970814				WO 1997-US17885 W
19971001				US 1996-724643 B2
19961001				US 1997-844419 B2
19970418				US 1997-846017 B2
19970425				US 1997-851843 A2
19970506				US 1997-845050 A2
19970509				US 1997-854050 A
19970509				AU 1997-48073 A
19971001				US 1999-402181 A1
19990929				
AB	The invention provides comps. and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. Genomic, cDNA, and encoded amino			

acid sequences are provided for hTERT from a protozoan (Euplotes aediculatus), Schizosaccharomyces pombe, Tetrahymena thermophila, and human. The human hTERT promoter can be used in recombinant vectors for the expression of proteins toxic to cells expressing hTERT, thereby rendering the cell more susceptible to toxicity of drugs. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases; for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

IT 315195-82-5
 RL: PRP (Properties)
 (unclaimed sequence; promoter for telomerase reverse transcriptase and its diagnostic and therapeutic use)
 RN 315195-82-5 CAPLUS
 CN L-leucine, L-leucyl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 LLRL

Absolute stereochemistry.



REFERENCE COUNT: 193 THERE ARE 193 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L16 ANSWER 5 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:545684 CAPLUS Full-text
 DOCUMENT NUMBER: 139:106414
 TITLE: Sequences of porcine reproductive and respiratory syndrome virus (prRSV) proteins and use in immunization
 INVENTOR(S): Paul, Prem S.; Meng, Xiang-jin; Halbur, Patrick;
 PATENT ASSIGNEE(S): Morozov, Igor; Lum, Melissa A.
 Inc., USA; Iowa State University Research Foundation,
 American Cyanamid Company

SOURCE: U.S., 124 pp., Cont.-in-part of U.S. Ser. No. 131,625.

DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION: English


DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	---	-----	-----
19940901	US 6592873	B1	20030715	US 1994-301435
19931005 <---	US 5695766	A	19971209	US 1993-131625
19950607	US 6251397	B1	20010626	US 1995-478316
19950901 <---	CA 2198461	AA	19960307	CA 1995-2198461
19950901 <---	WO 9606619	A1	19960307	WO 1995-US10904
19950901 <---	W: CA			
PT, SE	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,			
EP 776209	A1	19970604	EP 1995-932336	
19950901 <---				
NL, PT, SE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,			
US 6380376	B1	20020430	US 1998-19793	
19980206				
US 6773908	B1	20040810	US 2000-601326	
20000925				
AU 771883	B2	20040408	AU 2001-68774	
20010906				
US 2002168379	A1	20021114	US 2002-104019	
20020325				
US 2003138442	A9	20030724	US 2003-428826	
US 2003186225	A1	20031002	US 1992-969071	B2
20030505				
PRIORITY APPLN. INFO.:				
19921030				
19931005				
19940901				
19950607				
19950901				
19980206				
19980729				
19990208				

20000925
AB The present invention provides a purified prepn. contg. a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORFs) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), proteins at least 80% but less than 100% homologous with those encoded by one or more of ORF 2, ORF 3, ORF 4 and ORF 5 of an Iowa strain of PRRSV, proteins at least 97% but less than 100% homologous with proteins encoded by one or both of ORF 6 and ORF 7 of an Iowa strain of PRRSV, antigenic regions of such proteins which are at least 5 amino acids in length and which effectively stimulate immunol. protection in a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof, in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a polypeptide encoded by such a polynucleic acid; a vaccine comprising an effective amount of such a polynucleic acid or protein; antibodies which specifically bind to such a polynucleic acid or protein; methods of producing the same; and methods of raising an effective immunol. response against a PRRSV, treating a pig infected by a PRRSV, and detecting a PRRSV.

IT 557771-51-4
RL: PRP (Properties)
(unclaimed sequence; sequences of porcine reproductive and respiratory syndrome virus (prrsv) proteins and use in immunization)
RN 557771-51-4 CAPLUS
CN Glycine, L-alanyl-L-seryl-L-glutamyl- (9CI) (CA INDEX NAME)

SEQ 1 ASQG

Absolute stereochemistry.



REFERENCE COUNT: 166 THERE ARE 166 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L16 ANSWER 6 OF 3256 CAPLUS COPYRIGHT 2004 ACS ON STN


ACCESSION NUMBER: 2003:507642 CAPLUS Full-text
 DOCUMENT NUMBER: 139:81311
 TITLE: Recombinant production and purification of human neutrophil protease prepro-PR-3 and its proteolytic processing and use for screening inhibitors of release of TNF α
 INVENTOR(S): Halenbeck, Robert F.; Krieglner, Michael; Perez, Carl;
 PATENT ASSIGNEE(S): Jewell, David A.; Koths, Kirston E. Chiron Corporation, USA
 SOURCE: U.S., 53 pp., Cont.-in-part of U. S. Ser. No. 230,428.
 DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 6
 PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19950228	US 6586222	B1	20030701	US 1995-395456
19900608 <---	AU 9059400	A1	19910403	AU 1990-59400
19900608 <---	EP 491878	A1	19920701	EP 1990-917939
19900608 <---	EP 491878	B1	19970219	
19900608 <---	JP 04507044	T2	19921210	JP 1990-509543
19900608 <---	JP 2930713	B2	19990803	
19900608 <---	EP 750037	A2	19961227	EP 1996-202206
19900608 <---	EP 750037	A3	19970115	
19920214 <---	NO 9200593	A	19920319	NO 1992-593
19940419	US 5983378	A	19991207	US 1994-230428
19950302 <---	CA 2185162	AA	19950914	CA 1995-2185162
19950302 <---	WO 9524501	A1	19950914	WO 1995-US2513
19950302 <---	W: AU, CA, JP, NO			
PT, SE	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,			
19950302 <---	AU 9513364	A1	19950925	AU 1995-19364
19950302 <---	AU 709054	B2	19990819	
19950302 <---	EP 749494	A1	19961227	EP 1995-912005

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 JP 10504441 T2 19980506 JP 1995-523506
 19950302 <--- US 659706 B1 20030729 US 1995-487453
 19950607 NO 9603726 A 19961031 NO 1996-3726
 19960906 <--- PRIORITY APPLN. INFO.:
 19890816 US 1989-395253 B2
 19920625 US 1992-905546 B2
 19940307 US 1994-208574 B2
 19940419 US 1994-230428 A2
 19900608 EP 1990-917939 A3
 19900608 WO 1990-US3266 A
 19950227 US 1995-394600 A
 19950228 US 1995-395456 A
 19950302 WO 1995-US2513 W
 19950302 US 1999-395253 A2
 19990816 OTHER SOURCE(S): MARPAT 139:81311
 AB Methods and materials are disclosed for the prodn. of purified, active recombinant human neutrophil protease, PR-3 (also known as myeloblastin), via activation of the prepro- and pro-forms. PR-3 is cloned by transfecting sf9 insect cells with a baculovirus vector and purified to >95% purity with an endotoxin content of <20 ng/mg PR-3 and a specific activity of .apprx.30 μ moles/min/mg PR-3 as assayed on Boc-Ala-ONP at pH 7.5 at 25°. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF α . Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF α to its mature active form.
 IT 170156-30-6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibition of PR-3 by; recombinant production and purification of human neutrophil protease prepro-PR-3 and its proteolytic processing and use for screening inhibitors of release of TNF α)
 RN 170156-30-6 CAPLUS
 CN L-Alanine, N-[(1,1-dimethylmethoxy)carbonyl]-L-leucyl-L-alanyl-L-glutaminyl-
 anhydride with diphenyl hydrogen phosphate (9CI) (CA INDEX NAME)
 NTE modified

SEQ 1 LAQA

Absolute stereochemistry.



REFERENCE COUNT: 180 THERE ARE 180 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE
 IN THE RE FORMAT

L16 ANSWER 7 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:319378 CAPLUS Full-text
 DOCUMENT NUMBER: 138:343951
 TITLE: Structures useful for bone engineering
 INVENTOR(S): Bhatnagar, Rajendra S.; Qian, Jing Jing
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part
 of U.S.

DOCUMENT TYPE: Ser. No. 561,554, abandoned.
 LANGUAGE: CODEN: USXXCO
 FAMILY ACC. NUM. COUNT: Patent
 PATENT INFORMATION: English 6

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
20020425	US 2003077825	A1	20030424	US 2002-133289
19940722	US 5635482	A	19970603	US 1994-278878
19970520	US 5958428	A	19990928	US 1997-859610
19990608	US 6268348	B1	20010731	US 1999-328347
20010323	US 2002037853	A1	20020328	US 2001-816737
20010329	WO 2001082773	A2	20011108	WO 2001-US10404


WO 2001082773 A3 20020131
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.:
 19940722 US 1994-278878 A3
 19970520 US 1997-859610 A1
 19990608 US 1999-328347 A1
 20000428 US 2000-561554 B1
 20010323 US 2001-816737 A2
 19890814 US 1989-339621 B2
 19911209 US 1991-804782 A2

AB A bone repair app. is provided where a biol. compatible structure has a compound carried on the structure that mimics collagen binding to cells. Living cells derived from fibroblasts are carried on the structure and display at least one morphol. change consistent with an osteogenic phenotype. The preferred method for practicing the invention includes harvesting a quantity of fibroblasts from a patient in need of a bone graft, growing the tissue under cell growth conditions, and seeding at least some cells of the cultured tissue on the biol. compatible structure with the collagen mimic thereon. The culture tissue cells are seeded on the structure and incubated under cell growth conditions, which results in the differentiation of the cells to bone-like cells and thus provides a tissue engineered apparatus ready for use as a bone graft. The peptide P-15, GTPGPGIAGQRRV was synthesized by a solid phase procedure. The P-15 was adsorbed on bovine bone derived porous ABM (bovine bone mineral) in a particulate form with a particle size of 250-420 µm and the binding of cells to ABM-P-15 was proportional to the amount of adsorbed P-15. There is a marked increase in the expression of type I collagen in dermal fibroblasts growing on ABM-P-15 matrices. Marked stimulation of alkaline phosphatase gene expression in HA-P-15 cultures is consistent with the induction of a bone-like phenotype.

IT 136266-47-2
RL: THU (Therapeutic use); BIOL (biological study); USES (uses)
(structures useful for bone engineering)
RN 136266-47-2 CAPLUS
CN glycine, N-[N-(N-glycyl)-L-isoleucyl]-L-alanyl]- (9CI) (CA INDEX NAME)

SEQ 1 GIAG

Absolute stereochemistry.



L16 ANSWER 8 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:113343 CAPLUS FULL-text
DOCUMENT NUMBER: 138:164723
TITLE: Vectors encoding chimeric fusion cytotoxins

ability of
receptor bearing
INVENTOR(S): tumor cells
Ira; Obiri, Puri, Raj K.; Debinski, Waldemar; Pastan,
PATENT ASSIGNEE(S): Nicholas
The United States of America as Represented
by the Department of Health and Human Services, USA
SOURCE: U.S., 26 pp., Cont.-in-part of U.S.
5,614,191.

DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION: English

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	---	-----	---
US 6518061	B1	20030211	US 1998-913370	
19980217				
US 5614191	A	19970325	US 1995-404685	
19950315 <---				
WO 9629417	A1	19960926	WO 1996-US3486	


19960315 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
US 2003129132 A1 20030710 US 2002-318608
20021213
PRIORITY APPLN. INFO.: US 1995-404685 A2
19950315 WO 1996-US3486 W
19960315 US 1998-913370 A1

19980217
AB The invention provides genetic vectors contg. nucleic acid mols. encoding chimeric fusion proteins (cytotoxins) composed of human interleukin 13 or circularly permuted IL-13 (CpIL-13) attached to toxins, such as mutant forms pseudomonas aeruginosa exotoxin A (PE38QQR or PE4E). The invention also provides host cells transformed with said vectors. The invention relates that said chimeric fusion proteins (IL-13-PE38QQR, CpIL-13-PE38QQR, IL-13-PE4E and CpIL-13-PE4E) are able to bind tumor cells bearing IL-13 receptors. The invention further provides a composition comprising a pharmaceutical acceptable carrier and said chimeric proteins. The invention is based in part on the discovery that certain tumor cells, such as renal cell carcinoma (RCC) overexpress IL-13 receptors, and on the premise that specific vectors encoding the IL-13-PE fusion proteins can be used to target such cells. The invention demonstrated that various cancer cell lines, including RCC cell lines, glioma cell lines, Kaposi's sarcoma cell lines, and/or neural cancer cell lines were sensitive to said chimeric proteins resulting in growth inhibition or cytotoxicity of cells.

IT 496847-20-2
RL: PRP (Properties)
(unclaimed sequences; vectors encoding chimeric fusion cytotoxins (IL-13 fused to mutant forms of exotoxin A), and ability of cytotoxins to bind and inhibit IL-13 receptor bearing tumor cells)
RN 496847-20-2 CAPLUS
CN glycine, glycy(glycy)-L-seryl]- (9CI) (CA INDEX NAME)

SEQ 1 GSSG

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L16 ANSWER 9 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:92421 CAPLUS Full-text
 DOCUMENT NUMBER: 138:147747
 TITLE: The γ -carboxyglutamic acid containing

INVENTOR(S): Abogadie, Fe C.; Cruz, Lourdes J.; Olivera, Baldomero

Hillyard, David M.; Walker, Craig; Colledge, Clark;

Li-ming; R.; Jimenez, Elsie; Layer, Richard T.; Zhou, Shen, Gregory S.; McCabe, R. Tyler; Rivier,

Jean E. PATENT ASSIGNEE(S): University of Utah Research Foundation, USA; Cognetix,

SOURCE: Inc.; Salk Institute
 684,742, U.S., 69 pp., Cont.-in-part of U.S. Ser. No. abandoned.

DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION: English

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
US 6515103	B1	20030204	US 2000-142080	
20000511				
WO 9803541	A1	19980129	WO 1997-US12618	
19970721				
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,			

VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
 US 2003194729 A1 20031016 US 2003-357467
 20030204 US 1996-684742 B2
 PRIORITY APPLN. INFO.: WO 1997-US12618 W
 19960722 19970721 US 2000-142080 A3

20000511 OTHER SOURCE(S): MARPAT 138:147747

AB The present invention provides sequences of conantokins, having 10-30 amino acids, including preferably two or more γ -carboxyglutamic acid residues. The conantokins are useful for the treatment of neuro1. and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.

IT 202984-85-8P 202984-89-2P 202984-91-6P


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(conantokin sequence; γ -carboxyglutamic acid containing conantokins and therapeutic use)


RN 202984-85-8 CAPLUS
 CN L-Alanine, L-leucyl-L- α -aspartyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202984-89-2 CAPLUS
 CN L-Alanine, L-leucyl-L- α -aspartyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202984-91-6 CAPLUS
CN L-Alanine, L-leucyl-L-α-glutamyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202984-96-1 CAPLUS
CN L-Valine, γ-L-asparaginyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 202984-75-6
RI: PRP (Properties)
(unclaimed sequence; γ-carboxyglutamic acid containing conantokins and therapeutic use)
RN 202984-75-6 CAPLUS

CN L-Alanine, L-leucyl-L-isoleucyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 LIRA

Absolute stereochemistry.



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L16 ANSWER 10 OF 3256 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:845512 CAPLUS Full-text
DOCUMENT NUMBER: 137:347555
TITLE: CDNA encoding human telomerase reverse
transcriptase

treatment of and its potential use in diagnosis and

INVENTOR(S): Cancer
Toru; Cech, Thomas R.; Lingner, Joachim; Nakamura,

Calvin B.; Chapman, Karen B.; Morin, Gregg B.; Harley,

PATENT ASSIGNEE(S): Andrews, William H.
Geron; University Technology Corporation, USA;

SOURCE: Corporation
5,743,518. U.S., 234 pp., cont.-in-part of U.S.

DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 13

PATENT NO.	KIND	DATE	APPLICATION NO.
US 6475789	B1	20021105	US 1997-912951

19970814	US 6093809	A	20000725	US 1997-851843	GB 2321642	B2	20000209	DE 1997-19743497	
19970506	GB 2317891	A1	19980408	GB 1997-20890	DE 19743497	A1	19980820		
19971001 <--	WO 2317891	B2	19980819		JP 10234384	A2	19980908	JP 1997-286182	
19971001 <--	WO 9814592	A2	19980409	WO 1997-US17618	EP 932686	A2	19990804	EP 1997-910737	
19971001 <--	WO 9814592	A3	19990401		MC, PT, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				
CZ, DE,	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,				CH 689672	A	19990813	CH 1997-2312	
KP, KR,	DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG,				JP 11253177	A2	19990921	JP 1998-320169	
NO, NZ,	KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				EP 954585	A2	19991110	EP 1997-910785	
UA, UG,	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				19971001				
BY, KG,	US, US, US, US, US, US, US, VU, ZW, AM, AZ,				MC, PT, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				
FI, FR,	KZ, MD, RU, TJ, TM				JP 11313689	IE, SI, LT, LV, FI, RO	19991116	JP 1999-42410	
CM, GA,	RW: GH, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,				19971001	BR 9711844	A	20000118	BR 1997-11844
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				19971001	BR 9712254	A	20000118	BR 1997-12254
	GN, ML, MR, NE, SN, TD, TG				19971001	CN 1254376	A	20000524	CN 1997-199534
19971001 <--	WO 9814553	A2	19980409	WO 1997-US17885	19971001	JP 2001081042	A2	20010327	JP 2000-227474
CZ, DE,	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,				19971001	CN 1291231	A	20010411	CN 1997-180256
KP, KR,	DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG,				19971001	NZ 334709	A	20010629	NZ 1997-334709
NO, NZ,	KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				19971001	JP 2001510985	T2	20010807	JP 1998-516909
UA, UG,	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				19971001	JP 2001523947	T2	20011127	JP 1998-516802
FI, FR,	US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				19971001	NZ 510761	A	20020628	NZ 1997-510761
CM, GA,	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,				19971001	SG 94355	A1	20030218	SG 2001-200101834
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				19971001	EP 1333094	A2	20030806	EP 2003-75454
19971001 <--	AU 9748036	A1	19980424	AU 1997-48036	19971001	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,			
19971001 <--	AU 9748073	A1	19980424	AU 1997-48073	MC, PT, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				
19971001 <--	AU 734089	B2	20010607		AT 245194	IE, SI, LT, LV, FI, RO, MK, AL	20030815	AT 1997-307757	
19971001 <--	EP 841396	A1	19980513	EP 1997-307757	19971001	ES 2205132	T3	20040501	ES 1997-307757
19971001 <--	EP 841396	B1	20030716		19971001	US 6166178	A	20001226	US 1997-974549
MC, PT,	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				19971119	US 6444650	B1	20020903	US 1998-52919
FR 2757177	IE, SI, LT, LV, FI, RO				19980331	FI 9900555	A	19990324	FI 1999-655
19971001 <--	GB 2321642	A1	19980805	GB 1998-4859	MX 9902841	A	20000331	MX 1999-2841	

19971001	US 1997-974549	A2
19971119	US 1997-974584	A2
19971119	US 1997-979742	B2
19971126	US 1998-42460	A2
19980316	US 1998-52919	A3
19980331	US 1999-244438	A1
19990204	US 1999-402181	A1
19990929		
AB	The invention provides compns. and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compds. and treatments useful for treatment of diseases such as cancers.	
IT	315195-82-5	
RL:	PRP (Properties)	
	(Unclaimed; cDNA encoding human telomerase reverse transcriptase and	
	its potential use in diagnosis and treatment of cancer)	
RN	315195-82-5 CAPLUS	
CC	L-Leucine, L-[Leucyl-L-[leucyl-L-arginyl]- (9CI) (CA INDEX NAME)	
SEQ	1 LLRL	
Absolute stereochemistry.		

REFERENCE COUNT:	138	THERE ARE 138 CITED REFERENCES
AVAILABLE FOR		THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE		FORMAT

```

=> 116 and paten
    10 PATEN
    504 PATENS
    513 PATEN
    (PATEN OR PATENS)
L17      0 L16 AND PATEN

=> 116 and patent
    20803 PATENT
    8924 PATENTS
    27579 PATENT
    (PATENT OR PATENTS)
L18      3 L16 AND PATENT

=> 116 and dt=patent
    NUMERIC VALUE NOT VALID 'PATENT'
    Numeric values may contain 1-8 significant figures. If range
    notation
    is used, both the beginning and the end of the range must be
    specified, e.g., '250-300/MW'. Expressions such as '250-/MW' are not
    allowed. To search for values above or below a given number, use the
    '>', '>=', '<', or '<=' operators, e.g., 'MW > 250'. Text terms cannot be
    used in numeric expressions. If you specify a unit, it must be
    dimensionally correct for that field code. To see the unit
    designations for field codes in the current file, enter "DISPLAY UNIT
    ALL" at an arrow prompt (=>).

=> 116 and patent/dt
    4426341 PATENT/DT
L19      441 L16 AND PATENT/DT

=> 116 not 119
L20      2815 L16 NOT L19

=> d his
    (FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)
L1      FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
L2      STRUCTURE UPLOADED
L3      50 S L1 SAM
L3      308369 S L1 FUL
L4      FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
L5      44 S L2
L5      0 S L4 AND PD<20000217
L6      FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
L7      STRUCTURE UPLOADED
L7      38 S L6 SAM
L8      FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004
L9      FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
L9      47 S L7
L9      41 S L8 AND PD<20020312
L10     33 S L9 AND PD<20000217

```

```

L11     2918396 S 10 AND PD<19990218
L12     32 S L10 AND PD<19990218

L13     FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
L13     3645970 S [GAVL][-FMHT][-FMHTP][GAVL]/SQSP
L14     5874 S L13 AND SQL=4

L15     FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004
L16     4169 S L14
L16     3256 L15 AND PD<19990218
L17     0 L16 AND PATEN
L18     3 L16 AND PATENT
L19     441 L16 AND PATENT/DT
L20     2815 L16 NOT L19

=> d 120 1-10 1b1b abs hitscq
L20     ANSWER 1 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STM
L20     ACCESSION NUMBER: 2000:784096 CAPLUS Full-text
L20     DOCUMENT NUMBER: 134:116212
L20     TITLE: Modeling the conformation of polyphenols and
L20     their association with polypeptides: Self-
L20     association of catechin and its complexation with L-proline
L20     glycine
L20     AUTHOR(S): oligomers
L20     Vergoten, Tobiason, Fred L.; Hemingway, Richard W.;
L20     Gerard
L20     CORPORATE SOURCE: Department of Chemistry, Pacific Lutheran
L20     University, Tacoma, WA, 98447, USA
L20     SOURCE: Basic Life Sciences (1999), 66(Plant
L20     polyphenols 2), 527-544
L20     CODEN: BLFSBY; ISSN: 0090-5542
L20     Kluwer Academic/Plenum Publishers
L20     PUBLISHER: Journal
L20     DOCUMENT TYPE: English
L20     LANGUAGE: The computational models for mols. such as L-prolyl-glycine and
L20     AB glycy1-L-prolyl[glycy1]-glycine ion (GPGG ion) interacting with
L20     (+)-catechin and (+)-catechin-(4a->8)-(+) -catechin (83) to form
L20     complexes were explored. These results are compared to the
L20     close-contact positions obtained from NOE NMR expts. in aqueous
L20     solution. The complex structures found using conformational
L20     search methods are discussed in terms of the specific
L20     hydrophobic and hydrophilic interactions observed
L20     IT 321349-65-9 321349-67-1
L20     RL: PRP (Properties)
L20     (Conformation of complexes of catechin with proline glycine
L20     oligomers)
L20     RN 321349-65-9 CAPLUS
L20     CN glycy1-L-prolyl[glycy1]-, compd. with (2R,3S)-2-(3,4-
L20     dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol (1:1)
L20     (9CI) (CA
L20     INDEX NAME)

```

NTE modified (modifications unspecified)

SEQ 1 GPGG


CM 1

CRN 13054-03-0

CMF C11 H18 N4 O5

SEQ 1 GPGG

Absolute stereochemistry.




CM 2

CRN 154-23-4

CMF C15 H14 O6

Absolute stereochemistry. Rotation (+).



RN 321349-67-1 CAPLUS

CN, glycine, glycy-L-prolylglycyl-, compd. with (2R,2'R,3S,3'S,4S)-2,2'-bis(3,4-dihydroxyphenyl)-3,3',4,4'-tetrahydro[4,8'-bi-2H-1-benzopyran]-3,3',5,5',7,7'-hexol (1:1) (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)


SEQ 1 GPGG

CM 1

CRN 23567-23-9

CMF C30 H26 O12

Absolute stereochemistry. Rotation (-).




CM 2

CRN 13054-03-0

CMF C11 H18 N4 O5

SEQ 1 GPGG

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

29 THERE ARE 29 CITED REFERENCES

RE FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE

L20 ANSWER 2 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:473249 CAPLUS Full-text
DOCUMENT NUMBER: 133:346293


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent) (Preparation and cyclization tendencies of tetrapeptides containing N-alkylated alanines)

RN 284666-66-6 CAPLUS
 CN L-Alanine, N-(carboxymethyl)-L-alanyl-L-alanyl-L-alanyl-N-(2-aminoethyl)-4-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AAAA

Absolute stereochemistry.




RN 284666-67-7 CAPLUS
 CN L-Alanine, N-(carboxymethyl)-L-alanylglycylglycyl-N-(2-aminoethyl)-4-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AGGA

Absolute stereochemistry.




RN 284666-69-9 CAPLUS
 CN L-Alanine, N-(carboxymethyl)-L-alanyl-L-alanyl-glycyl-N-(2-aminoethyl)-4-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AAGA

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:288575 CAPLUS full-text
 DOCUMENT NUMBER: 134:1500

TITLE: Relationship between structure and

of cyclic tetrapeptides, AM-toxin

analog
 AUTHOR(S): Miyashita, Masahiro; Nakamori, Tomoko;

Murai, Takahiro; Miyagawa, Hisashi; Akamatsu, Miki;

Ueno, Tamio
 CORPORATE SOURCE: Graduate School of Agriculture, Kyoto

UNIVERSITY: Kyoto, 606-8502, Japan

SOURCE: Peptides 1998, Proceedings of the European Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (

Editor(s): Bajusz, Sandor; Hudetz, Ferenc. Akademiai

Kiado: Budapest, Hung.

DOCUMENT TYPE: CODEN: 68WKAY
 LANGUAGE: English
 AB In this study, an AM-toxin I analog in which the L-Ala residue

was replaced by β -Ala as well as analogs in which a Gly residue was inserted at either terminus of L-Ala were synthesized and their structure-activity relationship was examined. The mol. hydrophobicity of these AM-toxin analogs was also determined in terms of the partition coefficient in a 1-octanol/water system and the HPLC retention time, in order to evaluate the effect of the penetration of the comps. through cell membranes of apple leaves. In conclusion, the AM-toxin I analogs having an

extended backbone-ring structure were synthesized and the effect of the structure on necrotic activity was investigated. The fact these compds. had the much lower activity than AM-toxin I suggests that the backbone structure of AM-toxin I is important for activity.

IT 308341-40-4P
RL: ADV (Adverse effect, including toxicity); PRP (Properties); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(Relationship between structure and phytotoxic activity of cyclic

tetradepsipeptides, AM-toxin analogs)

RN 308341-40-4 CAPLUS


CN 1-Oxa-4,7,10-triazacyclododecane-2,5,8,11-tetrone, 9-[3-(4-methoxyphenyl)propyl]-6-methylene-12-(1-methylethyl)-, (9S,12S)-(9CI)

(CA INDEX NAME)

NTE cyclic
modified (modifications unspecified)

SEQ 1 AGXX

Absolute stereochemistry.



REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L20 ANSWER 5 OF 2815

CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:288538

CAPLUS Full-text

DOCUMENT NUMBER: 133:17814

TITLE:

Synthesis, conformation and interaction of peptides

AUTHOR(S):

containing 9-aminofluorene-9-carboxylic acid
Yamada, Takashi; Makthira, Kazumari; Suzuki, Satomi;

Yanagihara, Ryoji; Miyazawa, Toshifumi

CORPORATE SOURCE: Konan

Department of Chemistry, Faculty of Science, University, Kobe, 658-8501, Japan

SOURCE: Peptide

Peptides 1998, Proceedings of the European Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1999, Meeting date 1998, 404-405.

1998 (

Editor(s):

Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado:

DOCUMENT TYPE:

AB

English

A symposium report. We report the synthesis of peptides contg.

9-aminofluorene-9-carboxylic acid (Afc), in order to compare them with α,α -diphenylglycine-containing peptides. Afc has a rigid planar side chain in which two Ph groups are forced to be coplanar.

IT 256381-25-6P 256381-26-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (Synthesis, conformation and interaction of peptides containing

aminofluorene-9-carboxylic acid)


RN 256381-25-6 CAPLUS

CN Glycine, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-alanyl-9-amino-9H-fluorene-9-carbonyl-, methyl ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 LAXG

Absolute stereochemistry.




RN 256381-26-7 CAPLUS

CN L-Leucine, N-[(phenylmethoxy)carbonyl]-L-alanyl-9-amino-9H-fluorene-9-

carbonyl]glycyl-, methyl ester (9CI) (CA INDEX NAME)
 NTE modified (modifications unspecified)
 SEQ 1 AXGL

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:288402 CAPLUS Full-text
 DOCUMENT NUMBER: 132:347920
 TITLE: Peptide synthesis catalyzed by subtilisin

AUTHOR(S): thermolysin in organic solvents
 Lysogorskaya, getun, Irina V.; Filipova, Irina Yu.;
 Elena S.; Elena N.; Anisimova, Veronika V.; Oksenoit,
 Bacheva, Anna V.; Stepanov, Valentin M.
 CORPORATE SOURCE: Department of Chemistry, Lomonosov Moscow
 State University, Russia

SOURCE: Peptides 1998, Proceedings of the European
 Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4,
 1998 (1999), Meeting Date 1998, 132-133.


Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai
 Kiado:

DOCUMENT TYPE: Budapest, Hung.
 LANGUAGE: CODEN: 68WKAY
 AB A symposium report. The purpose of the present work is to study
 the possibility of dissolving and using subtilisin 72 and
 thermolysin as catalysts for peptide bond synthesis in organic
 solvents.
 IT 197719-42-9p

RL: BPN (Biosynthetic preparation); BIOL (Biological study);
 PREP (Preparation)
 (peptide synthesis catalyzed by subtilisin and thermolysin in
 organic solvents)
 RN 197719-42-9 CAPLUS
 CN L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-alanyl-L-alanyl-
 leucyl-
 (9CI) (CA INDEX NAME)

NTE modified
 SEQ 1 AALL

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:264469 CAPLUS Full-text
 DOCUMENT NUMBER: 133:105301
 TITLE: Synthesis of oligopeptides containing

AUTHOR(S): α , α -diphenylglycine
 Ryoji; Yamada, Takashi; Urabe, Yuka; Yanagihara,
 Miyazawa, Toshifumi
 CORPORATE SOURCE: Department of Chemistry, Faculty of Science,
 konan University, Kobe, 658-8501, Japan

SOURCE: Peptide Science (1999), 36th, 143-146
 CODEN: PSCIRJ; ISSN: 1344-7661
 PUBLISHER: Japanese Peptide Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB By elongation in the N- and C-terminals of tripeptides contg.
 α , α -diphenylglycine (Dph), Z-AA1-Dph-AA3-OMe (AA1, AA3 = Gly,
 Alb), which were obtained by a modified Ugi reaction, Dph-
 containing tetra-, penta- and hexapeptides were synthesized by
 the EDC-HOBT and EDC-HOAT methods. Both couplings of Z-Alb-OH

with Aib-Dph-Aib-Aib-OMe and Z-Aib-Dph-Aib-OH with Aib-Dph-Aib-OMe were very difficult.

IT 283168-05-8p 283168-09-2p
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 283168-05-8 CAPLUS
 CN glycine, N-[[(phenylmethoxy)carbonyl]glycyl-2,2-diphenyl]glycyl-1-methyl ester (9CI) (CA INDEX NAME)

NTE modified
 SEQ 1 GXXG



RN 283168-09-2 CAPLUS
 CN glycine, N-[[(phenylmethoxy)carbonyl]glycyl]glycyl-2,2-diphenyl ester (9CI) (CA INDEX NAME)

NTE modified
 SEQ 1 GXXG



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 2815 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:264431 CAPLUS Full-text
 DOCUMENT NUMBER: 133:4981
 TITLE: Synthesis of amyloid β-peptides in solution: chloroform-phenol mixed solvent is essential for segment condensation of sparingly soluble protected

AUTHOR(S): peptides
 Inui, Tatsuya; Nishio, Hideki; Nishiuchi, Yuji;

CORPORATE SOURCE: Institute Inc.,
 KIMURA, Terutoshi
 Protein Research Foundation, peptide

SOURCE: Osaka, 562-8686, Japan
 peptide science (1999), 36th, 5-8
 CODEN: PSCIFQ; ISSN: 1344-7661

PUBLISHER: Japanese Peptide Society
 DOCUMENT TYPE: journal

AB A symposium report. A new solvent system, a mixt. of chloroform and phenol, was developed for the segment condensation of sparingly soluble protected peptides in solution and successfully applied to the synthesis of amyloid β-peptide (1-42), (1-43) and [Pyr3]-(3-42). These peptides of high homogeneity were used to examine the relation between structure and amyloidogenesis by means of CD spectra and fluorimetric assay.

IT 270083-73-3p
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(Synthesis of amyloid β-peptides in solution using chloroform-phenol mixed solvent for segment condensation of sparingly soluble protected peptides)

RN 270083-73-3 CAPLUS
 CN glycine, N-[[(1,1-dimethylethoxy)carbonyl]-L-alanyl-L-isoleucyl]-L-isoleucyl-2-oxo-2-phenylethyl ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AIIG

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE

(antitumor drug screening and US National Cancer Institute testing procedures)

testing procedures)	INDEX NAME)
RN 128517-07-7 CAPLUS	
CN Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercaptop-4-heptenyl-D-valyl-D-cysteinyl], cyclic (3→5)-disulfide (9CI)	
(CA	


SEQ 1 VCXV

Absolute stereochemistry.
double bond geometry as shown.

PAGE 1-A

9.

PAGE 2-A



REFERENCE COUNT: AVAILABLE FOR THIS RE FORMAT	21	THERE ARE 21 CITED REFERENCES RECORD. ALL CITATIONS AVAILABLE IN THE
L20 ANSWER 10 OF 2815 DOCUMENT NUMBER: ACCESSION NUMBER:	CAPLUS COPYRIGHT 2004 ACS on STN 2000:96608 CAPLUS Full-text 132:334737	

L20 ANSWER 10 OF 2815 CAPLUS, COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:96808 CAPLUS Full-text
DOCUMENT NUMBER: 132:334737

TITLE: FR901228: Antineoplastic antibiotic
 AUTHOR(S): Wang, Hwa-Chain R.
 CORPORATE SOURCE: Dept. of Comparative Medicine, University of Tennessee, Knoxville, TN, 37901-1071, USA
 SOURCE: Drugs of the Future (1999), 24(11), 1184-1188
 CODEN: DRFUD4; ISSN: 0377-8282

PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review with 18 ref. on bicyclic depsipeptide FR901228. Synthesis, fermentation, isolation and pharmacol. actions are discussed.

IT 128517-07-7p, FR901228


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation, fermentation, isolation and pharmacol. actions of antineoplastic antibiotic FR901228)

RN 128517-07-7 CAPLUS
 CN Cyclo[(2Z)-2-amino-2-butenyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenyl-D-valyl-D-cysteiny], cyclic (3→5)-disulfide (9CI)
 (CA INDEX NAME)

SEQ 1 VCV

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

=> FTL STNGUIDE
 COST IN U.S. DOLLARS
 TOTAL SINCE FILE
 ENTRY

SESSION
 FULL ESTIMATED COST 194.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE
 TOTAL ENTRY

SESSION
 CA SUBSCRIBER PRICE -14.00

FILE 'STNGUIDE' ENTERED AT 12:21:11 ON 09 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELEASED: SEP 3, 2004 (20040903/UP).

=> file reg
COST IN U.S. DOLLARS
TOTAL

SINCE FILE

SESSION

ENTRY

FULL ESTIMATED COST

0.42

736.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

ENTRY

CA SUBSCRIBER PRICE

0.00

36.40

FILE 'REGISTRY' ENTERED AT 12:25:06 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SMARTSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for
details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s [gavl][-fwht][-gfwhtp][gavl]/sqsp
L21 3624012 [gavl][-fwht][-gfwhtp][gavl]/sqsp
75% OF LIMIT FOR TOTAL ANSWERS REACHED

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
STRUCTURE UPLOADED

L1 50 S L1 SAM
L2 308369 S L1 FUL
L3

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
44 S L2

L5 0 S L4 AND PD<20000217

L6 FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
STRUCTURE UPLOADED
L7 38 S L6 SAM

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004

L8

FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004

L9 47 S L7
L10 41 S L8 AND PD<20020312
L11 33 S L9 AND PD<20000217
L12 2918396 S L10 AND PD<19990218
L13 32 S L10 AND PD<19990218

FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004

L13 3645970 S [gavl][-fwht][-gfwhtp][gavl]/sqsp
L14 5874 S L13 AND SQL=4

FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004

L15 4169 S L14
L16 3256 L15 AND PD<19990218
L17 0 L16 AND PATENT
L18 3 L16 AND PATENT
L19 441 L16 AND PATENT/DT
L20 2815 L16 NOT L19

FILE 'STNGUIDE' ENTERED AT 12:21:11 ON 09 SEP 2004

L21 FILE 'REGISTRY' ENTERED AT 12:25:06 ON 09 SEP 2004
3624012 S [gavl][-fwht][-gfwhtp][gavl]/sqsp

=> file caplus
COST IN U.S. DOLLARS
TOTAL

SINCE FILE

SESSION

ENTRY

FULL ESTIMATED COST

27.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

ENTRY

CA SUBSCRIBER PRICE

0.00

FILE 'CAPLUS' ENTERED AT 12:26:40 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2004 VOL 141 ISS 11
FILE LAST UPDATED: 8 Sep 2004 (20040908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 121
TOO MANY TERMS FOR FILE CROSSOVER IN L21
There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> file reg	
COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY
SESSION	
FULL ESTIMATED COST	0.44
764.61	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	ENTRY
SESSION	
CA SUBSCRIBER PRICE	0.00
36.40	-

FILE 'REGISTRY' ENTERED AT 12:27:20 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)
Property values tagged with IC are from the ZIC/VINITI data file provided by Infochem.

STRUCTURE FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8
DICTIONARY FILE UPDATES: 8 SEP 2004 HIGHEST RN 741635-85-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> 121 and sq1=4
62048 SQL=4
L22 4775 L21 AND SQL=4

=> file caplus
COST IN U.S. DOLLARS
TOTAL

SESSION	SINCE FILE
FULL ESTIMATED COST	ENTRY
769.46	4.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	ENTRY
SESSION	
CA SUBSCRIBER PRICE	0.00
36.40	-

FILE 'CAPLUS' ENTERED AT 12:27:30 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2004 VOL 141 ISS 11
FILE LAST UPDATED: 8 Sep 2004 (20040908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 122
L23 2994 L22

=> s 123 and 119
L24 346 L23 AND L19

=> d 124 1-5 1b1b abs hitseq

L24 ANSWER 1 OF 346 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2003:667404 CAPLUS Full-text
DOCUMENT NUMBER: 139:192555
TITLE: Promoter for telomerase reverse

transcriptase and its

INVENTOR(S): diagnostic and therapeutic use
Morth, Gregg B.; Andrews, William H.
PATENT ASSIGNEE(S): Geron Corporation, USA
SOURCE: U.S., 202 pp., Cont.-in-part of U.S. Ser.
No. 912,951.

DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 13

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19990929	US 6610839	B1	20030826	US 1999-402181
19970814	US 6475789	B1	20021105	US 1997-912951
19971001	WO 9814593	A2	19980409	WO 1997-US17885
	WO 9814593	A3	19990218	
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
20010523	AU 763956	B2	20030807	AU 2001-47992
20021220	US 2003204069	A1	20031030	US 2002-325810
19970814	PRIORITY APPLN. INFO.:			US 1997-911312
19970814				US 1997-912951
19970814				US 1997-915503
19970814				WO 1997-US17885
19971001				US 1996-724643
19961001				US 1997-844419
19970418				US 1997-846017
19970425				US 1997-851843
19970506				A2


19970509 US 1997-845050 A2
19970509 US 1997-854050 A
19971001 AU 1997-48073 A
19990929 US 1999-402181 A1

AB The invention provides comps. and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. Genomic, cDNA, and encoded amino acid sequences are provided for hTERT from a protozoan (Euplotes aediculatus), Schizosaccharomyces pombe, Tetrahymena thermophila, and human. The human hTERT promoter can be used in recombinant vectors for the expression of proteins toxic to cells expressing hTERT, thereby rendering the cell more susceptible to toxicity of drugs. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases; for changing the proliferative capacity of cells and organisms, and for identification and screening of comps. and treatments useful for treatment of diseases such as cancers.

IT 315195-82-5
RL: PRP (Properties)
(unclaimed sequence; promoter for telomerase reverse transcriptase and its diagnostic and therapeutic use)
RN 315195-82-5 CAPLUS
CN L-leucine, L-leucyl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 LLRL

Absolute stereochemistry.



REFERENCE COUNT: 193 THERE ARE 193 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L24 ANSWER 2 OF 346 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:545684 CAPLUS Full-text

DOCUMENT NUMBER: 139:106414
 TITLE: Sequences of porcine reproductive and
 respiratory syndrome virus (prsv) proteins and use in
 immunization
 INVENTOR(S): Paul, Prem S.; Meng, Xiang-Jin; Halbur,
 Patrick;
 PATENT ASSIGNEE(S): Morozov, Igor; Lum, Melissa A.
 Inc., USA; Iowa State University Research Foundation,
 American Cyanamid Company
 SOURCE: No. 131,625. U.S., 124 pp., Cont.-in-part of U.S. Ser.
 DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 9


DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
19940901	US 6592873	B1	20030715	US 1994-301435
19931005	US 5695766	A	19971209	US 1993-131625
19950607	US 6251397	B1	20010626	US 1995-478316
19950901	CA 2198461	AA	19960307	CA 1995-2198461
19950901	WO 9606619	A1	19960307	WO 1995-US10904
19950901	W: CA			
PT, SE	RW: AT, BE, CH, DE, ES, FR, GB, GR, IE, IT, LU, MC, NL,			
EP 776209	EP 1995-932336			
19950901	AL 19970604			
NL, PT, SE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,			
US 6380376	US 1998-19793			
19980206	B1 20020430			
US 6773908	US 2000-601326			
20000925	B1 20040810			
AU 771883	AU 2001-68774			
20010906	B2 20040408			
US 2002168379	US 2002-104019			
20020325	A1 20021114			
US 2003138442	US 2003-428826			
US 2003186225	A9 20030724			
20030505	US 20031002			
PRIORITY APPLN. INFO.:				
19921030	US 1992-969071			
19931005	US 1993-131625			
19940901	US 1994-301435			

19950607 US 1995-478316 A2
 19950901 WO 1995-US10904 W
 19980206 US 1998-19793 A2
 19980729 AU 1998-78586 A3
 19990208 WO 1999-US2630 W
 20000925 US 2000-601326 A3

AB The present invention provides a purified prepn. contg. a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRSV). proteins at least 80% but less than 100% homologous with those encoded by one or more of ORF 2, ORF 3, ORF 4 and ORF 5 of an Iowa strain of PRSV, proteins encoded by one or both of ORF 6 and ORF 7 of an Iowa strain of PRSV, antigenic regions of such proteins which are at least 5 amino acids in length and which effectively stimulate immunol. protection in a porcine host against a subsequent challenge with a PRSV isolate, and combinations thereof, in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a polypeptide encoded by such a polynucleic acid; a vaccine comprising an effective amount of such a polynucleic acid or protein; antibodies which specifically bind to such a polynucleic acid or protein; methods of producing the same; and methods of raising an effective immunol. response against a PRSV, treating a pig infected by a PRSV, and detecting a PRSV.

IT 557771-51-4
 RL: PRP (Properties)
 (unclaimed sequences; sequences of porcine reproductive and respiratory syndrome virus (prsv) proteins and use in immunization)
 RN 557771-51-4 CAPLUS
 CN Glycine, L-alanyl-L-seryl-L-glutaminyl- (9CI) (CA INDEX NAME)

SEQ 1 ASQG
 Absolute stereochemistry.



REFERENCE COUNT: 166 THERE ARE 166 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE
 IN THE RE FORMAT

L24 ANSWER 3 OF 346 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:507642 CAPLUS Full-text
 DOCUMENT NUMBER: 139:81311
 TITLE: Recombinant production and purification of
 human neutrophil protease prepro-PR-3 and its
 proteolytic processing and use for screening inhibitors
 of release

INVENTOR(S): of TNF α
 Perez, Carl; Halenbeck, Robert F.; Kriegler, Michael;

PATENT ASSIGNEE(S): Jewell, David A.; Koths, Kirston E.
 SOURCE: Chiron Corporation, USA
 No. 230,428. U.S., 53 pp., Cont.-in-part of U. S. ser.

DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 6

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	-----	-----	-----
19950228	US 6586222	B1	20030701	US 1995-395456
19900608 <--	AU 9059400	A1	19910403	AU 1990-59400
19900608 <--	EP 491878	A1	19920701	EP 1990-917939
19900608 <--	EP 491878	B1	19970219	
19900608 <--	JP 04507044	B1	19921210	JP 1990-509543
19900608 <--	JP 2930713	B2	19990803	

19900608 <--	EP 750037	A2	19961227	EP 1996-202206
19900608 <--	EP 750037	A3	19970115	
19900608 <--	NO 9200593	A	19920319	NO 1992-593
19920214 <--	US 5998378	A	19991207	US 1994-230428
19940419	CA 2185162	AA	19950914	CA 1995-2185162
19950302 <--	WO 9524501	A1	19950914	WO 1995-US2513
19950302 <--	W: AU, CA, JP, NO			
PT, SE	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,			
19950302 <--	AU 9519364	A1	19950925	AU 1995-19364
19950302 <--	AU 709054	B2	19990819	
19950302 <--	EP 749494	A1	19961227	EP 1995-912005
19950302 <--	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,			
NL, PT, SE	JP 10504441	T2	19980506	JP 1995-523506
19950302 <--	US 659706	B1	20030729	US 1995-487453
19950607	NO 9603726	A	19961031	NO 1996-3726
19960906 <--	PRIORITY APPLN. INFO.:			
19890816	19920625			US 1989-395253
19940307	19940307			US 1992-905546
19940419	19940419			US 1994-208574
19900608	19900608			US 1994-230428
19900608	19900608			EP 1990-917939
19950227	19950227			WO 1990-US3266
19950228	19950228			US 1995-394600
19950302	19950302			US 1995-395456
19990816	19990816			WO 1995-US2513
19990816	19990816			US 1999-395253

OTHER SOURCE(S): MARPAT 139:81311
 AB Methods and materials are disclosed for the prodn. of purified, active recombinant human neutrophil protease, PR-3 (also known as myeloblastin), via activation of the prepro- and pro-forms. PR-3 is cloned by transfecting Sf9 insect cells with a baculovirus vector and purified to >95% purity with an endotoxin content of <20 ng/mg PR-3 and a specific activity of .apprx.30 μ moles/min/mg PR-3 as assayed on Boc-Ala-ONP at pH 7.5 at 25°.

Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF α . Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF α to its mature active form.

IT 170156-30-6
RL: 85U (Biological study, unclassified); BIOL (Biological study)

(inhibition of PR-3 by; recombinant production and purification of human neutrophil protease prepro-PR-3 and its proteolytic processing and use

for screening inhibitors of release of TNF α)


RN 170156-30-6 CAPLUS

CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-L-alanyl-L-glutaminyl-anhydride with diphenyl hydrogen phosphate (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 LAQA

Absolute stereochemistry.



REFERENCE COUNT: 180 THERE ARE 180 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L24 ANSWER 4 OF 346 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:319378 CAPLUS Full-text

DOCUMENT NUMBER: 138:343951

TITLE: Structures useful for bone engineering

INVENTOR(S): Bhatnagar, Rajendra S.; Qian, Jing Jing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S.

Ser. No. 561,554, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:


DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
20020425	US 2003077825	A1	20030424	US 2002-133289
19940722	US 5635482	A	19970603	US 1994-278878
19970520	US 5958428	A	19990928	US 1997-859610
19990608	US 6268348	B1	20010731	US 1999-328347
20010323	US 2002037853	A1	20020328	US 2001-816737
20010329	WO 2001082773	A2	20011108	WO 2001-US10404
2001082773	WO 2001082773	A3	20020131	
CH, CN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,	YU, ZA, ZW		
BY, KG,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:				
19940722				US 1994-278878 A3
19970520				US 1997-859610 A1
19990608				US 1999-328347 A1
20000428				US 2000-561554 B1
20010323				US 2001-816737 A2
19890814				US 1989-393621 B2
19911209				US 1991-804782 A2
AB	A bone repair app. is provided where a bio[. compatible structure has a compound carried on the structure that mimics collagen binding to cells. Living cells derived from fibroblasts			

are carried on the structure and display at least one morphol. change consistent with an osteogenic phenotype. The preferred method for practicing the invention includes harvesting a quantity of fibroblasts from a patient in need of a bone graft, growing the tissue under cell growth conditions, and seeding at least some cells of the cultured tissue on the bio1. compatible structure with the collagen mimic thereon. The culture tissue cells are seeded on the structure and incubated under cell growth conditions, which results in the differentiation of the cells to bone-like cells and thus provides a tissue engineered apparatus ready for use as a bone graft. The peptide P-15, GTPGPGIAGQRVV was synthesized by a solid phase procedure. The P-15 was adsorbed on bovine bone derived porous ABM (bovine bone mineral) in a particulate form with a particle size of 250-420 μ m and the binding of cells to ABM-P-15 was proportional to the amount of adsorbed P-15. There is a marked increase in the expression of type I collagen in dermal fibroblasts growing on ABM-P-15 matrices. Marked stimulation of alkaline phosphatase gene expression in HA-P-15 cultures is consistent with the induction of a bone-like phenotype.

IT 136266-47-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (uses) (structures useful for bone engineering)
RN 136266-47-2 CAPLUS
CN Glycine, N-[N-(N-glycyl-L-isoleucyl)-L-alanyl]- (9CI) (CA INDEX NAME)

SEQ 1 GIAG

Absolute stereochemistry.



L24 ANSWER 5 OF 346 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:113343 CAPLUS Full-text
DOCUMENT NUMBER: 138:164723
TITLE: Vectors encoding chimeric fusion cytotoxins (IL-13)

ability of fused to mutant forms of exotoxin A), and
receptor bearing cytotoxins to bind and inhibit IL-13
tumor cells
INVENTOR(S): Puri, Raj K.; Debinski, Waldemar; Pastan, Ira; Obiri,

PATENT ASSIGNEE(S): Nicholas
by the The United States of America as Represented
SOURCE: Department of Health and Human Services, USA
5,614,191. U.S., 26 pp., Cont.-in-part of U.S.

DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 6

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
------	------------	------	------	-----------------

19980217	US 6518061	B1	20030211	US 1998-913370
19950315	US 5614191	A	19970325	US 1995-404685
19960315	WO 9629417	A1	19960926	WO 1996-US3486

DK, EE, W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN US 2003129132 A1 20030710 US 2002-318608

20021213 US 1995-404685 A2
PRIORITY APPLN. INFO.:
19950315 WO 1996-US3486 W
19960315 US 1998-913370 A1


AB The invention provides genetic vectors contg. nucleic acid mol's. encoding chimeric fusion proteins (cytotoxins) composed of human interleukin 13 or circularly permuted IL-13 (cpIL-13) attached to toxins, such as mutant forms pseudomonas aeruginosa exotoxin A (PE38QQR or PE4E). The invention also provides host cells transformed with said vectors. The invention relates that said chimeric fusion proteins (IL-13-PE38QQR, cpIL-13-PE38QQR, IL-13-PE4E and cpIL-13-PE4E) are able to bind tumor cells bearing IL-13 receptors. The invention further provides a composition comprising a pharmaceutical acceptable carrier and said chimeric proteins. The invention is based in part on the discovery that certain tumor cells, such as renal cell carcinoma (RCC) overexpress IL-13 receptors, and on the premise that specific vectors encoding the IL-13-PE fusion proteins can be used to target such cells. The invention demonstrated that various cancer cell lines, including RCC cell lines, glioma cell lines,

kaposi's sarcoma cell lines, and/or neural cancer cell lines were sensitive to said chimeric proteins resulting in growth inhibition or cytotoxicity of cells.

IT 496847-20-2
RL: PRP (Properties)
(unclained sequence; vectors encoding chimeric fusion cytotoxins (IL-13 fused to mutant forms of exotoxin A), and ability of cytotoxins to bind and inhibit IL-13 receptor bearing tumor cells)
RN 496847-20-2 CAPLUS
CN glycylglycyl-L-seryl- (9CI) (CA INDEX NAME)

SEQ 1 GSGG

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
L2 STRUCTURE UPLOADED
L3 308369 S L1 FULL

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
L5 44 S L2
0 S L4 AND PD<20000217

L6 FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
L7 STRUCTURE UPLOADED
38 S L6 SAM

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004
L8 FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
L9 47 S L7
41 S L8 AND PD<20020312

L10 33 S L9 AND PD<20000217
L11 2918396 S L10 AND PD<19990218
L12 32 S L10 AND PD<19990218

L13 FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
L14 3645970 S [GAVL][--FWHTP][GAVL]/SQSP
5874 S L13 AND SQL=4

L15 FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004
L16 4169 S L14
L17 3256 L15 AND PD<19990218
L18 0 L16 AND PATENT
L19 3 L16 AND PATENT
L20 441 L16 AND PATENT/DT
2815 L16 NOT L19

L21 FILE 'STNGUIDE' ENTERED AT 12:21:11 ON 09 SEP 2004
FILE 'REGISTRY' ENTERED AT 12:25:06 ON 09 SEP 2004
3624012 S [GAVL][--FWHTP][GAVL]/SQSP

L22 FILE 'CAPLUS' ENTERED AT 12:26:40 ON 09 SEP 2004
FILE 'REGISTRY' ENTERED AT 12:27:20 ON 09 SEP 2004
4775 L21 AND SQL=4

L23 FILE 'CAPLUS' ENTERED AT 12:27:30 ON 09 SEP 2004
L24 2994 S L22
346 S L23 AND L19

=> 123 not 124
L25 2648 L23 NOT L24

=> d 125 1-5 ibib abs hitseq

L25 ANSWER 1 OF 2648 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2004:634089 CAPLUS Full-text
DOCUMENT NUMBER: 141:167846
TITLE: Binding peptides for the KDR receptor and
vascular endothelial growth factor/KDR complex and
their use in

INVENTOR(S):
Dransfield, Daniel

Bussat,
Philippe; Fan, Hong; Khurana, Sudha; Linder,

Karen E.;
Marinelli, Edmund R.; Nanjappan, Palaniappa;

Nunn,
Adrian; Pillai, Radhakrishna; Pochon,

Sibylla;
Ramalingam, Kondareddiar; Shrivastava, Ajay;
Song, Bo;
Swenson, Rolf E.; Von Wronski, Mathew A.

PATENT ASSIGNEE(S): DYAX Corp., USA; Bracco International B.V.
 SOURCE: PCT Int. Appl., 470 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
20030911	WO 2004065621	A1	20040805	WO 2003-US28787
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SN, TD, TG</p> <p>WO 2003074005 A2 WO 20030912 WO 2003-US6731</p> <p>20030303 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SN, TD, TG</p> <p>PRIORITY APPLN. INFO.: US 2002-360851P P</p>				

20020301 US 2003-440411P P
 20030115 US 2003-382082 A2
 20030303 WO 2003-US6731 A2
 20030303

AB The present invention provides peptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR receptor or vascular endothelial growth factor (VEGF)/KDR complex, which have a variety of uses wherever treating, detecting, isolating, or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated peptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a $K_D < 1 \mu M$), and dimer and multimeric constructs comprising these polypeptides. The involvement of VEGF and KDR in angiogenesis makes the binding peptides particularly useful for imaging important sites of angiogenesis, e.g., neoplastic tumors, for targeting substances, e.g., therapeutics, including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis.


IT RL: DGN (Diagnostic use); RIOL (biological study); USES (uses) (chelator); binding peptides for the KDR receptor and vascular endothelial growth factor/KDR complex and their use in diagnosis, therapy, and imaging of angiogenesis-related disorders)

RN 612494-16-3 CAPLUS
 CN glycine, N,N-dimethylglycyl-O-(1,1-dimethylethyl)-L-seryl-S-(triphenylmethyl)-L-cysteinyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 GSCG

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 2648 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:633438 CAPLUS Full-text
DOCUMENT NUMBER: 141:150974
TITLE: Use of histone deacetylase inhibitors as synergistic
INVENTOR(S): agents in cancer therapy
ANATOLOGY Jung, Mira; Jung, Manfred; Dritschilo,
PATENT ASSIGNEE(S): Georgetown University, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
20040116	WO 2004064727	A2	20040805	WO 2004-US1019
W: AE, AE, AG, AL, AL, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MX, MX, MZ, MZ, NA, NI				
PRIORITY APPLN. INFO.: US 2003-440349P P				
20030116				

AB The invention relates to the use of inhibitors of histone deacetylase (HDAC) as synergistic agents in improved cancer therapies. The present invention relates to a treatment for cancer that combines the administration of a synergistically effective amount of at least one inhibitor of histone deacetylase with at least one other anticancer treatment. The increased effectiveness of radiation therapy provided by the present invention is believed to arise, at least in part, because de-condensed chromatin appears to be more sensitive to radiation damage than condensed chromatin. In the present invention, without wishing to be bound by theory, it is believed that HDAC inhibitors function to disrupt the equilibrium of acetylation states and thereby increase cell killing by ionizing radiation and chemotherapy. On the basis of these and other observations, the authors have discovered that histone deacetylase (HDAC) inhibitors can be employed in conjunction with radiation treatment of neoplastic disorders such as various cancers to provide a synergistic effect. In the present study, they observed that several potent HDAC inhibitors, including trichostatin A, suberoylanilide hydroxamic acid, M344 (an analog

of hydroxamic acid), and the cyclic tetrapeptide, desipeptide (FR90228), modulate cellular responses to ionizing radiation in cells of two human squamous carcinoma lines (SQ-208 and SCC-35), previously characterized as intrinsically resistant to radiation. Also exposure to IC50 concns. of these inhibitors, radiation sensitivities were enhanced in both cell lines; desipeptide exhibited the greatest effect on SQ-208 cells, decreasing D0 values from 2.62 Gy to 1.64 Gy. M344 was the most active drug in sensitizing SCC-35 cells, decreasing D0 values from 1.91 Gy to 1.21 Gy. The mechanisms underlying HDAC inhibitor-induced radiosensitization were further investigated by extending trichostatin A studies to assess cell cycle distributions and levels of apoptosis. Treatment of SQ-208 cells with radiosensitizing concns. of trichostatin A resulted in cell cycle arrest in G1 phase (>70%) and inhibition of DNA synthesis. Contrary to previous reports, induction of apoptosis was very low and caspase 3 and 9 were not activated. Taken together, these results implicate G1 arrest and inhibition of DNA synthesis in the mechanisms underlying radiation sensitization by trichostatin A and support the use of HDAC inhibitors for targeting radioresistant cancers.

IT 128517-07-7, FR901228
RI: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
- (Biological study); USES (Uses)
(histone deacetylase inhibitor; use of histone deacetylase inhibitors
as synergistic agents in cancer therapy)
RN 128517-07-7 CAPLUS
CN Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl]-(3S,4E)-3-hydroxy-7-mercaptop-4-heptenyl-D-valyl-D-cysteinyl], cyclic (3-5)-disulfide (9CI)
(CA INDEX NAME)


SEQ 1 VCVV
Absolute stereochemistry.
Double bond geometry as shown.

9.

PATENT INFORMATION:			
DATE	PATENT NO.	KIND	DATE
20030911	WO 2004064595	A2	20040805
			WO 2003-US28838
CZ, DE,	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,		
KE, KG,	DK, EE, ES, FI, GB, GD, GE, GH, HU, ID, IL, IN, IS, JP,		
MM, MX,	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,		
TT, UA,	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR,		
TM	UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,		
BE, BG,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT,		
LU, MC,	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,		
GN, GQ,	NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,		
	GW, ML, MR, NE, SN, TD, TG		
20030303	US 2004018974	A1	20040129
PRIORITY	APPLN. INFO.:		US 2003-379287
20030115			US 2003-440201P
			US 2003-379287
			A
20030303			US 2002-360821P
			P
AB	The invention features multivalent constructs using small targeting moieties which bind to different sites of the same target allowing for improved localization to the desired target and providing improved means for detecting, imaging and/or treating the target site. These targeting constructs may be linked or conjugated to a detectable label and/or a therapeutic agent and used to deliver the detectable label and/or therapeutic agent to the target of interest. The target may be a receptor involved in angiogenesis, hyperproliferative disorders or wound healing. Among examples provided are human carcinoma cell growth inhibition by an antiangiogenic heterodimeric peptide binding to VEGF receptor 2 (KDR), and ultrasound imaging using microbubbles derivatized with a KDR-binding heterodimer.		
IT	612494-16-3		
	RL: RCT (Reactant); RACT (Reactant or reagent)		
	(multivalent constructs for therapeutic and diagnostic applications)		
CN	612494-16-3 CAPLUS		
	glycine, N,N-dimethylglycyl-0-(1,1-dimethyl-ethyl)-L-seryl-S-(triphenylmethyl)-L-cysteiny]- (9CI) (CA INDEX NAME)		
NTE	modified (modifications unspecified)		

SEQ 1 GSCG

Absolute stereochemistry.



L25 ANSWER 4 OF 2648 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:612485 CAPLUS Full-text
DOCUMENT NUMBER: 141:156097
TITLE: Immunodominant epitopes capable of evoking
MHC class

INVENTOR(S): I- or II-mediated immune response
PATENT ASSIGNEE(S): Mittelman, Abraham; Kanduc, Darja
SOURCE: USA
U.S. Pat. Appl. Publ., 30 pp., Cont. of U.S.
Ser. No.

DOCUMENT TYPE: 306,541.
LANGUAGE: CODEN: USXXCO
FAMILY ACC. NUM. COUNT: Patent
PATENT INFORMATION: English 1


DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	-----	-----	-----
US 2004147044	A1	20040729	US 2003-648547	
20030825				
US 2004171081	A1	20040902	US 2002-306541	
20021125				
PRIORITY APPLN. INFO.:				
20011123				
US 2001-333249P	P			
20021125				
US 2002-306541	A1			
AB				
The invention provides a method for identifying amino acid sequences in antigens of interest that are useful for evoking immune responses. The amino acid sequences have low sequence similarity to the host proteome and are predicted to bind to MHC. Also disclosed are HPV epitopes that evoke class I or class II mediated immune responses.				
IT 211555-82-7 727976-43-4				
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);				
THU (Therapeutic use); ANST (Analytical study); BIOL (Biological				

study);
USES (Uses)
(Immunodominant epitopes capable of evoking MHC class I- or II-mediated immune response)

II-mediated
RN 211555-82-7 CAPLUS
CN Glycine, glycyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 GPAG


Absolute stereochemistry.



RN 727976-43-4 CAPLUS
CN L-leucine, L-leucyl-L-α-glutamyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

SEQ 1 LEDL

Absolute stereochemistry.



L25 ANSWER 5 OF 2648 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:610076 CAPLUS Full-text
DOCUMENT NUMBER: 141:134068
TITLE: Use of cyclin D1 inhibitors following breast cancer therapy
INVENTOR(S): Kronblad, Asa; Stendahl, Maria; Landberg, Goeran
PATENT ASSIGNEE(S): Forskarpatent I Syd Ab, swed.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
------	------------	------	------	-----------------

20040109	WO 2004062654	A1	20040729	WO 2004-SE6
----------	---------------	----	----------	-------------

W: AE, AE, AG, AL, AL, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ

PRIORITY APPLN. INFO.: SE 2003-98 A

AB The invention relates to use of certain cyclin D1 inhibitors at the manuf. of pharmaceutical preps. to be used in the treatment of patients to improve their response to tamoxifen treatment following a breast cancer treatment, either surgically, using cytotoxic compds. and/or irradiation, as well as a method of treatment.

IT 128517-07-7, FR-901228

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of cyclin D1 inhibitors following breast cancer therapy)


RN 128517-07-7 CAPLUS

CN Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl]-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3→5)-disulfide (9CI)

(CA INDEX NAME)

SEQ 1 VCV

Absolute stereochemistry.
Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
STRUCTURE UPLOADED

L1 50 S L1 SAM
L2 308369 S L1 FUL
L3

FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
L4 44 S L2
L5 0 S L4 AND PD<20000217

FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
STRUCTURE UPLOADED
L6 38 S L6 SAM
L7

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004
FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
L8 47 S L7
L9 41 S L8 AND PD<20020312
L10 33 S L9 AND PD<20000217
L11 2918396 S 10 AND PD<19990218

L12 32 S L10 AND PD<19990218

L13 FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
3645970 S [GAVL][-FMHT][GAVL]/SQSP

L14 5874 S L13 AND SQL=4

L15 FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004
4169 S L14

L16 3256 L15 AND PD<19990218

L17 0 L16 AND PATENT

L18 3 L16 AND PATENT

L19 441 L16 AND PATENT/DT

L20 2815 L16 NOT L19

L21 FILE 'STRINGUIDE' ENTERED AT 12:21:11 ON 09 SEP 2004

L22 FILE 'REGISTRY' ENTERED AT 12:25:06 ON 09 SEP 2004
3624012 S [GAVL][-FMHT][GAVL]/SQSP

L23 FILE 'CAPLUS' ENTERED AT 12:26:40 ON 09 SEP 2004

L24 FILE 'REGISTRY' ENTERED AT 12:27:20 ON 09 SEP 2004
4775 L21 AND SQL=4

L25 FILE 'CAPLUS' ENTERED AT 12:27:30 ON 09 SEP 2004
2994 S L22
346 S L23 AND L19
2648 L23 NOT L24

L26 => 123 and patent/dt
4426341 PATENT/DT
642 L23 AND PATENT/DT

L27 => 1 23 not 126
1357467 L
399811 23
168 L 23
(L(W)23)

L28 168 L 23 NOT L26

=> s 123 not 126

L28 2352 L23 NOT L26

=> d 128 1-5 ibtb abs hitsseq

L28 ANSWER 1 OF 2352 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:526860 CAPLUS Full-text
DOCUMENT NUMBER: 141:116700
TITLE: T-cell lymphoma as a model for the use of
histone deacetylase inhibitors in cancer therapy:
Impact of depeptide on molecular markers,
therapeutic targets, and mechanisms of resistance
AUTHOR(S): Piekarz, Richard L.; Robey, Robert W.; Zhan,
Zhiqiong;

Abdelidaim, Amina Kayastha, Ganesh; Sayah, Anousheh;

CORPORATE SOURCE: H.; Torrico, Sonia; Bates, Susan E.
Cancer Cancer Therapeutics Branch, Center for
Research, National Cancer Institute (NCI),
National Institutes of Health (NIH), Bethesda, MD,

USA blood (2004), 103(12), 4636-4643

SOURCE: CODEN: BLOODAW; ISSN: 0006-4971

PUBLISHER: American society of Hematology
JOURNAL

DOCUMENT TYPE: English

LANGUAGE: English

AB Depeptide (FK228) is a novel histone deacetylase inhibitor currently in clin. trials and the first to demonstrate clin. activity in patients. Responses have been observed in patients with T-cell lymphomas, despite prior treatment with multiple chemotherapeutic agents. To better understand the effects of histone deacetylase inhibitors on T-cell lymphoma, the human T-cell lymphoma cell line HUT78 was tested for sensitivity and mol. response to depeptide. Treatment with depeptide, as well as other histone deacetylase inhibitors, caused induction of histone acetylation, induction of p21 expression, and substantial apoptosis without significant cell cycle arrest. Treatment with the caspase inhibitor z-VAD-fmk significantly inhibited depeptide-induced apoptosis, enabling detection of cell cycle arrest. Treatment with depeptide increased expression of the interleukin-2(IL-2) receptor, and combination with the IL-2 toxin conjugate denileukin diftiox resulted in more than additive toxicity. Cells selected for resistance to depeptide overexpressed the multidrug resistance pump, P-glycoprotein (Pgp). However, cells selected for resistance to depeptide in the presence of a Pgp inhibitor had a Pgp-independent mechanism of resistance. These studies confirm the activity of depeptide in a T-cell lymphoma model and suggest a general sensitivity of T-cell lymphoma to histone deacetylase inhibitors, an emerging new class of anticancer agents.

IT 128517-07-7, FK228
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Impact of depeptide on mol. markers, therapeutic targets, and mechanisms of resistance in T-cell lymphoma)

RN 128517-07-7 CAPLUS
CN Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl]-(3S,4E)-3-hydroxy-7-mercaptop-4-heptenoyl-D-valyl-D-cysteiny], cyclic (3->5)-disulfide (9CI)


(CA INDEX NAME)

SEQ 1 VCXV

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L28 ANSWER 2 OF 2352 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:514097 CAPLUS Full-text
TITLE: A study of a α,β -didehydroalanine
homo-oligopeptide series in the solid-state
by 13C
AUTHOR(S): Cross-polarization magic angle spinning NMR
Wildman, Katherine A.; Henzler; Ramamoorthy,
Ayyalusamy; Wakamiya, Tateaki; Yoshikawa,
Taichi; Crisma, Marco; Tonio, Claudio; Formaggio,
Ferrando
CORPORATE SOURCE: Department of Chemistry, University of
Michigan, Ann Arbor, MI, 48109-1055, USA
SOURCE: Journal of Peptide Science (2004), 10(6),
336-341
CODEN: JPSEI; ISSN: 1075-2617
PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE:


Journal
English

LANGUAGE:

AB The fully extended peptide conformation (2.05-helix) has been investigated for the first time in the solid-state by 13C cross-polarization magic angle spinning NMR. The compounds examined are members of a terminally protected, homo-oligopeptide series (from monomer through hexamer) based on α,β -didehydroalanine.
IT 223778-49-2
RL: PRP (Properties)
(Secondary structure of didehydroalanine homooligopeptides in solid-state by 13C cross-polarization magic angle spinning

NMR) 223778-49-2 CAPLUS
RN Alanine, N-(4-bromobenzoyl)-2,3-didehydro[any]-2,3-
CN dididehydro[any]-2,3-
NAME) dididehydro[any]-2,3-didehydro-, methyl ester (9CI) (CA INDEX
NTE modified (modifications unspecified)

SEQ 1 AAAA



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L28 ANSWER 3 OF 2352 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:469027 CAPLUS Full-text
DOCUMENT NUMBER: 141:174468
TITLE: Structure-dependent nonenzymatic deamidation
of glutamyl and asparagyl pentapeptides
AUTHOR(S): Robinson, N. E.; Robinson, Z. W.; Robinson,
B. R.; Robinson, A. L.; Robinson, J. A.; Robinson,
M. L.; Robinson, A. B.
CORPORATE SOURCE: Division of Chemistry and Chemical
Engineering, California Institute of Technology,
Pasadena, CA, USA
SOURCE: Journal of Peptide Research (2004), 63(5),
426-436
CODEN: JPERFA; ISSN: 1397-002X

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nonenzymic deamidation rates for 52 [glutaminyl and 52 asparaginyl] pentapeptides in pH 7.4, 37.0 °C. 0.15 M Tris-HCl buffer have been determined by direct injection mass spectrometry. These and the previously reported 306 asparaginyl rates have been combined in a self-consistent model for peptide deamidation. This model depends quant. upon peptide structure and involves succinimide, glutarimide and hydrolysis mechanisms. The exptl. values and suitable interpolated values have been combined to provide deamidation rate values in pH 7.4, 37.0 °C. 0.15 M Tris-HCl buffer for the entire set of 648 single-amide permutations of ordinary amino acid residues in GlyxxxAsnYYGly and GlyxxxGlnYYGly. Thus, knowledge about sequence-dependent deamidation in peptides is extended to include very long deamidation half-times in the range of 2-50 yr.


IT 55673-24-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

peptides)
RN 55673-24-0 CAPLUS
CN L-Alaninamide, L-alanyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 AAAA

Absolute stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L28 ANSWER 4 OF 2352 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:465491 CAPLUS Full-text
DOCUMENT NUMBER: 141:157465
TITLE: Synthesis and SAR of bis-statine based
peptides as

AUTHOR(S): BACE 1 inhibitors
Hu, Baithua; Fan, Kristi Yi; Bridges,
Kristie; Chopra,

Ping;


Rebecca;

CORPORATE SOURCE:
Sciences, Wyeth

SOURCE:
(2004),

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:
GI

rajiv; Lovering, Frank; Cole, Derek; Zhou,
ellingboe, John; Jin, Guixiang; Cowling,
Bard, Jonathan
Department of Chemical and Screening
Research, Collegeville, PA, 19426, USA
Bioorganic & Medicinal Chemistry Letters
14(13), 3457-3460
CODEN: BMCLB; ISSN: 0960-894X
Elsevier Science B.V.
Journal
English



AB A new series of bis-statine based peptidomimetic inhibitors of human β -secretase (BACE 1) was developed by structure-based modification of the three regions of initial bis-statine peptidomimetic I. Introduction of a 4-aminomethylbenzoic acid on the C-terminus resulted in a potent BACE 1 inhibitor with an IC50 value of 21 nM. The general requirements for the optimal substrate-enzyme interaction are disclosed herein.

IT 731860-42-7P 731860-43-8P 731860-44-9P
731860-45-0P 731860-46-1P 731860-47-2P
731860-48-3P 731860-49-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(synthesis and β -secretase-inhibiting structure-activity
relationship of bis-statine based peptides)

RN 731860-42-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 LXXV

Absolute stereochemistry.




RN 731860-43-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 LXXL

Absolute stereochemistry.




RN 731860-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 LXXV


Absolute stereochemistry.



RN 731860-45-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified (modifications unspecified)
SEQ 1 LXXV

Absolute stereochemistry.





RN 731860-46-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 LXXV

Absolute stereochemistry.




RN 731860-47-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified (modifications unspecified)

SEQ 1 LXXV

Absolute stereochemistry.




RN 731860-48-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 VXXV

Absolute stereochemistry.




RN 731860-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 GXV

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

17 THERE ARE 17 CITED REFERENCES

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L28 ANSWER 5 OF 2352 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 2004:459215 CAPLUS Full-text

DOCUMENT NUMBER: 141:162318

TITLE: Conjugates of gadolinium complexes to bile

acids as hepatocyte-directed contrast agents for

magnetic resonance imaging

AUTHOR(S): Anelli, Pier Lucio; Lattuada, Luciano;

Lux, Giovanna; Morisetti, Alberto; Morosini,

Pierfrancesco; Serletti, Michele; Uggeri,

Fulvio

CORPORATE SOURCE: Bracco Imaging spa, Milano Research Centre,

20134, Italy

SOURCE: Journal of Medicinal Chemistry (2004),

47(14),

3629-3641

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of structurally different Gd(III) conjugates

incorporating a bile acid moiety have been prepared

polyaminopolycarboxylic ligands such as

diethylenetriaminopentaacetic acid (DTPA) and 1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA) have been

selected as chelating subunit for the Gd(III) ion. Cholic acid,

choylglycine, and cholytaurine have been incorporated as the

bile acid moieties. In first generation conjugates the Gd(III)

complex was linked to the carboxyl group of cholic acid. Second

generation conjugates featured the attachment of the Gd(III)

complex to the 3 position of the steroid backbone of the bile

acid. Finally, in third generation conjugates the Gd(III)

complex was attached to the ε nitrogen atom of cholylllysine. The conjugates were eliminated through the biliary route to a various extent (7.5 to 77% in rats) according to their structural features. Among the most promising terms, a second generation conjugate in which the Gd(III) complex was linked to cholic acid through the 3α hydroxy group seems to enter hepatocytes using the Na+/taurocholate transporter. Noticeably, some of the second generation conjugates were characterized by very high tolerabilities (LD50 up to 9.5 mmol/kg) after i.v. administration in mice.

IT 731009-28-2DP, gadolinium complexes

RL: ADV (Adverse effect, including toxicity); PKT

(Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(Preparation of gadolinium conjugates with bile acids as hepatocyte-directed

contrast agents for magnetic resonance imaging)

RN 731009-28-2 CAPLUS

CN glycineamide, N-[2-[[2-


bis(carboxymethyl)amino]ethyl]](carboxymethyl)amino]

ethyl]-N-(carboxymethyl)glycyl-N-[(3α,5β,7α,12α)-24-


[(carboxymethyl)amino]-7,12-dihydroxy-24-oxocholan-3-yl]- (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 731009-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reaction) or reagent

(Preparation of gadolinium conjugates with bile acids as

hepatocyte-directed contrast agents for magnetic resonance imaging)

RN 731009-28-2 CAPLUS

CN glycineamide, N-[2-[[2-

bis(carboxymethyl)amino]ethyl]](carboxymethyl)amino]

ethyl]-N-(carboxymethyl)glycyl-N-[(3α,5β,7α,12α)-24-

[(carboxymethyl)amino]-7,12-dihydroxy-24-oxocholan-3-yl]- (9CI)


(CA INDEX NAME)


NTE modified (modifications unspecified)

SEQ 1 GGXG

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:50:19 ON 09 SEP 2004)

L1 FILE 'REGISTRY' ENTERED AT 10:50:27 ON 09 SEP 2004
 L2 STRUCTURE UPLOADED
 L3 308369 S L1 FUL

L4 FILE 'CAPLUS' ENTERED AT 10:52:16 ON 09 SEP 2004
 L5 44 S L2
 L6 0 S L4 AND PD<20000217

L7 FILE 'REGISTRY' ENTERED AT 10:54:26 ON 09 SEP 2004
 L8 STRUCTURE UPLOADED
 L9 38 S L6 SAM

FILE 'REGISTRY' ENTERED AT 11:34:50 ON 09 SEP 2004

L8 FILE 'CAPLUS' ENTERED AT 11:34:54 ON 09 SEP 2004
 L9 47 S L7
 L10 41 S L8 AND PD<20020312
 L11 33 S L9 AND PD<20000217
 L12 2918396 S L10 AND PD<19990218
 L13 32 S L10 AND PD<19990218

FILE 'REGISTRY' ENTERED AT 12:10:10 ON 09 SEP 2004
 L13 3645970 S [GAVL] [-FWHT] [GAVL]/SQSP
 L14 5874 S L13 AND SQL=4

FILE 'CAPLUS' ENTERED AT 12:14:56 ON 09 SEP 2004
 L15 4169 S L14
 L16 3256 L15 AND PD<19990218

L17 0 L16 AND PATEN
 L18 3 L16 AND PATENT
 L19 441 L16 AND PATENT/DT
 L20 2815 L16 NOT L19

FILE 'STNGUIDE' ENTERED AT 12:21:11 ON 09 SEP 2004

L21 FILE 'REGISTRY' ENTERED AT 12:25:06 ON 09 SEP 2004
 3624012 S [GAVL] [-FWHT] [GAVL]/SQSP

FILE 'CAPLUS' ENTERED AT 12:26:40 ON 09 SEP 2004

L22 FILE 'REGISTRY' ENTERED AT 12:27:20 ON 09 SEP 2004
 4775 L21 AND SQL=4

FILE 'CAPLUS' ENTERED AT 12:27:30 ON 09 SEP 2004

L23 2994 S L22
 L24 346 S L23 AND L19
 L25 2648 L23 NOT L24
 L26 642 L23 AND PATENT/DT
 L27 168 L 23 NOT L26
 L28 2352 S L23 NOT L26

=> s 128 and pd<19990218
 19597386 PD<19990218
 (PD<19990218)

L29 1915 L28 AND PD<19990218

=> d 129 1-5 ibib abs hitseq

L29 ANSWER 1 OF 1915 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2000:288578 CAPLUS FULL-text
 DOCUMENT NUMBER: 133:120640
 TITLE: Study on the cyclization tendency of
 tetrapeptides

AUTHOR(S):
 Rakefet;
 containing N-alkylated alanines
 Besser, Diana; Ollender, Roberto; Rosenfeld,

CORPORATE SOURCE:
 07743,
 Reissmann, Siegmund
 Institute of Biochemistry and Biophysics,
 Friedrich-Schiller-University of Jena, Jena,

SOURCE:
 Peptide
 Symposium, 25th, Budapest, Aug. 30-Sept. 4,
 1999), Meeting date 1998, 484-485.

Editor(s):
 Bajusz, Sandor; Hudecz, Ferenc. Akademiai

kiado:
 Budapest, Hung.
 CODEN: 68WKAY
 Conference

DOCUMENT TYPE:
 LANGUAGE:

English

AB A symposium report. Linear tetrapeptide nitrophenyl esters, contg. Na-(carboxymethyl)alanine at position 1 and Na-(aminoethyl)alanine at position 4, were synthesized via solid-phase synthesis. Cyclization for these peptide esters was studied in solution and their cyclization rates were obtained.

IT 284666-66-6P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) and cyclization tendencies of tetrapeptides containing N-alkylated alanines)


RN 284666-66-6 CAPLUS

CN L-Alanine, N-(carboxymethyl)-L-alanyl-L-alanyl-N-(2-aminoethyl)-4-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AAAA

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 2 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:288575 CAPLUS Full-text
 DOCUMENT NUMBER: 134:1500
 TITLE: Relationship between structure and
 phytotoxic activity
 of cyclic tetrapeptides, AM-toxin
 analogs
 AUTHOR(S): Miyashita, Masahiro; Nakamori, Tomoko;
 Murai, Takahiro; Miyagawa, Hisashi; Akamatsu, Miki;
 Ueno, Tamio
 CORPORATE SOURCE: Graduate School of Agriculture, Kyoto
 University, Kyoto, 606-8502, Japan
 SOURCE: Peptides 1998, Proceedings of the European

Peptide
 1998 (Symposium, 25th, Budapest, Aug. 30-sept. 4,
 1999), Meeting Date 1998, 478-479.
 Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai
 kiado:

DOCUMENT TYPE: Budapest, Hung.
 CODEN: 68WKAY
 LANGUAGE: English Conference

AB In this study, an AM-toxin I analog in which the L-Ala residue was replaced by β -Ala as well as analogs in which a gly residue was inserted at either terminus of L-Ala were synthesized and their structure-activity relationship was examined. The mol. hydrophobicity of these AM-toxin analogs was also determined in terms of the partition coefficient in a 1-octanol/water system and the HPLC retention time, in order to evaluate the effect of the penetration of the comps. through cell membranes of apple leaves. In conclusion, the AM-toxin I analogs having an extended backbone-ring structure were synthesized and the effect of the structure on necrotic activity was investigated. The fact these comps. had the much lower activity than AM-toxin I suggests that the backbone structure of AM-toxin I is important for activity.

IT 308341-40-4P
 RL: ADV (Adverse effect, including toxicity); PRP (Properties);

SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


cyclic (relationship between structure and phytotoxic activity of tetrapeptides, AM-toxin analogs)

RN 308341-40-4 CAPLUS
 CN 1-Oxa-4,7,10-triazacyclododecane-2,5,8,11-tetrone, 9-[3-(4-methoxyphenyl)propyl]-6-methylene-12-(1-methylethyl)-, (9S,12S)-(9CI)
 (CA INDEX NAME)

NTE Cyclic modified (modifications unspecified)

SEQ 1 AGXX

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:288538 CAPLUS Full-text
DOCUMENT NUMBER: 133:17814

TITLE: Synthesis, conformation and interaction of peptides

AUTHOR(S): containing 9-aminofluorene-9-carboxylic acid Yamada, Takashi; Makihira, Kazunari; Suzuki, Satomi;

CORPORATE SOURCE: Yanagihara, Ryoji; Miyazawa, Toshifumi Department of Chemistry, Faculty of Science, University, Kobe, 658-8501, Japan

SOURCE: Peptides 1998, Proceedings of the European Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (

Editor(s): 1999), Meeting date 1998, 404-405.

Kiado: Bajusz, Sandor; Hudecz, Ferenc. Akademiai Budapest, Hung.

DOCUMENT TYPE: CODEN: 68WKAY
LANGUAGE: Conference English

AB A symposium report. We report the synthesis of peptides contg. 9-aminofluorene-9-carboxylic acid (Afc), in order to compare them with α,α -diphenylglycine-containing peptides. Afc has a rigid planar side chain in which two Ph groups are forced to be coplanar.


IT 256381-25-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (Synthesis, conformation and interaction of peptides containing

aminofluorene-9-carboxylic acid)
RN 256381-25-6 CAPLUS

CN glycine, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-alanyl-9-amino-9H-fluorene-9-carboxyl-, methyl ester (9CI) (CA INDEX NAME)
NTE modified (modifications unspecified)
SEQ 1 LAXG

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:288402 CAPLUS Full-text
DOCUMENT NUMBER: 132:347920

TITLE: Peptide synthesis catalyzed by subtilisin and thermolysin in organic solvents

Getun, Irina V.; Filipova, Irina Yu.;

AUTHOR(S): Elena N.; Anisimova, Veronika V.; Oksenoit, Elena S.;

CORPORATE SOURCE: Bacheva, Anna V.; Stepanov, Valentin M. Department of Chemistry, Lomonosov Moscow University, Russia

SOURCE: Peptides 1998, Proceedings of the European Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (

Editor(s): 1999), Meeting date 1998, 132-133.

Kiado: Bajusz, Sandor; Hudecz, Ferenc. Akademiai Budapest, Hung.

DOCUMENT TYPE: CODEN: 68WKAY
Conference

LANGUAGE: English

AB A symposium report. The purpose of the present work is to study the possibility of dissolving and using subtilisin 72 and thermolysin as catalysts for peptide bond synthesis in organic solvents.

IT 19719-42-9p

RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)


organic solvents) CAPLUS 19719-42-9

CN L-leucinamide, N-[(phenylmethoxy)carbonyl]-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 AALL

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 5 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:264469 CAPLUS Full-text

DOCUMENT NUMBER: 133:105301

TITLE: Synthesis of oligopeptides containing α,α -diphenylglycine

AUTHOR(S): Yamada, Takashi; Urabe, Yuka; Yanagihara, Ryoji;

Corporate Source: Miyazawa, Toshifumi

Konan Department of Chemistry, Faculty of Science, University, Kobe, 658-8501, Japan

SOURCE: Peptide Science (1999) 36th, 143-146

PUBLISHER: CODEN: PSCIRQ; ISSN: 1344-7661

DOCUMENT TYPE: Japanese Peptide Society Journal

LANGUAGE: English

AB By elongation in the N- and C-terminals of tripeptides containing α,α -diphenylglycine (Dph), Z-AA1-Dph-AA3-OMe (AA1, AA3 = Gly, Aib), which were obtained by a modified Ugi reaction, Dph-containing tetra-, penta- and hexapeptides were synthesized by the EDC-HOBT and EDC-HOAT methods. Both couplings of Z-Aib-OH with Aib-Dph-Aib-OMe and Z-Aib-Dph-Aib-OH with Aib-Dph-Aib-OMe were very difficult.

IT 283168-09-2p

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


CN 283168-09-2 CAPLUS

RN 283168-09-2 CAPLUS

CN glycine, N-[(phenylmethoxy)carbonyl]glycylglycyl-2,2-diphenylglycyl-, methyl ester (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 GGXG



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STINGUIDE

COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY
SESSION	192.76
FULL ESTIMATED COST	
962.22	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	ENTRY
SESSION	-14.00
CA SUBSCRIBER PRICE	
50.40	

FILE 'STINGUIDE' ENTERED AT 12:31:53 ON 09 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 3, 2004 (20040903/UP).

=> d 129 6-10 ibib abs hitseq
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:Y

L29 ANSWER 6 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:264431 CAPLUS FULL-text
DOCUMENT NUMBER: 133:4981

TITLE: Synthesis of amyloid β -peptides in solution:
chloroform-phenol mixed solvent is essential
for

protected segment condensation of sparingly soluble
peptides

AUTHOR(S): Inui, Tatsuya; Nishio, Hideki; Nishiuchi,
Yuji;

CORPORATE SOURCE: Kimura, Terutoshi
Institute Inc., Protein Research Foundation, Peptide

SOURCE: Osaka, 562-8686, Japan
Peptide Science (1999), 36th, 5-8
CODEN: PSCIFQ; ISSN: 1344-7661

PUBLISHER: Japanese Peptide Society
DOCUMENT TYPE: Journal

LANGUAGE: English
AB A symposium report. A new solvent system, a mixt. of chloroform
and phenol, was developed for the segment condensation of
sparingly soluble protected peptides in solution and

successfully applied to the synthesis of amyloid β -peptide (1-
42), (1-43) and [Pyr3]-(3-42). These peptides of high
homogeneity were used to examine the relation between structure
and amyloidogenesis by means of CD spectra and fluorimetric

assay.

IT 270083-73-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT

(Reactant or reagent)
(Synthesis of amyloid β -peptides in solution using
chloroform-phenol

mixed solvent for segment condensation of sparingly soluble
protected


peptides)
RN 270083-73-3 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-L-isoleucyl]-
L-isoleucyl]-

, 2-oxo-2-phenylethyl ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 AIIG

absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L29 ANSWER 7 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:242552 CAPLUS FULL-text
DOCUMENT NUMBER: 133:290568

TITLE: US-NCI testing procedures
AUTHOR(S): Plowman, J.; Camalier, R.; Alley, M.;
Sausville, E.;

CORPORATE SOURCE: Schepartz, S.
Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, National Cancer

Institute,

SOURCE: MD, USA
Contributions to Oncology (1999),
54(Relevance of tumor models for anticancer

Drug

Development), 121-135

CODEN: COONEV; ISSN: 0250-3220

S. Karger AG

Journal; General Review
English

PUBLISHER: A review with 21 refs. The US National Cancer Institute (NCI)
DOCUMENT TYPE: has carried out a highly integrated, formal program of
LANGUAGE: anticancer drug discovery and development. One of the key
components of this program has been a systematic screening
program to identify materials worthy of further development to
clin. trials. Anticancer screening must utilize exptl. model
systems that are hoped to identify agents that will be effective
clin., with the decision on the value of a given model being
made retrospectively. For many years, a variety of transplanted
rodent models were utilized for in vivo tests. Many of the
agents developed during that period were effective largely in
hematopoietic malignancies. Later, in hopes of identifying
agents active against solid tumor malignancies, a number of
human tumor xenografts were developed and used as models. A
major shift in strategy occurred in the mid 1980s, when the
decision was made to shift the initial screen to an in vitro

panel of 60 human tumor cell lines, representing nine histol. types. Comps. exhibiting activity in the in vitro screen and selected for further investigation are then evaluated for their effects on a series of human tumors utilizing the hollow fiber assay, and then tested in selected human tumors growing as s.c. xenografts in athymic (nude) mice. Materials demonstrating activity in vivo are then considered as potential candidates for development to clin. trial. Six agents have entered clin. trials and these are: dolastatin 10; quincocarmycin analog DX-52-1; desipeptide FR901228; UCN-01; flavopiridol (L86-8275); and semi-synthetic spicamycin analog KRN5500.

IT 128517-07-7, FR901228
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(Antitumor drug screening and US National Cancer Institute testing procedures)

RN 128517-07-7 CAPLUS
CN Cyclo[(2Z)-2-amino-2-butenyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenyl-D-valyl-D-cysteinyll], cyclic (3→5)-disulfide (9CI)

(CA INDEX NAME)

SEQ 1 VCV

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 8 OF 1915 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2000:96808 CAPLUS Full-Text
DOCUMENT NUMBER: 132:334737
TITLE: FR901228: Antineoplastic antibiotic
AUTHOR(S): Wang, Hwa-Chain R.
CORPORATE SOURCE: Dept. of Comparative Medicine, University of Tennessee, Knoxville, TN, 37901-1071, USA
SOURCE: Drugs of the Future (1999), 24(11), 1184-1188
CODEN: DRFUD4; ISSN: 0377-8282

PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review

LANGUAGE: English
AB A review with 18 ref. on bicyclic desipeptide FR901228. Synthesis, fermentation, isolation and pharmacol. actions are discussed.


IT 128517-07-7P, FR901228
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation, fermentation, isolation and pharmacol. actions of antineoplastic antibiotic FR901228)
RN 128517-07-7 CAPLUS
CN Cyclo[(2Z)-2-amino-2-butenyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenyl-D-valyl-D-cysteinyll], cyclic (3→5)-disulfide (9CI)
(CA INDEX NAME)

SEQ 1 VCV

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 2-A



0- PAGE 2-A

REFERENCE COUNT:
AVAILABLE FOR THIS

18 THERE ARE 18 CITED REFERENCES

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 9 OF 1915
ACCESSION NUMBER:
DOCUMENT NUMBER:

CAPLUS COPYRIGHT 2004 ACS on STN
2000:71997 CAPLUS Full-text
132:251420

TITLE:
Solid-phase synthesis of hydrophobic

peptides on

polystyrene

1,6-hexanediol diacrylate crosslinked

AUTHOR(S):
CORPORATE SOURCE:

resin: comparison with merrifield resin
Arunan, C.; Pillai, V. N. Rajasekharan
School of Chemical Sciences Mahatma Gandhi
University, Kottayam, 686 560, India
Protein and Peptide Letters (1999), 6(6),
391-398

SOURCE:

CODEN: PRELEN; ISSN: 0929-8665
Bentham Science Publishers

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

AB A novel polymer support based on 1,6-hexanediol diacrylate and
polystyrene was developed. The resin showed better solvation in
solvents used for peptide synthesis than Merrifield resin. The
synthetic utility of the new support has been illustrated with

the synthesis of some hydrophobic peptides which have high
affinity for aggregation. The yield and purity of the peptides
were high compared to when Merrifield resin was used.

IT

262445-90-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Solid-phase synthesis of hydrophobic peptides on hexanediol
diacrylate crosslinked polystyrene resin)

RN


262445-90-9 CAPLUS

CN

Glycine, L-valyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 VAAG

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

27 THERE ARE 27 CITED REFERENCES

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 10 OF 1915
ACCESSION NUMBER:
DOCUMENT NUMBER:

CAPLUS COPYRIGHT 2004 ACS on STN
2000:71433 CAPLUS Full-text
132:237364

TITLE:
Inhibition
of verotoxin binding to globotrioolceramide

AUTHOR(S):
qin, Huiping;

Shuqiong;

CORPORATE SOURCE:

for

Council of

SOURCE:

Canada, Ottawa, ON, K1A 0R6, Can.
Bioorganic & Medicinal Chemistry (1999),
7(12), 2823-2833
CODEN: BMCEP; ISSN: 0968-0896
Elsevier Science Ltd.

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

AB soln. and solid phase strategies for the synthesis of α -
galactose based neoglycopeptide derivs. 2-13 were developed.
Neoglycopeptides generated were tested for the inhibition of
verotoxin binding to globotrioolceramide (Gb3) using ELISA.

Among all of the compds. tested, only the lipid derivs. of neoglycopeptides, 11, 12 and 13 were found to be inhibitors. IC₅₀ = 2.0 mM (11b and 12c) and 0.2 mM (11c and 13c). All of the inhibitors (11b, 11c, 12c and 13c) have a similar branching of the two α -galactosyl units at the N-terminal glycine residue of a short peptide and a lipid moiety attached at the C-terminal site. Both of these factors seem to be crucial for the inhibition. It is interesting to note that the inhibitors have only a portion of the natural trisaccharide ligand. The secondary groups either may contribute in sub-site oriented interactions with the protein receptors or may mimic the internal sugar units of the cell-surface ligand, Gb3.

IT 261724-14-5DP, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(inhibition of verotoxin binding to globotriosylceramide by α -galactose based neoglycopeptides)

RN 261724-14-5 CAPLUS
 CN Glycine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl[glycyl-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucos-8-onyl)]-L-tyrosyl- (9CT) (CA INDEX NAME)


NTE modified (modifications unspecified)

SEQ 1 AGKG

Absolute stereochemistry.



PAGE 1-A



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

=> FIL CAPLUS
 COST IN U.S. DOLLARS
 TOTAL

SESSION
 FULL ESTIMATED COST
 1008.50


DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SESSION
 CA SUBSCRIBER PRICE
 53.90

FILE 'CAPLUS' ENTERED AT 12:34:25 ON 09 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2004 VOL 141 ISS 11



REFERENCE COUNT:
AVAILABLE FOR THIS

28 THERE ARE 28 CITED REFERENCES

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 12 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:46397 CAPLUS Full-text
DOCUMENT NUMBER: 132:237357
TITLE: Asymmetric syntheses of unsaturated amino
acids and
peptides via chelate-enolate Claisen

rearrangements
AUTHOR(S): Kazmaier, Uli
CORPORATE SOURCE: Organisch-Chemisches Institut der
Universität,
Heidelberg, 69120, Germany
Journal of the Indian Chemical Society (1999
, 76(11-12), 631-639
CODEN: JICSAH; ISSN: 0019-4522
Indian Chemical Society
Journal; General Review
English
CASREACT 132:237357

OTHER SOURCE(S): N-protected amino acid allylic esters can easily be deprotonated
AB by LDA at -78° and transmetalated by addition of metal salts.
upon warming up to room temperature, these enolates undergo
Claisen rearrangements giving rise to unsatd. amino acids.
starting from chiral allylic alcs., optically active amino acids
are obtained. This chirality transfer can also be used for
stereoselective peptide modifications. If tosylated peptide
allylic esters are subjected to Claisen rearrangement, the
chirality of the peptide chain can also be used as a
stereocontrolling element. Another possibility to introduce
chirality is given by the rearrangement in the presence of
chiral ligands, such as Cinchonina alkaloids.


PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:
OTHER SOURCE(S):

AB N-protected amino acid allylic esters can easily be deprotonated
by LDA at -78° and transmetalated by addition of metal salts.
upon warming up to room temperature, these enolates undergo
Claisen rearrangements giving rise to unsatd. amino acids.
starting from chiral allylic alcs., optically active amino acids
are obtained. This chirality transfer can also be used for
stereoselective peptide modifications. If tosylated peptide
allylic esters are subjected to Claisen rearrangement, the
chirality of the peptide chain can also be used as a
stereocontrolling element. Another possibility to introduce
chirality is given by the rearrangement in the presence of
chiral ligands, such as Cinchonina alkaloids.

IT RL: RCT (Reactant): RACT (Reactant or reagent)
(asym. syntheses of unsatd. amino acids and peptides via
chelate-enolate Claisen rearrangements)
RN 233591-86-1 CAPLUS
CN Glycine, N-[4-methylphenyl]sulfonyl-L-valyl-L-prolyl-L-leucyl-
,
2-propenyl ester (9CI) (CA INDEX NAME)
NTE modified (modifications unspecified)

SEQ 1 VPLG

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

34 THERE ARE 34 CITED REFERENCES

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 13 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:39686 CAPLUS Full-text
DOCUMENT NUMBER: 132:189736
TITLE: 5-HT-moduline controls serotonergic
activity:
regulation
mechanisms
AUTHOR(S): Grimaldi, B.; Fillion, G.
CORPORATE SOURCE: Unité de Pharmacologie
neuroimmunodocrinienne,
Institut
de Pharmacologie neuroimmunodocrinienne,
Pasteur, Paris, 75724, Fr.
Progress in Neurobiology (Oxford) (1999),
Volume Date 2000, 60(1) 1-12
CODEN: PGNBA5; ISSN: 0301-0082
Elsevier Science Ltd.
Journal; General Review
English

AB A review, with 76 refs. The serotonergic neurotransmission is
known as a neuromodulatory system exerting its activity in the
central nervous system (CNS) as well as at the periphery. The
anatomical and morphol. organization of the system based on a
marked centralization of the cellular bodies and the large,
almost ubiquitous, presence of axonal projections of the neurons
is in good agreement with this modulatory role. Furthermore, a
very high number of varicosities located along the axonal
branches are capable of releasing serotonin (5-HT). The amine
stimulates a number of different specific receptor types which
allows 5-HT to exert different activities on its various
cellular targets. Among these receptors, the 5-HT_{1B} subtypes
play a particular role as they are autoreceptors located on 5-HT
neurons terminals and heteroreceptors located on non-
serotonergic terminals where they control the release of the
neurotransmitter. 5-HT-moduline, an endogenous tetrapeptide,

SOURCE: Pasteur, Paris, 75724, Fr.
Progress in Neurobiology (Oxford) (1999),
Volume Date 2000, 60(1) 1-12
CODEN: PGNBA5; ISSN: 0301-0082
Elsevier Science Ltd.
Journal; General Review
English

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:
OTHER SOURCE(S):

AB A review, with 76 refs. The serotonergic neurotransmission is
known as a neuromodulatory system exerting its activity in the
central nervous system (CNS) as well as at the periphery. The
anatomical and morphol. organization of the system based on a
marked centralization of the cellular bodies and the large,
almost ubiquitous, presence of axonal projections of the neurons
is in good agreement with this modulatory role. Furthermore, a
very high number of varicosities located along the axonal
branches are capable of releasing serotonin (5-HT). The amine
stimulates a number of different specific receptor types which
allows 5-HT to exert different activities on its various
cellular targets. Among these receptors, the 5-HT_{1B} subtypes
play a particular role as they are autoreceptors located on 5-HT
neurons terminals and heteroreceptors located on non-
serotonergic terminals where they control the release of the
neurotransmitter. 5-HT-moduline, an endogenous tetrapeptide,

regulates the efficacy of these 5-HT_{1B} receptors, hence, is able to control the serotonergic activity in a synchronous manner for the various varicosities from a single neuron and thus may favor the differential effect of that neuron on distinct cerebral functions. Accordingly, the peptide allows the "fine tuning" of the cerebral activity by the serotonergic system to elaborate the response given by the brain to a particular stimulus, i.e., stress situations. At the periphery, the serotonergic system also appears to possess a regulatory activity via 5-HT_{1B} receptors. In particular, the receptors located on immunocompetent cells control their activity and are themselves regulated by 5-HT-moduline likely originating from adrenal medulla and released after acute stress. The serotonergic system appears to play a major role in the reciprocal signaling existing between the neuronal and the immune system. The participation of 5-HT-moduline is likely in physiological functions as well as in pathological disorders affecting central and peripheral activities.


IT 169249-03-0, 5-HT-moduline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BROL (Biological study)

in (5-HT-moduline controls serotonergic activity and implication in neuroimmune reciprocal regulation mechanisms)

RN 169249-03-0 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSAL

Absolute stereochemistry.



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 14 OF 1915 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2000:18144 CAPLUS FULL-TEXT
DOCUMENT NUMBER: 132:222850
TITLE: Preferred solution conformation of peptides rich in
the tipophilic, chiral, Ca-methylated
α-amino acid (Came)Aoc
Peggion, Cristina; Formaggio, Fernando;

AUTHOR(S):

Crisma, Marco; Toniolo, Claudio; Kaptein, Bernard;
Broxterman, Quirinus B.; Kamphuis, Johan
CORPORATE SOURCE: Biopolymer Research Centre, CNR, Department
of Organic Chemistry, University of Padova, Padua,
35131, Italy
SOURCE: Journal of Peptide Science (1999), 5(12),
547-554
CODEN: JPSEI; ISSN: 1075-2617
John Wiley & Sons Ltd.
English

PUBLISHER: Journal
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The tipophilic, chiral, Ca-methylated α-amino acid L-(Came)Aoc (2-methyl-2-amino-octanoic acid) was prepared using a chemo-enzymic approach. Two series of terminally protected model peptides, from dimer through to hexamer, containing L-(Came)Aoc in combination with either Gly or Ala, were synthesized by solution methods and were fully characterized. A solution conformational analysis, based on FT-IR absorption, 1H-NMR and CD techniques, was performed with the aim at determining the preferred conformation of this novel amino acid and the relationship between chirality at its α-carbon atom and screw sense of the helix that is formed. The results obtained strongly support the view that L-(Came)Aoc favors the formation of the right-handed 310-helical conformation.

IT 261517-55-9p
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(Preferred solution conformation of peptides rich in the tipophilic,


chiral, Ca-methylated α-amino acid (Came)Aoc (2-methyl-2-amino-octanoic acid))

RN 261517-55-9 CAPLUS
CN Glycine, N-[1(phenylmethoxy)carbonyl]glycyl-(2S)-2-amino-2-methyloctanoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 GGXG

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L29 ANSWER 15 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:809520 CAPLUS Full-text
 DOCUMENT NUMBER: 133:16465
 TITLE: process scale chromatographic isolation,
 characterization and identification of
 tryptic

AUTHOR(S): bioactive casein phosphopeptides
 Ellgaard, Kattrine H.; Gammelgaard-Larsen,
 Claus;


CORPORATE SOURCE: Sorensen, Esben S.; Fedosov, Sergey
 MD Foods R and D, Viby, DK-8260, Den.
 SOURCE: International Dairy Journal (1999), 9(9),
 639-652
 CODEN: IDAJE6; ISSN: 0958-6946
 Elsevier Science Ltd.

PUBLISHER: English
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A process scale isolation of 40 kg tryptic casein
 phosphopeptides (CPP) was implemented using tryptic hydrolysis,
 acid precipitation, diafiltration and anion exchange chromatog.
 The obtained yield corresponded to 20% (weight/weight) CPPs from
 caseinate. The CPP-product was obtained either as Ca-CPP (6.97%
 Ca, 0.23% Na) or Na-CPP (0.01% Ca, 8.53% Na). These products
 were completely soluble at pH as low as 0.5 and displayed no
 particular taste. All produced CPPs were phosphorylated
 peptides which exhibited calcium binding ability and inhibited
 calcium phosphate crystallization. The peptides were identified
 by mass spectrometry and N-terminal sequencing as genuine
 truncated tryptic peptides. A high purity CPP product,
 available as Na-CPP and Ca-CPP, was obtained by this high yield
 process scale isolation of tryptic CPPs.

IT 271788-41-1
 RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
 (process scale chromatog. isolation, characterization and
 identification of tryptic bioactive casein phosphopeptides)
 RN 271788-41-1 CAPLUS
 CN L-Leucine, L-valyl-L-asparaginy-L- α -glutamy- (9CI) (CA INDEX
 NAME)

SEQ 1 VNEL
 Absolute stereochemistry.



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L29 ANSWER 16 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:799430 CAPLUS Full-text
 DOCUMENT NUMBER: 132:194651
 TITLE: Synthesis and activity of NH2- and COOH-
 terminal

AUTHOR(S): elastase recognition sequences on cotton
 Edwards, J. V.; Batisse, S. L.; Gibbins, E.
 M.;

CORPORATE SOURCE: Goheen, S. C.
 Regional Agricultural Research Service, Southern
 Research Center, Cotton Textile Chemistry
 Unit, United States Department of
 Agriculture, New Orleans, LA, 70124, USA

SOURCE: Journal of Peptide Research (1999), 54(6),
 536-543
 CODEN: JPPEFA; ISSN: 1397-002X
 Munksgaard International Publishers Ltd.

PUBLISHER: English
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The application of peptide recognition sequences of elastase to
 fibers of wound dressings is a possible route to inhibiting high
 levels of destructive elastase in the chronic wound. For this
 reason we have synthesized the elastase recognition sequence
 Val-Pro-Val on both cotton cellulose, and carboxymethylated
 cellulose cotton (CMC) and prepared chromatog. columns of these
 to examine elastase retention. The tripeptide was synthesized
 on cotton-based cellulose fibers both in sequence and as a
 tripeptide Me ester. Glycine was employed as a linker of the
 recognition sequence to the cotton cellulose. Pre-treatment of
 cotton cellulose with cellulase improved the substitution level
 of glycine. The peptidocellulose conjugates were employed as a
 chromatog. stationary phase to assess elastase retention. The
 sequence Val-Pro-Val-OMe was amino-terminally anchored to
 carboxymethylated cotton and demonstrated retention of up to 58%
 of elastase when first applied to the column. Higher repetitive
 retention was demonstrated subsequently. Cotton gauze similarly

modified with Val-Pro-Val-Gly cellulose was compared with untreated gauze for reduction of elastase activity in buffered saline. Solns. of elastase that were treated with Val-Pro-Val-Gly cellulose, cotton gauze, demonstrated reduced elastase activity. This study demonstrates the use of elastase recognition sequences as sequestering agents of elastase when attached to cotton fibers and constitutes a model for the design of peptidocellulose analogs in dressing fibers for chronic wounds.

IT 135069-63-5DP, cellulose-bound

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); BIOL

(Biological

study); PREP (Preparation)

(Synthesis and activity of elastase recognition sequences on cotton for


use in wound dressings)

RN 135069-63-5 CAPLUS

CN Glycine, L-valyl-L-prolyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VPVG

Absolute stereochemistry.



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L29 ANSWER 17 OF 1915

CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1999:763313 CAPLUS Full-text

DOCUMENT NUMBER:

132:45114

TITLE:

Structural requirements of 5-

hydroxytryptamine-

moduline analogues to interact with the

5-hydroxytryptamine1B receptor

Plantefol, Mathieu; Rousselle, Jean Claude;

Olivier; Bernardi, Elizabeth; schoofs, Alain

Rene;

Pourrias, Bernard; Olivier, Roland;

unite de Pharmacologie Neuro-Immuno-

Endocrinienne,

Fillion, Gilles
CORPORATE SOURCE:
Endocrinienne,

SOURCE:

Institut Pasteur, Paris, Fr
Journal of Neurochemistry (1999), 73(6),
2617-2620

PUBLISHER:

CODEN: JONRA9, ISSN: 0022-3042
Lippincott Williams & Wilkins

DOCUMENT TYPE:

LANGUAGE:

English
Journal

AB

5-Hydroxytryptamine-moduline is an endogenous cerebral tetrapeptide that regulates the activity of 5-hydroxytryptamine1B receptors. Direct binding of 5-[3H]hydroxytryptamine-moduline on rat brain homogenate evidenced the existence of two interacting sites for the peptide, very likely corresponding to different conformations of the 5-hydroxytryptamine1B receptor. The peptide first binds to a low-affinity state of the receptor (pK50 = 7.68) and then induces (or stabilizes) a high-affinity complex (pK50 = 11.62). This work focuses on the ability of 5-hydroxytryptamine-moduline analogs to recognize the high- and low-affinity sites for 5-hydroxytryptamine-moduline. The results obtained show that the two conformers of the 5-hydroxytryptamine1B receptor have similar but not identical binding pockets for 5-hydroxytryptamine-moduline. These two sites proved to be stereoselective and selective for tetrapeptides and favored the binding of peptides with hydrophobic amino acids in positions 1 and 4, serine in position 2, and a short amino acid in position 3. However, the serine in position 2 seems to be more important for the interaction of the peptide with the low-affinity site than the high-affinity one, which only needs a short hydrophobic amino acid in position 2.

IT

169249-03-0 169249-03-0D, 5-HT-moduline, analogs
169249-06-3 169249-07-4 252985-19-6,
Leu-Ala-Ala-Leu 252985-20-9, Leu-Abu-Ala-Leu 252985-21-0
Leu-Pro-Ala-Leu 252985-22-1 252985-24-3,
Ala-Ser-Ala-Leu 252985-25-4, Leu-Ser-Abu-Leu 252985-26-5
252985-27-6, Leu-Ser-Ala-D-Leu 252985-28-7
252985-29-8 252985-30-1 252985-31-2
252985-32-3 252985-33-4 252985-34-5
252985-35-6 252985-36-7 252985-37-8
252985-38-9 252985-39-0 252985-40-3
252985-41-4

RL: BPR (Biological process); BSU (Biological study, unclassified); PREP

(Properties); BIOL (Biological study); PROC (Process)

(5-HT-moduline analog interaction with high- and low-affinity

5-HT1B


Receptor states and structural requirements therein)

RN 169249-03-0 CAPLUS

CN L-Leucine, L-leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSAL


Absolute stereochemistry.



RN 169249-03-0 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSAL

Absolute stereochemistry.




RN 169249-06-3 CAPLUS
CN L-Leucine, N-acetyl-L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 LSAL

Absolute stereochemistry.




RN 169249-07-4 CAPLUS
CN L-Leucinamide, L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 LSAL


Absolute stereochemistry.



RN 252985-19-6 CAPLUS
CN L-Leucine, L-Leucyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LAAL


Absolute stereochemistry.



RN 252985-20-9 CAPLUS
CN L-Leucine, L-Leucyl-(2S)-2-aminobutanoyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LXAL


Absolute stereochemistry.



RN 252985-21-0 CAPLUS
CN L-Leucine, L-Leucyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LPAL

Absolute stereochemistry.




RN	252985-22-1	CAPLUS	
CN	L-leucine, L-leucyl-O-methyl-L-seryl-L-alanyl-	(9CI)	(CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 LSAL


Absolute stereochemistry.



RN	252985-24-3	CAPLUS
CN	L-leucine, L-alanyl-L-seryl-L-alanyl- (9CI)	(CA INDEX NAME)

SEQ 1 ASAL


Absolute stereochemistry.



RN	252985-25-4	CAPLUS
CN	L-leucine, L-[leucyl-(2S)-2-aminobutanoyl]- (9CI)	(CA
INDEX NAME)		



Absolute stereochemistry.




INDEX NAME	252985-26-5	CAPLUS	L-leucine, L-1eucyl-3-cyclohexyl-L-alanyl-L-alanyl- (9ci)	(CA
RN	252985-26-5	CAPLUS	L-leucine, L-1eucyl-3-cyclohexyl-L-alanyl-L-alanyl- (9ci)	(CA
CN	L-leucine, L-1eucyl-3-cyclohexyl-L-alanyl-L-alanyl- (9ci)			

NTE modified (modifications unspecified)

SEQ 1 LAAL


Absolute stereochemistry.



RN	252985-27-6	CAPLUS
CN	D-Leucine, L-[Leucyl-L-seryl-L-alanyl- (9CI)	(CA INDEX NAME)

SEQ 1 LSAL


Absolute stereochemistry.



RN 252985-28-7 CAPLUS
CN L-Leucine, L-Leucyl-L-leucyl-3-amino-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LXAL


Absolute stereochemistry.



RN 252985-29-8 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-D-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSAL


Absolute stereochemistry.



RN 252985-30-1 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-β-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSXL


Absolute stereochemistry.



RN 252985-31-2 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-2-methylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSXL


Absolute stereochemistry.



RN 252985-32-3 CAPLUS
CN L-Leucine, L-Leucyl-O-phosphono-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)
SEQ 1 LSAL


Absolute stereochemistry.



RN 252985-33-4 CAPLUS
CN D-Leucine, D-Leucyl-D-alanyl-D-seryl- (9CI) (CA INDEX NAME)

SEQ 1 LASL


Absolute stereochemistry.



RN 252985-34-5 CAPLUS
CN L-Alanine, L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LSAA


Absolute stereochemistry.



RN 252985-35-6 CAPLUS
CN L-Leucine, L-Leucyl-L-homoseryl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 LXAL


Absolute stereochemistry.



RN 252985-36-7 CAPLUS
CN L-Leucine, L-Leucyl-1-aminocyclopentanecarbonyl-L-alanyl- (9CI)
(CA INDEX NAME)

SEQ 1 LXAL


Absolute stereochemistry.



RN 252985-37-8 CAPLUS
CN L-Leucine, N-methyl-L-Leucyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)
SEQ 1 LSAL


Absolute stereochemistry.



RN 252985-38-9 CAPLUS
CN L-Leucine, L-Leucyl-L-seryl-w(CH2-NH)-L-alanyl- (9CI) (CA INDEX NAME)


NTE modified (modifications unspecified)
SEQ 1 LSAL

Absolute stereochemistry.



RN 252985-39-0 CAPLUS
CN D-Leucine, D-Leucyl-D-seryl-D-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN	252985-40-3	CAPLUS	
CN	L-leucine, L-[Leuyl-D-seryl-L-alanyl- (9CI)	(CA INDEX NAME)	

SEQ 1 LSAL


Absolute stereochemistry.



RN	252985-41-4	CAPLUS
CN	L-leucine, D-[leucyl-L-seryl-L-alanyl- (9CI)	(CA INDEX NAME)

SEQ 1 LSAL

Absolute stereochemistry.



REFERENCE COUNT:

5

1
2
3
4
5
6
7
8

THERE ARE 5 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE

L29 ANSWER 18 OF 1915 CAPLUS COPYRIGHT 2004 ACS ON STN

TITLE:

Containing

AUTHOR(S):
Catherine M. J.

CORPORATE SOURCE:
Mississauga, ON, L4V

SOURCE:
(1999)

1999: 757943 CAPLUS Full-text
132:180846
A Convenient Method of Preparing High
Activity Technetium Complexes Using Thio-
Chelators Adsorbed on Gold
Pollak, Alfred; Roe, David G.; Pollack,
Lu, Linda F. L.; Thornback, John R.
Resolution Pharmaceuticals Inc.,
Iv7, Can.
Journal of the American Chemical Society

PUBLISHER:
DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S) :
AB The phys.

The physico-chemical properties of technetium-99m make it an ideal radioisotope for use in medical imaging agents. Here, the preparation and labeling of the thiol-containing dimethylglycine-serine-cysteine-glycine (RP14), adsorbed onto a gold surface, is described. The chelator having the cysteine protected by the acetamidomethyl (AcM) group was easily prepared by standard solid-phase peptide synthesis techniques employing Fmoc chemical removal of the AcM group using mercury acetate in the presence of acetic acid, followed by precipitation of the mercury with H₂S gas, gave the chelator as the free thiol. A solution of this chelator in phosphate buffered saline (PBS) and ethanol was then used to load the gold surface. Unreacted chelator was removed by thorough washing of the gold and complete removal was confirmed by HPLC anal. of the supernatant. Utilization of this attachment provides an ideal opportunity to develop a procedure to generate high specific activity formulations of technetium radiopharmaceuticals. Radio-labeling of the gold-bound chelator with Tc-99m pertechnetate was carried out. Initial complexation of the surface bound chelator with the technetium (after reduction) weakens the gold-sulfur bond. This bond breaks and a sulfur-technetium bond forms causing the technetium complex to be released into solution. The uncomplexed chelator remains attached to the gold surface. The end result of this is the generation of technetium complexes having high specific activity in which the only receptor-targeting moiety in the solution is the radiopharmaceutical.

IT 231614-43-0P 259198-91-9DP, gold surface bonded
259198-91-9P, RP 414

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(convenient method of preparing high specific activity technetium complexes for radioimaging agents using thiol-containing chelators adsorbed on gold)

RN 231614-43-0 CAPLUS
CN glycine, N,N-dimethylglycyl-L-seryl-S-[(acetylaminomethyl)-L-cysteinyl]-
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 GSCG

Absolute stereochemistry.




RN 259198-91-9 CAPLUS
CN glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl-
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 GSCG

Absolute stereochemistry.




RN 259198-91-9 CAPLUS
CN glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl-
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 GSCG

Absolute stereochemistry.



REFERENCE COUNT:
AVAILABLE FOR THIS

24 THERE ARE 24 CITED REFERENCES

RE FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE

L29 ANSWER 19 OF 1915
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
Assay for an

CAPLUS COPYRIGHT 2004 ACS on STN
1999:757434 CAPLUS Full-text
132:77704

Development of a stable isotope dilution

AUTHOR(S):
Hofmann, T.
CORPORATE SOURCE:
of Naples

Accurate quantification of protein-bound
Ne-(1-deoxy-D-fructos-1-yl)-L-lysine using a
13C-labeled internal standard
Vinale, F.; Fogliano, V.; Schieberle, P.;
Department of Food science, The university

SOURCE:

Federico II, Portici, 80055, Italy
Journal of Agricultural and Food Chemistry (

PUBLISHER:
DOCUMENT TYPE:

CODEN: JAFCAU; ISSN: 0021-8561
American Chemical Society
Journal

LANGUAGE:

English

AB Syntheses of the labeled Amadori compd. [13C6]-Ne-(1-deoxy-D-fructos-1-yl)-L-lysine ([13C6]-DFlys) and the labeled glycosylated tetrapeptide Ala-[13C6]-DFlys-Leu-Gly are presented. The compds. were used in the development of stable isotope dilution assays for the quantification of the degree of glycosylation of bovine serum albumin treated for 20 min at 95 °C in the presence of glucose. The expts. revealed that the use of the labeled stds. in combination with LC/MS allowed the exact quantification of protein-bound DFlys with the high recovery rate of 95% (at a spike level of 150 nmol/mg of protein) and a low detection limit of 5 nmol/mg of protein. The data revealed, however, that DFlys is significantly degraded during the enzymic hydrolysis of the protein backbone generally needed in the quantification procedure and, furthermore, incomplete digestion of the protein was observed. Both sources of errors were clearly overcome by using in particular the labeled peptide as the internal standard

IT

253584-91-7P

RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(development of a stable isotope dilution assay for an

accurate


L- quantification of protein-bound Ne-(1-Deoxy-D-fructos-1-yl)-

RN lysine using a 13C-labeled internal standard

CN 253584-91-7 CAPLUS

lysyl-L- glycine, L-alanyl-N6-(1-deoxy-β-D-fructopyranos-1-yl)-13C6)-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253584-98-4P 253585-00-1P 253585-01-2P

253585-02-3P

RL: RCT (Reactant): SPN (Synthetic preparation); PREP

(Preparation): RACT

(Reactant or reagent)

accurate (development of a stable isotope dilution assay for an


L- quantification of protein-bound Ne-(1-Deoxy-D-fructos-1-yl)-

RN lysine using a 13C-labeled internal standard

CN 253584-98-4 CAPLUS

glycine, N-[(9H-fluoren-9-yl)methoxy]carbonyl]-L-alanyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253585-00-1 CAPLUS


CN glycine, N-[(9H-fluoren-9-yl)methoxy]carbonyl]-L-alanyl-L-lysyl-L-leucyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

CM 1

CRN 253584-99-5

CMF C32 H43 N5 O7


Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 253585-01-2 CAPLUS
 CN glycine, N-[[(9H-fluoren-9-yl)methoxy]carbonyl]-L-alanyl-N6-(1-deoxy-β-D-fructopyranos-1-yl)-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 253585-02-3 CAPLUS
 CN glycine, N-[[(9H-fluoren-9-yl)methoxy]carbonyl]-L-alanyl-N6-(1-deoxy-β-D-fructopyranos-1-yl)-13C6)-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



IT 253585-03-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (development of a stable isotope dilution assay for an accurate quantification of protein-bound N6-(1-Deoxy-D-fructos-1-yl)-L-lysine using a 13C-labeled internal standard)
 RN 253585-03-4 CAPLUS
 CN glycine, L-alanyl-N6-(1-deoxy-β-D-fructopyranos-1-yl)-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)
 NTE modified (modifications unspecified)
 SEQ 1 AKLG

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES
 AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L29 ANSWER 20 OF 1915 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:754627 CAPLUS Full-text
 DOCUMENT NUMBER: 132:166498
 TITLE: Correlation between the mobility of spin-labeled
 approach to
 sequences
 AUTHOR(S): Shirley; Nakaie; Clovis R.
 CORPORATE SOURCE: Department of Biophysics, Universidade
 Federal de Sao
 SOURCE: Paulo, Sao Paulo, CEP 04044-020, Brazil
 Journal of Organic Chemistry (1999), 64(25),
 9118-9123
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English


AB Resin solvation properties affect the efficiency of the coupling reactions in solid-phase peptide synthesis. Here, the authors report a novel approach to evaluate resin solvation properties, making use of spin label ESR (EPR) spectroscopy. The aggregating peptide sequences VVLGAIV and ING were assembled in benzhydrylamine-resin with different amino group contents (up to 2.6 mmol/g) to examine the extent of chain association within the beads. These model peptidyl-resins were first labeled at their N-terminus with the amino acid spin label 2,2,6,6-tetramethylpiperidine-N-oxyl-4-amino-4-carboxylic acid (Toac). Their solvation properties in different solvents were estimated, either by bead swelling measurement or by assessing the dynamics of their polymeric matrixes through the anal. of Toac EPR spectra, and were correlated with the yield of the acylation reaction. In most cases the coupling rate was found to depend on bead swelling. Comparatively, the EPR approach was more effective. Line shape anal. allowed the detection of more than one peptide chain population, which influenced the reaction. The results demonstrated the unique potential of EPR spectroscopy not only for improving the yield of peptide synthesis, even in challenging conditions, but also for other relevant polymer-supported methodologies in chemical and biol.

IT 258511-39-60P, benzhydrylamine resin-bound
RL: PEP (Physical, engineering or chemical process); SPN

(Synthetic preparation); PREP (Preparation); PROC (Process)
(determination of optimal resin solvation for solid-phase peptide coupling by studying spin-labeled, resin-bound peptides with EPR spectroscopy and bead swelling methods)

RN 258511-39-6 CABLUS
CN L-Valinamide, L-alanyl-L-alanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 258511-38-50P, benzhydrylamine resin-bound
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(determination of optimal resin solvation for solid-phase peptide coupling by

studying spin-labeled, resin-bound peptides with EPR spectroscopy and bead swelling methods)

RN 258511-38-5 CABLUS
CN L-Valinamide, 4-amino-2,2,6,6-tetramethyl-1-oxo-4-piperidinecarboxyl-L-alanyl-L-alanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)
SEQ 1 AAIV

Absolute stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> FIL STINGUIDE COST IN U.S. DOLLARS 1 SINCE FILE
TOTAL

SESSION FULL ESTIMATED COST 92.52
TOTAL

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE
TOTAL ENTRY

SESSION CA SUBSCRIBER PRICE -7.00
TOTAL

FILE 'STINGUIDE' ENTERED AT 12:36:04 ON 09 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 3, 2004 (20040903/UP).

=>

=> executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY
SESSION	0.06
FULL ESTIMATED COST	
1101.08	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	ENTRY
SESSION	0.00
CA SUBSCRIBER PRICE	
60.90	

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:36:30 ON 09 SEP 2004